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ABSTRACT 
This report describes a five gear studg to develop -- and ultimatelg to market -- an implantable prosthetic sphincter for the control of urinarg incontinence. The studg was divided into three phases; bench development studies, animal trials, and human clinical trials. This work was performed under the direction of a Researah Team at Rochester General Hospital (RGH). Bench trials were completed on prototgpe hardware and provided earlg veri-fication of the device's abilitg to withstand repeated cgclic testing. Configurational variants were evaluated and a preferred design concept was establiShed. Silicone rubber (medical grade) l,ras selected as the preferred material for the prosthesis. 
A keg component for the prosthesis is the pressure regulating check valve which limits the fluid pressure applied to the urethra. This valve was provided as Government Furnished Equipment (GFE) from a qualified manu-facturer. Stringent demands for low leakage rates, low operating pressure levels and long-term compatibilitg with salt water (saline solution) caused several changes in both valve configuration and valve materials. These changes del aged the program. Initial animal trials were performed using six prostheses in female canine test subjects. The prostheses were fabri-cated bg several suppliers and were assembled into a functioning sgstem at Rochester General Hospital. Despite problems with long-term management of animals with prosthetic sphincters, tests -- coupled with dailg observa-tions -- verified device performance. Several configurational changes were recommended and an integrated approach to sgstem assemblg was proposed. The manufacturer of silicone rubber cuffs used for animal trials elected to discontinue further work based on business considerations. A new manufac-turer was selected and a second animal trial phase was initiated using an improved prosthesis. The new prosthesis was evaluated in 10 subjects and was successful in causing continence. In one instance, testing resulted in death, but it was not directlg attributable to performance of the device. On balance, test results -- coupled with histological findings -- ccnfirm the effectiveness of the prosthesis. 
The manufacturer, Medical Engineering Corporation (MEC) of Racine, Wisconsin has elected to market this device. MEC is currentlg active in developing detailed plans for clinical trial.~. An F.D.A. approval request is in preparation. RGH has transferred technical data to MEC in support of their emerging program. The clinical development program presentlg being structured bg MEC is expected to require several gears. RGH has provided medical and technical consultation to MEC on a continuing basis. This relationship is expected to continue until a successful prosthesis is introduced in the marketplace or until non-technical factors (e.g. business considerations) demonstrate to the manufacturer that the concept is not commerciallg viable. 
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1. INTRODUCTION 
This report describes contract work in support of contract NAS 8-32815, 
Development and Marketing of a Prosthetic Urinary Control Valve System. The 
valve system is a key element in the development of a prosthetic sphincter 
for the control of urinary incontinence. The specific objective of the 
contract was to "achieve a NASA technology transfer in the biomedical field 
through the contractor-developed simple and reliable prosthetic urinary 
sphincter control system to enable urinary incontinent patients to achieve 
external voluntary control of bladder function."* The work described in 
this report has been in progress for more than five years; since 8/9/78. 
This problem was originally identified to NASA-Technology Utilization 
Office by the NASA Biomedical Applications Team at the Research Triangle 
Institute. During the timeframe of the original RFQ, several prostheses 
for urinary incontinence were available to surgeons. These devices 
aChieved some degree of success but many of the failures reported in the 
medical literature were due to mechanical malfunctions which -- in a 
technical sense -- appeared to be resolvable using good design, engineering, 
and manufacturing practices. In addition, none of the systems available in 
1977 employed a technique for controlling the direct pressure applied to 
the urethra in a precise manner. NASA proposed the adaptation of valve 
technology based on a joint activity by contractors and MSFC personnel to 
the problems of urinary incontinence. 
This report describes a three phase program to develop a prosthesis 
for controlling urinary incontinence in both men and women. During the 
time period covered by this report, the technology has evolved continually. 
A section of this report will deal with advances in the state-of-the-art 
which have occurred concurrently with the project. The original prosthesis 
proposed in the early phases of this study has evolved through a series of 
changes and refinements which have reflected both analytical considerations 
and "in-vivo" test experience. An understanding of these evolutionary 
changes is important in understanding the prosthesis -- and the work which 
has occurred during its development. Accordingly, this report will treat 
not only the end results of work during this period -- but will briefly 
discuss the evolutionary stages in the development of the prosthesis. 
Work on this project was performed by a team comprised of NASA, 
Rochester General Hospital, Parker Hannifin Corporation (supplier of the 
valve) and the Medical Engineering Corporation (Racine, Wisconsin), 
fabricator of the system. 
In the early stages of this program, RGH contacted several qualified 
manufacturers of prosthetic devices to affect a suitable teaming arrange-
ment. Initially, the project team included Dow Corning (Midland, Michigan) 
as the fabricator of the prosthesis. Following their involvement in the 
initial animal stUdies for the project, Dow Corning elected -- for business 
* From NASA RFQ preceding contract NAS 8-32815 
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reasons -- to decline further participation. Subsequently, teaming arrange-
ments were made with MEC. At the present time, MEC is making appropriate 
preparations to begin clinical trials l?ith human subjects. 
This report summarizes key activities and findings for more than five 
years work. All keg activities are reviewed and summarized; and appropriate 
conclusions and recommendations are made. 
The chronologg which follows brieflg summarizes some of the keg events 
during the program. 
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8/78: 
9/78: 
CHRONOLOGY OT? KEY EVENTS (URINllRY SPHINCTER PROJECT) 
Initial contract award. 
Kick off meeting, RGH (Rochester, NY). Attendees: RGH, NASA (HQ and MST?C), PH. 
Design requirements established. 
RGH installs laminar bench (Gl?E) and fabricates pre-prototype cuff. 
Bench tests begin. 
Contacts initiated with potential manufacturers, Wright-Dow Corning (Arlington, TN) and Codman Shurtleff (Randolph, MA). 
10/78: Initial pre-prototype cuffs pass 130,000 cycles at 4x working pressures. 
Design dimensions established. 
11/78: RGH visits Wright-Dow Corning (Arlington, TN). Meetings 
set up to arrange teaming wi th Dow Corning (Midland, MI). T?D.A. regulations requiring the development of a PDP (Product Development Protocol) surface. 
12/78: RGH designs and fabricates pre-prototypes for self-sealing 
septa. 
1/79: 
2/79: 
3/79: 
4/79: 
Penetration testing initiated. 
RGH submits request for scope change (incremental 6-month period) for development and submission of a PDP for P.D.A. 
approval. 
RGH conducts internal design review. 
RGH completes septum penetration tests. 
RGH (E. Tenney, Dr. H. Harrison) visits WDC (Arlington, TN) for further teaming arrangements. 
RGH receives non-functioning valve-bulbs from PH for 
evaluation. 
RGH performed initial surgical procedure to create controlled 
"incontinence- in a test subject. 
DC agrees to participate in initial phase of program as cuff fabricator. Hardware schedules negotiated. 
Program meeting, DC (Midland, MI). Attendees: RGH, NASA, PH, DC. Subject: Team arrangements; design review. DC agrees to provide cuffs on a cost sharing basis. PDP concerns 
reviewed. 
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4/79: 
7/79: 
8/79: 
9/79: 
Design review meeting. Attendees: NASA, Research Triangle 
Institute (RTI), RGH, DC. Cuff design (as adapted from 
RGH pre-prototypes) was reviewed. 
PH completes acceptance testing of valve/pump-bulb. 
Prototype cuffs fabricated by DC are received at RGH. 
PDP plan completed, circulated to Program Team. 
RGH completed evaluation of DC cuff. 
PH changes valve material from stainless steel to titanium; 
impact on schedule not known. 
Ingrowth studies (in rat models) underway at RGH. 
RGH continues surgical attempts to create controlled 
incontinence in animal models. 
Program Team meeting, RGH (Rochester, NY). Participants: 
RGH, DC, PH, NASA. Subject: Design review. 
Program delays encountered due in part to materials problems 
with PH valves; shift from stainless steel I>,ire to titanium 
wire springs. 
10/79: PH discusses business teaming arrangements with business 
evaluations in progress at DC. 
1/80: DC agrees to support initial auimal phase, but no commitment 
to human clinical phase. 
F.D.A. position on role of PDP changes. 
2/80: RGH implants two prototype sphincter systems in canine 
subjects. 
3/80: PH begins fabrication of septum elements per RGH design. 
4/80: 
5/80: 
6/80: 
PDP requirements relaxed by F.D.A. 
Program meeting, RGH (Rochester, NY). Attendees: NASA, PH, 
DC, RGH. Subject: Design review. 
RGH (D. Rogers, J. Naim) attend NIH conference on Implant 
Retrieval and Biological Analysis, NIH, Bethesda, MD. 
DC elects to drop out of long-term commitment to program 
as a device manufacturer. 
PH identifies MBC as potential device fabricator. MBC joins 
the design team. 
Cuff received from DC for use in Phase II in vivo tests. 
Initial functioning system implanted. Employed stainless 
steel prototype valve (PH), RGH fabricated septum and 
DC cuff. 
Program meeting, RGH (Rochester, NY). MBC visits for 
initial teaming arrangements. 
1-4 
~ ::1' 
I, 
I,! 
" ! 
{' , 
!~ 
" 
" 
~ 
; 
r7' { ! l 
-
, 
l-
-;; 
tl, 
r.: 
I 
" 
-f\ 
! 
J. 
~ 
,~ 
I.' 
~ 
! I 
J 
~. 
,i 
J. 
J 
IT' 
l' 
·il 
J 
1 
I 
I 
7/80: 
8/80: 
9/80: 
, 
RGH visits DC to review fabrication process, materials. PH proposes design modifications to subsequent valves. Changes involve internal details and reduce valve height by half. 
PH initiates discussions with M8C as potential systems fabricator. 
PH (K. Bragg) visits RGH to review proposed design changes to valve. 
System #2 (first phase) implanted. 
RGH and PH conduct discussions with M8C (at Rochester). 
PH and RGH agree on valve redesign for subsequent. Dow Corning declines further participation after initial 6 subjects. 
RGH implants system #3 (first phase). 
10/80: Program meeting, M8C (Racine, WI). Attendees: RGH, M8C, PH, NASA. Subject: Design review. 
11/80: J.B. Tenney presents paper on "Urinary Sphincter Prosthesis" 
at conference on "Urinary Incontinence in the Elderly", at National Institute of Health, Bethesda, MD. PH reports valve bodies to be fabricated from polysulfone instead of titanium. RGH compiles literature review on polysulfone for PH (RGH 80-19). 
12/80: USD #6 (last device of initial in vivo tests, Phase II) implanted. 
2/81: 
5/81: 
6/81: 
7/81: 
9/81: 
PH proposes polysulfone valve body. 
First phase of animal trials (6 subjects) was completed. Overall assessment; functional performance verified, histological studies favorable to clinical trials. 
M8C and PH executives visit RGH for technical review and planning development. 
Program meeting, M8C (Racine, WT) to review silicone 
rubber components. 
Experimental protocols reviewed, updated; bench testing, in 
vivo testing, septum adjustment tests, post-implant teardown 
analyses, etc. 
Program meeting, M8C (Racine, WT). Attendees: PH, M8C, RGH. Topics: Program plans, patent status. RGH obtains Browne urodynamic measuring system. 
Program meeting, NASA-MSFC (Huntsville, AL). Attendees: RGH, PH, M8C, NASA-MSFC. Draft invention disclosure 
reviewed with NASA Patent Attorney Joseph Beumer. 
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11/81: 
1/82: 
2/82: 
4/82: 
Program meeting, MEC (Raoine, WI). Attendees: PH, l1BC, RGH. 
Topios: Design problems with PH valve bodies, teohnioal 
reviews, review of experimental protoools. 
MEC and PH evaluated and rejeoted BE-26 silioone rubber in 
favor of an MEC proprietary formulation. 
MEC visits RGH; hardware design review and review of all 
experimental protoools. 
RGH reviews NASA patent draft for ooolusive ouff 
(oase l1FS-25740). 
J.B. Tenney joins RGH for one year full-time researoh. 
5/82: Program team meeting, PH (Irvine, CA). Attendees: RGH, 
PH, MEC. Topios: Hardware, experimental protoools, 
sohedules, eto. 
Disolosed ileostomy prosthesis in monthly report #45. 
6/82: RGH develops ner~ explant protoool. 
7/82: USD #1 and USD #2 implanted. First devioes of Phase II 
trials based on improved design. 
9/82: USD #3 and #4 implanted. Devioes USD #1 and #2 explanted 
(approximately 60 days). 
Initial slide-tape paokage desoribing USD to NASA-~ISFC. 
10/82: Prosthetio devioe for oontinent ileostomy disolosed to 
Teohnology Utilization, NASA-l1SFC as spinoff from USD work. 
11/82: Planning meeting at MEC (Raoine, WI). Attendees: MEC, RGH. 
Topios: Review of experimental results, planning for 
olinioal trials. 
Updated slide-tape paokage desoribing USD surgioal prooedure 
and in vivo testing sent to NASA-l1SFC. 
12/82: Changes to Contraot Work Statement requested refleoting 
arrangements with MEC. 
RGH implants final prosthesis (USD #11) of animal trials. 
RGH transmits data files to MEC. 
1/83: Last surgioal prooedure (USD #11) oompleted. 
3/83: Last implanted prosthesis (USD #11) explanted. 
Contraot ends. 
4/83: J.B. Tenney oompletes year of full-time work. 
Animal Trial phase (surgioal) is oompleted. 
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7/83: 
9/83: 
Accelerated life tests (by MEC) stopped after 2.5 x 106 
cycles. 
Cuff redesigned to reflect RGH recommendations. 
Final recommendations closeout. N~w Technology report 
submitted. 
10/83: Patent issued to J .B. Tenney. Assignee: NASA. Prosthetic 
Occlusive Device for an Internal Passageway (2 Chamber 
Cuff). 
MEC discontinues testing after more than 500,000 cycles. 
MEC is acquired by Bristol-Myers. Name is changed to 
SURGITEK. Actively involved in planning for clinical 
trials. 
12/83: Final report completed for submission to NASA-MSFC. 
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2. PROBLEM S'J!A'J!EJMEJN'J! 
"Urinary incontinence is a distressing condition I?hich may occur from 
congenital defects, neurogenic bladder disease, stroke, multiple sclerosis, 
as well as trauma. (It may also result from disease, e.g. diabetes, or as 
a consequence of childbirth or surgical procedures such as prostatectomy, 
etc.) 'J!he consequent inability to control voiding is often a result of 
urethral sphincter malfunction. 'J!his condition generally leads to bladder 
deterioration, infections of the urinary tract and, in some cases, damage 
to the kidney. In treating patients who cannot control urinary function, 
it is important that the bladder be allowed to fill and then be emptied 
rapidly eve~y three to four hours. This periodic voiding allows the bladder 
muscles to be exercised and to remain healthy." 
This problem was identified as a serious public need by the N.A.s.A. 
Biomedical Applications Team at the Research Triangle Institute. 'J!he above 
statement was extracted from the work statement for N.A.s.A. contract 
NAS 8-32815. In treating urinary incontinence phYSicians and surgeons have 
employed numerous treatment modalities. One of the first methods employed 
in treating urinary incontinence was urethral compression. This method is 
the most commonly used approach in the treatment of neurogenic and post-
prostatectomy urinary incontinence. 
Urethral compression devices may be considered in two general 
categories: (1) Those which apply a fixed static pressure to the urethra, 
and (2) those in which the pressure may be varied within limits by the 
patient at I?ill. Urologic studies of both types of devices are readily 
found in the medical literature, such as those studies by Scott, Rosen, 
Merrill and Kaufman. Passive devices are limited in application. They 
are less likely to provide total continence under all conditions than the 
technically more complex and less reliable volitional devices. Active 
devices have been plagued by a number of mechanical and technical problems 
which, coupled with their increased complexity, have slowed their 
introduction. 
The most successful devices (American Medical Prosthesis Systems) 
solve the problem of actively compressing the urethra following implanta-
tion by using an inflatable occlusive cuff around the urethra, a reservoir, 
an inflating pumping mechanism and a deflating pumping mechanism. This 
device has recently been upgraded (AMS 791/792) to a system whiCh uses an 
inflating cuff, an active self-closure mechanism, and an active pump to open 
the system by pumping fluid from the cuff into a reservoir. Problems with 
the original device have led to the need for improvements which address 
the following concerns: device component failure, complex surgery due 
to implantation of multiple components (in the original system), and need 
for complex or specialized tools for implantation. 
The purpose of this program, "Development and Marketing of a Prosthetic 
Urinary Sphincter Control Valve System", is to use NASA-MSFC's press-to-
relieve (PT.R) valve concept with a aosign for an occluding cuff which takes 
into account the physiology and anatomy of the lOI?er urinary tract. One of 
the major problems encountered in the AMS and other systems is the lack of a 
pressure control valve. The MSFC-PTR bulb-valve addresses this problem and 
Simplifies the overall system. 
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The proposed study addresses the development and clinical evaluation 
of an improved, active urinary incontinence prosthesis. The approach to 
this problem is to build off of previous ideas and success of previous 
investigators by employing improved design fabrication techniques along 
with the manufacture of high reliability component elements. In addition, 
development of a simplified surgical procedure will be adopted. Design of 
the prosthesis will take into consideration the need for a simple operation 
without the need for special instruments and instrumentation. In addition, 
system design should incorporate management techniques to identify ways to 
locate system malfunctions in a simple way. 
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3. PROGRAM OBJECTIVES 
The objective of this project as stated in the contract, NAS 8-32815, 
is "to achieve a NASA technology transfer in the biomedical field through 
the contractor developed simple and reliable prosthetic urinary sphincter 
control system to enable urinary incontinent patients to achieve external 
voluntary control of bladder function." A teaming arrangement was estab-
lished between N.A.S.A. Technology Utilization Office, Parker Hannifin 
Corporation and Rochester General Hospital in order to desiglJ, develop, 
manufacture, assemble, test prototypes and to assess the artificial 
hydraulic sphincter in animal and human trial subjects. A three-phase 
program was established. Briefly, these phases are: Phase 1 - to design, 
develop, manufacture and test two prototypes and two life cycle systems; 
Phase 2 - manufacture of in vivo systems and implantation of in vivo 
systems with assessment of results. In addition, phase 2 objective was 
to achieve an understanding of F.D.A. requirements which would lead to 
appropriate testing and documentation ~?hich would allow subsequent F.D.A. 
approval. Phase 3 - the manufacture of clinical systems and implantation 
of clinical systems in at least 20 patients. An additional objective in 
this phase is also to assess results of the clinical implantation. 
"The technical objective is to develop an implantable device that will 
restore urinary incontinence to meet the follol?ing design guidelines as 
closely as possible: (1) Minimum surgery for implantation, (2) simplicity 
for maximum reliability, (3) adjustable urethral compression after the cuff 
is installed to avoid necrosis, (4) use of proven compatible materials, (5) 
no detrimental effect on sexual activity, (6) make different designs for 
male and female if needed to prevent compromise of either, (7) consider 
mechanical and hydraulic designs, (8) minimum compression drift, (9) 
maximum flexibility of connecting tubing, (10) manufacturability, (11) 
minimum susceptibility to blood contamination, (12) ease of assembly during 
implantation, (13) minimum cuff size, (14) minimum actuator size." 
Descriptions of each phase appear in Section 5, Program Plan, along 
with evolutionary changes in the program objectives which have occurred 
during the five year interval of this contract. Changes in objectives 
occurred due to improved knowledge of design, management, manufacturing 
teChniques, teaming arrangements with the manufacturer, Medic~l Engineering 
Corporation. 
The nature of work on this contract, the length of time involved due 
to technical difficulties with the valve -- a key element of the system --
and the inherent difficulties of establishing a firm timetable for ac-
complishing tasks which require the support and approval of such a broad 
range of advisory and administrative agencies, led to a series of modifica-
tions in the objectives for this program. 
Objectives were modified to reflect increased bench testing, additional 
design iterations, and increased in vivo testing, including time for design 
iterations reflecting in vivo test experience. The implantation of devices 
in human subjects for clinical observations requires the support of mUltiple 
participating surgeons and their supporting institutions, as well as coordi-
nation between the manufacturer and the F .D.A. These tasks -- which are 
underway at this time -- cannot be managed to a strict schedule and must 
evolve on a time scale which is inconsistent with this contract. 
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4. BACKGROUND: STATE OF THE ART 
Overview: 
During the course of this project, Rochester General Hospital has monitored the teohnical literature in order to understand the prostheses used to aohieve urinary continenoe. The magnitude of the inoontinenoe problem has led to the development of a very wide range of surgioal and non-surgioal approaohes. Both internal and external devioes have been used. The internal or implantable devioes are oonfigured in both aotive and passive forms, and the aotive devioes may be aotivated in a number of ways. Table 4-1 suggests the diversity of approaohes that have been pursued. 
In our studies we have monitored devices of all types, but primary attention in the paragraphs whioh follow will be paid to aotive, hydraulio devioes. Based on the medioal and the patent literature, we have identi-fied four distinot devioe categories. 
Giori Patent: 
A patent by Giori defines a simI.le flutter valve devioe in which fluid moves between two chambers through a s,Zi t in an elastio membrane. In order to aotivate the system, pressure is applied to the ohamber containing the fluid which is then foroed through the slit into the opposite ohamber. This approach, when used with a oonstrioting band around the bulbous urethra, oan be oonfigured into a prosthetio sphinoter. This devioe has been used in limited quantities by Dr. Maurioe Gondor at the Veterans Administration Hospital in Buffalo, New York. After a limited number of trials (results unpublished), work with this device '~as discontinued. There is no evidenoe that the Giori pat-ent has been used by other investi-gators. 
Rosen prosthesis: 
The Rosen prosthesis employs a fluid-filled balloon held in oontaot with the urethra by means of a two-pronged silicone enoapsulated wire form. The balloon may be inflated by applying pressure to an ellipsoidal pump-bulb looated in the sorotum (males) or the labia. This system has been used with some suocess in humans and is ourrently marketed by the Heyer-Schulte Corporation of Goleta, California. This system employs a very simple oheok valve whioh can be upset by manual pressure. There is no provision to monitor internal pressure within the system. Despite numerous reported suocesses, there are complioations with this devioe. These may be due primarily to its inability to adequately limit applied pressures. 
Merri12-Teague prosthesis: 
The hydraulio sphinoter developed by Drs. Merrill and Teague and 
marketed by the Heyer-Sohulte Corporation employs a flattened urethral ooclusive cuff with a pump-bulb which is similar to the Rosen device. The system appears to offer advantages relative to the Rosen prosthesis, but there is no evidence of widespread use in human clinical trials. The cuff configuration developed by Merrill and Teague bears some resemblance to 
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that employed in the AMS (Scott) prosthesis. 
Scott prosthesis: 
The urinary sphincter system which is in most widespread use is referred to as the Scott prosthesis or the A~!S system. This system was originally patented by Buuck and initial reports in the literature were made by Dr. Brantley Scott and his co-workers. This system evolved through a number of iterations, several of which occurred during the course of this study. The literature on the AMS sphincter is extensive. 
Beginning in 1972, the AMS device has gone through a series of modifi-cations. The initial prosthesis was marketed as ilS-721. The next major mOdification was the AS-761, which incorporated a pressure regulating balloon. The AS-742 eliminated the inflation valve and varied the concept so that the system was constantly pressurized so that voiding occurred only when the patient compressed a deflation valve. Each of these approaches created unique problems which appear to have been resolved with the development of the AS-791/792 artificial sphincter. This configuration, by far the simplest of all the AMS devices, employs a silicone rubber balloon, a pump, a cuff, and a metal control assembly. It represents a significant improvement over the types of devices which were available at the beginning of this program. A comprehensive description of this device is contained in "Implantation of an Artificial Sphincter for Urinary Incontinence" by F. Brantley Scott et al, Contemporary Surgery, vol. 18, February 1981. 
Evolution of the AMS device has resulted in improved reliability, increased success rates, and a SUbstantially simplified surgical procedure. 
Outlook for the future: 
This study has been primarily concerned with developing a highly reliable, safe, effective prosthesis that is readily accepted by surgeons. Concurrent with development activities on this program, the manufacturers of other devices have been moving in the same direction. Devices currently available from AMS have success rates which have been improved over those which were reported when this study began. Surgical procedures to implant commercially available prostheses have been simplified. In the broadest sense, these improvements must be applauded. 
RGH and its team members MEC and PH will continue to monitor state-of-the-art developments. The outlook in this area is for continued improve-ments in reliability, effectiveness and surgical simplicity. The ultimate success of the RGH prosthesis will depend on its ability to improve upon the performance characteristics of devices which currently exist in the marketplace. This marketplace is not static, as demonstrated by the improvements which have occurred in the AMS device. We expect that addi-tional improvements will be made in available prostheses as problems are encountered and as experience continues to build. 
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TABLE 4-1: TYPES OF PROSTHESES: URINARY INCONTINENCE 
Principle Key Investigator 
Internal Active Hydraulic Rosen 
(implantable) Merrill-Teague 
Scott 
~!echanical Swenson 
Electrical Caldwell 
Passive Fixed Berry 
Kaufman , 
Adjustable I 
(fillable) I 
( 
I External Electrical Anal , , 
I Vaginal I I , I 
I 
Compression Cunningham (male) I I Mechanical Habib (female) I 
Edwards (female) 
Velcro cuff 
Pneumatic I Bonnar (female) , I 
, 
Vincent (female) I , 
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5. PROGRAM PLAN 
The original contract work statement defined a three phase program consisting of the following phases: 
Bench Phase - Design and Test 
Animal Trials Phase (12 subjects) 
Human Clinical Trials Phase (20 subjects) 
From the onset, questions were raised by all members of the program team concerning the number of tests in both animal and human categories. 
Bench testing and design studies were successful in demonstrating a viable design which could withstand the cyclic tests required to verify long-term use. Concern for long-term compatibility of the valve body and spring (GFE) with the fluid medium (physiological saline) led to material and configurational changes which delayed completion of Phase 1. In general, considerably more test hardware was employed in Phase 1 than specified in the contract. Cyclic testing was also continued on mUltiple pre-prototype and prototype configurations, well beyond the 100,000 cycles specified. As the program team began to consider specific steps necessary to obtain F .D.A. approval, the use of a PRODUCT DEVELOPMBNT PROTOCOL (PDP) was recommended. This protocol was -- at the time of its recommendation --a teChnique proposed by F.D.A. to facilitate approval from devices such as the urinary sphincter. 
Based on recommendations by members of the design team, a change was proposed to NASA-MSFC for the development of a PDP. 
approval of this change, a PDP was developed. 
contract 
Following 
Concurrent with its development, the manufacturing member of the program team recommended against submission based upon changing F.D.A. policies. This recommendation was accepted following confirmation with F.D.A. personnel that the PDP no longer constituted a useful step in gaining needed approvals. The PDP was -- and has been -- a useful compen-dium of information concerning the prosthesis. 
Initial animal trials were performed using a device which was assembled from elements made by different organizations using different teChniques. Although the system functioned as required, it was not repres-entative of a product which could be taken to market.. It was, however, successfully employed to demonstrate performance in vivo. 
The original manufacturer (Dow Corning) of key silicone rubber parts declined to participate in the clinical development phase based on business considerations. This made it necessary to select a new manufacturer. The decision by DC to decouple from the program was not totally unexpected. From the beginning, the program team had discussed factors whiCh a parti-cipating manufacturer would have to consider. These included: 
Prolonged development cycles 
Extensive testing 
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Long approval cycles (F.D.A. approvals) 
Uncertain market acceptance 
Difficulties in meeting business criteria for return on 
investment, etc. 
All of these factors were cited by Dow Corning in their decision to dis-
continue participation. The same factors had to be faced by the incoming 
manufacturer, Medical Engineering Corporation. Encouraging results from 
the initial animal phase were a factor in their decision. 
A second animal phase was recommended by all team members. This phase 
was broadened to include 10 animals. The device for this phase was 
assembled and tested by MEC. Acceptance testing was performed at RGH 
prior to implanting devices in test subjects. 
The changing nature of program requirements and the changing composi-
tion of team members led to new recommendations for changes to the contract 
work statement. Following several months of discussions a formal recom-
mendation for a no-cost scope change was submitted. The thrust of these 
changes was to place the responsibility for clinical development in the 
hands of the manufacturer. This request was submitted formally in 
December 1982 and is repeated here in abbreviated form. 
A list of tasks (phase 3) which should be deleted or added to the work 
statement follows and was submitted to NASA for approval: 
Delete from Work Statement 
Task 16 
Task 17 
Manufacture operational units. Manufacture up to 20 
operational units for clinical trials. 
Rationale: MaC is currently moving in the direction of 
making changes to the prosthesis. This activity is the 
subject of detailed planning within MaC and they coordinate 
directly with Parker Hannifin with regard to valves. This 
is an MEC task. 
Clinical implants. Perform clinical implants. 
Rationale: The contract calls for a 20-unit clinical phase. 
In practice it may be necessary to test more than 20 units. 
In any event, however, all trials will not be conducted at a 
single institution. It is possible that several institutions 
may participate. MaC intends to coordinate these activities 
and has considerable experience in this area. Our original 
proposal assumed that surgical and medical costs for the 
clinical phase would be borne by third party insurers and 
that the cost of the prosthesis would be borne by the device 
manufacturer. This is essentially consistent with MEC's 
plans. They intend to take a leading role for this portion 
of the program. 
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Task 18 
Task 19 
Task 20 
Assessment of clinical trials. Perform objective and sub-jective assessments of results obtained from clinical 
trials. 
Rationale: As the manufacturer, USC will be required to 
evaluate, consolidate, submit and present results to the FDA. They plan to apply for approval under the pro-
visions of 510K in the second quarter of 1984. 
Presentation to FDA. Present clinical trial results to FDA. 
Rationale: This task is an USC responsibility. 
Marketing stratsgy. The proposal should indicate a 
marketing strategy for the system. 
Rationale: During the beginning phases of our contract this task seemed appropriate. In the years which have elapsed during the program, considerable market research has been done by several organizations; all have confirmed a place for a significantly improved prosthesis. We believe that USC's plan to proceed into the market with this device 
constitutes a defacto strategy. At this point, additional 
marketing strategy work is the role for the device 
manufacturer. 
Add to Contract Work Statement 
Task 16 
Task 17 
Task 18 
Support manufacture of clinical trial units. RGH will make 
specific recommendations for design changes to support 
clinical trials. During the build of clinical units RGH 
will act as a design consultant to the device manufacturer 
utilizing learning from animal studies, expertise of project personnel, and experience of surgeons familiar with the device. 
Rationale: The best role for RGH during this activity is as 
a consultant to the device manufacturer. 
Develop a data base for the device manufacturer. Transfer 
essential data on device performance, experience with animal trials, and pressure performance of the device to the device 
manufacturer. Provide support and consultation as required in evaluating this data. 
Rationale: The large body of data collected by RGH during the course of this program is key to success in reconfiguring the system for clinical trials. 
Support development of clinical trial planning. RGH will 
report on animal trial activities in a form that will be useful to potential clinical investigators. RGH will assist in the preparation of surgical protocols (males and females) 
and will assist the device manufacturer in establishing 
screening criteria for patients, participating institutions 
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Task 19 
Task 20 
and investigators. During all phases of planning for the 
aliniaal phase, RGH will aat in a aonsultative aapaaity to 
the deviae manufaaturer. 
Develop aids for aliniaal investigators. RGH will develop 
appropriate visual aids for use in training aliniaal inves-
tigators. Speaifiaally, RGH will prepare a videotape 
desaribing the prosthesis, teahniques for implanting the 
device in animals, and general reaommendations for aliniaal 
usage. RGH will aonsult to the device manufaaturer in the 
area of training requirements for alinical investigators. 
Provide on-going support to the device manufaaturer into 
the cliniaal trial phase. 
Rationale: The current l~C schedule for clinicals indiaates 
a six-month period preaeding appliaation to FDA for approval 
under 510K. In praatiae, a aonsiderably longer period aould 
be required, partiaularly if the deviae is assessed as a 
Class 3 item. For this reason r~e propose to limit RGH 
involvement to the start-up of the aliniaal phase and in no 
aase to extend beyond the end of aalendar year 1983. 
There are limited resouraes remaining on the program and for 
this reason we reaommend a finite aut-off point for the 
aontraat; one whiah is aonsistent with program objectives 
and whiah also satisfies M8C's requirements for support. 
Sinae M8C has suggested that the "landmark event ending RGH 
partiaipation will be the suacessful start of the last 
aliniaal investigator, this should occur no later than 
November 1983. After this time any assistanae required by 
M8C will be arranged on an ad hoa basis." We feel that our 
reaommendation to establish a finite end point at 12/83 is 
aonsistent with program objectives, M8C needs, the general 
spirit of the aontract and limited remaining resouraes. 
Following the submission of this request, informal approval to proaeed 
was reaeived. The contract period expired formally in March 1983 and work 
has aontinued along the lines of our reaommendations. 
The sucaessful aompletion of the second animal phase has encouraged 
the manufaaturer to proceed into the market. Tooling changes and design 
modifiaations are in progress. Conaurrently, plans are being developed for 
the formation of a cliniaal investigating team. 
In late 1983, the manufacturer was aaquired by BRISTOL-MYERS and may 
undergo some ahange as a aonsequence. They have announaed their intention 
to pursue this device into the marketplace. 
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DESCRIPTION OF THE PROSTHESIS 
During the course of this program, the approach to both design and 
manufacture of this prosthesis evolved continuously. The final design 
proposed for clinical studies is manufactured by MEC using hard tooling 
consistent with production runs in an F.DoA. approved, Class 100 olean room 
manufaoturing environment. 
Initial units liere made by the simpler teohnique of hand lay-up 
working with medical grade silicone rubber oomponents inside a Class 100 
laminar flow enclosure. Sinoe neither the oonfiguration, nor the method of 
fabrioation, for these early prototypes bears any close resemblance to the 
final design, a detailed review of this work is inappropriate. There are, 
however, several interesting lessons to be learned from reviewing the 
evolution of this prosthesis. These deal with tailoring the construotion 
and test methodologies to the maturity of the design. 
In general, early designs do not justify large expenditures for 
tooling or for test fixturing. As the design matures, however, the level 
of tooling and test equipment must continually keep pace. 
With a product or oomponent whose oharacteristics and requirements are 
well known it may be possible to move directly into a hard tooled design. 
With a new device, an evolutionary approach is more appropriate and this is 
how development proceeded on the urinary sphincter prosthesis. 
In reviewing the evolution of the prosthesis, it is necessary to con-
sider the fabrication and test methods Which were employed at each stage. 
Five major stages can be identified as follows: 
Pre-prototypes 
Prototypes 
Animal trial units - Stage 1 
Animal trial units - Stage 2 
Clinical trial units 
These units evolved through the following stages: 
Pre-prototypes: 
Made by: Rochester General Hospital 
Fabrioation techniques: Hand lay-up in Class 100 eno1osure 
Materials: Silioone rubber sheet, tubing, block. Med Grade A 
adhesive. Off the shelf oomponents. Adaptation of 
existing parts or components from off the shelf 
components or devices. 
Test equipment: Life oyo1e testing of cuff elements -- considered 
to be most oritical -- was acoomplished by adapting 
in-house respirators to oyo1e hand built units at 
specified pressure levels. Crude prototypes oould 
withstand more than 100,000 operational cycles. 
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Configurational factors: 
Cuff: The concept of a two-chambered system was introduced. 
This reflected a desire to avoid possible particulate 
contamination in the fluid contacting the PH valve. By 
isolating the cuff in two chambers, fluid could be added 
subsequently (post-operatively) through a self-sealing 
septum. 
Septum: The concept of a septum for, post-op adjustment was 
introduced. Bench tests were conducted to confirm that 
such a device could successfully withstand repeated 
penetrations by a needle. 
Fluid reservoir: Dimensions for the reservoir were established 
by considering the volume of fluid required to activate an 
expected range of cuff sizes. The initial configuration 
for the reservoir was based on subjective considerations 
relating to the expected areas of placement. Since the 
fluid reservoir interacts directly with the valve, it was 
agreed that initial responsibility for this device would 
rest with PH. RGH focus was on cuff design and septum 
design. 
Comments: During this period, RGH experimented with dipcoating forms 
over mandrels made from epolene wax, indium alloys and 
glass. In general, these approaches were difficult, time 
consuming and inconsistent with schedule pressures. The 
obvious advantage was the ability to produce doubly curved 
forms. While this work was in progress, RGH was involved 
in an active search to identify a qualified manufacturer 
of implantable prostheses who would become a co-participant 
in the study. Typical cuff configurations produoed by RGH 
during this period are shown in Figures 6-1 and 6-2. 
Prototypes: 
During these early studies, emphasis was placed on testing 
the cuff and the reservoir with the PH valve -- unavailable 
at that time -- treated as an independent component. Firms 
contacted during this period included Codman Shurtleff, 
Howmedica (Division of Pfizer Corporation), Wright-Dow 
Corning (Arlington, Tennessee), and Dow Corning (Midland, 
Michigan). Dow Corning in Midland, Michigan became inter-
ested and undertook prototype development • 
Made by: Dow Corning Corporation, Midland, Michigan 
Fabrication techniques: Hand lay-up with some pre-production soft 
tooling. This work was conducted by experienced techni-
cians with background in hand construction of biomedical 
prostheses. As a major supplier/formulator of silicone 
rubber materials for biomedical applications, Dow Corning 
was able to formulate, fabricate and join these prototype 
units with ease. During this phase, emphasis was placed 
on construction of the cuff since the initial septum 
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design by RGH Was adequate. 
Materials: Silicone rubber for cuff. Needle stops for septa were 
made from 316 stainless with recognition that titanium 
was preferable and that a subsequent switch to polysulfone 
was acceptable. 
Test equipment: Cuff testing continued on respirator equipment. Tests on fully assembled systems were not conducted during this period. 
Configurational factors: 
Cuff: Initial cuff confiqurations by Dow Corning reflected their concerns for production manufacturing and were not 
well suited for anatomical/physiological considerations. 
Septum: The septum for initial prototypes was fabricated by RGH, the needle stop was made from stainless steel, and the 
external jacket was fabricated from medical grade Silicone 
rubber. 
Valve: The valve and valve body were provided by PH. Metallic parts of the valve were made from stainless steel. The 
external jacket for the valve and the fluid reservoir bulb were fabricated from medical grade silicone rubber. 
Comments: Prototype designs were used primarily for bench testing and 
related developmental studies. 
Animal Trial Units (P!lase 2A): 
Made by: Cuffs - Dow Corning Corporation, septum elements - RGH, 
valves/fluid reservoirs - PH 
Fabrication techniques: Silicone rubber parts for the septum were fabricated by !land lay-up. Cuff elements were fabricated by hand lay-up over metallic molds. Silicone parts for the fluid reservoir. Metallic parts for the valve were 
made from both stainless steel and titanium. 
Test equipment: Cyclic testing of valve elements was performed by PH 
using production type test equipment. Cycle testing at RGH continued to employ in-house respirators. 
Configurational factors: 
Cuff: A two-chambered cuff was proposed by Dow Corning in res-ponse to sketches from RGH. Dow Corning's initial 
attempts to fabricate a cuff resulted in a device which 
was compatible with production molding, but which was too 
stiff for practical application. This device is shown in Figures 6-3 and 6-4. Following an iterative cycle, Dow Corning produced an improved cuff configuration as shown in Figures 6-5 and 6-6. 
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Valve: The valve and valve bodg developed bg PH reflected the 
change from stainless steel to titanium. The external jacket for the valve and the bulb were made from medical grade silicone rubber, 
Fluid reservoir: Fluid reservoir for the initial animal phase 
reflected the RGH design, in which the needle stop was 
made of stainless steel. 
Comments: The sgstem used for initial animal trials was assembled from components produced bg three different sources. In 
spite of numerous integration meetings, these elements used different tubing sizes and qualitg varied between each 
element. 
Animal Trial Units (Phase 2B): 
Made bg: Medical Engineering Corporation 
Fabrication teChniques: Elerents were molded on soft tooling which 
was representativ~ of production techniques. 
Materials: All elements of the sgstem were made from silicone rubber, 
medical grade, in a formulation which is proprietarg to NEC. The valve bodg was made from polgsulfone and the 
spring was fabricated from titanium. 
Test equipment: NEC emploged sophisticated test equipment (controller driven) to run keg elements of the sgstem through multiple 
cgcles around the clock. At this stage, the tgpe of test 
equipment used for the assembled sgstem is representative 
of that which would be required to satisfg F.D.A. require-
ments. 
Configurational factors: 
Cuff: ~!&C's cuff reflected considerations of manufacturabilitg, 
an improved latch design, and improved tubing leads. The NEC cuff is shown in Figure 6-7. 
Septum: The NEC septum was fabricated from the stainless steel 
with the understanding that elements for human clinicals 
would be made from polgsulfone for compatibility with PH's valve body. The septum employed in phase 2B is 
shown in Figure 6-8. 
Valve body and fluid reservoir: Fluid reservoir jacket for the 
valve body continues to be made by PH in order to provide 
control over the assembly process. This element is shown in Figure 6-9. The completely assembled system is shown in Figure 6-10. 
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Comments: The prosthesis at this stage has the appearance o£ a pro-
fessionally designed system from a single source. There 
is some evidence of hand work on cu££ elements, reelecting 
low production volumes. 
Human Clinical Trials: 
Made by: Medical Engineering Corporation; using valve supplied by PH 
Fabrication techniques: Production molding using tools which are 
compatible with production volumes. 
Materials: Proprietary formulations of medical grade silicone rubber 
Test equipment: Equipment which is compatible with F.D.A. require-
ments for cyclic testing. 
Configurational factors: 
All elements of the prosthesis will be reconfigured to reflect 
changes stemming from animal trials. In general, wherever 
possible, components will be made smaller and will reflect a 
more smoothly contoured physiological surface. 
A summary of the evolutionary process for the urinary sphincter 
prosthesis is given in Table 6-l. 
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TABLE 6-1: EVOLUTION OF URINARY SPHINCTER PROSTHESIS 
Device Fabricated by Technique Figure 
Pre-prototypes Rochester General Hospital Hand layup 6-1 
Rochester, Nel~ York 6-2 
Prototype Dow Corning Corporation Hand layup 6-3 
Animal Phase 1 Midland, Michigan 6-4 
Anirra1 Trial Units Dow Corning Corporation Soft tooling 6-5 
Phase 1 Midland, ftichigan 6-6 
Prototypes Medical Engineering Corporation Soft tooling Not 
Animal Phase 2 Racine, rvisconsin shown 
Animal Trial Units Medical Engineering Corporation Hard tooling 6-7 
Phase 2 Racine, Wisconsin 6-8 
6-9 
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FIGURE 6-1: 
TYPICAL CLOSED CONFIGURATION, 
PRE-PROTOTYPE CUFF UNDERGOING 
CYCLIC PRESSURE/FLEXURAL TEST 
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FIRST ATTEMPT BY row CORNING 
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CUFF FABRICATED BY MEC 
USING PRODUCTION TECHNIQUES, 
I MPROVED LATCH DESIGN & TUBING LEADS 
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(PHASE 2B) FABRICATED BY MEC. 
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7.10 SUPPORTING STUDIES 
J 7.10.1 TEXTURED vs SMOOTH SURFACES 7.10.2 LATCH DESIGN AND ~!ATERIALS 
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7.1 OVERVIEW 
During phase 1, the prosthesis was evaluated by a number of benen 
tests. Various tests were carried out throughout the entire program as 
needed. The purpose of bench studies was "the development and research 
of system design and performance characteristics." In addition, fabri-
cation methods were identified that led to a commercially manufactured 
component system. These studies were designed to answer and identify 
requirements for the technical objectives as stated in section 3. 
Once prototype components of the urinary sphincter system were 
fabricated, bench studies were performed to determine material per-
formance characteristics, pressure characteristics, and cyclic flexural 
tests. Requirements for system performance were determined by revic,w-
ing literature an hydraulic sphincter systems, and considerations of 
human and canine anatomy, physiology and urodynamics. Surgical con-
siderations were of the utmost importance in designing a prosthetic 
urinary sphincter system in order to meet technical objectives of: 
(1) Ease of assembly during operation 
(2) Minimum component size 
(3) Elimination of specialized tools needed for implantation 
Supporting studies were performed in order to characterize 
various materials, biological response and component performance. 
To insure the marketability of this sphincter system, early consider-
ation of F.DoA. requirements and documentation led to a six month 
extension for the development of a PDP (Product Development Protocol), 
along with an outline for recommended implant retrieval or the imp-
lanted device. 
During the course of the work on this project, all technical docu-
ments were assigned an RGH document number. Since this document list 
is extensive and covers five years of work, only a list of the docu-
ments is included in section 22. Key reports and protocols are 
included in the appendix. 
7.2 COMPONENT llND SYSTEM DESIGN CRITERIA 
llNATOMICAL 
An initial system design was identified after considering anatomy 
of the lower urinary tract for both males and females. To begin our 
study, human cadavers were examined for sizes and anatomical relation-
ships of the lower urinary tract for placement of the artificial urinary 
sphincter system (RGH 78-lA). In addition, non-functioning full scale 
models of the valve/bulb were supplied by the Parker Hannifin Corpora-
tion. These were evaluated in several human subjects to determine the 
appropriate size and shape of the valve reservoir (RGH 78-1Bj. Results 
show that the valve/bulb system should be composed of a 4 cc reservoir 
(approx.). The shape should be either spherical or ellipsoidal, with 
a valve no smaller than the original PH design. This permits manual 
identification and ease of palpation. A recommendation coming out of 
this study was that the valve button have more tactile properties by 
incorporating a spring underneath the button. 
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Concurrent with studies of human anatomy, a comprehensive liter<l-
ture search was performed. Areas pertaining to the study of urinary 
incontinence were identified as: 
(1) Physiology, etiology and urodynamics 
(2) Urinary Incontinence Society 
(3) Mechanical devices 
( 4) Surveys or reviews 
Rationale and arguments supporting the description and measure-
ments of component size appear in RGS 79-3, "Review of Component 
Dimensions of the Artificial Urinary Sphincter System." 
7.2.2 SURGICAL DESIGN CRITERIA 
Not all cases of urinary incontinence are candidates for arti-
ficial urinary sphincters. Specific guidelines for the selection of 
procedure according to type of incontinence (i.e. stress, urgency, 
precipitate, nocturnal, total or overflow) are given by Furlow (RGS 
79-10). 
Surgical procedures for implantable sphincters depend on sex, 
the location of the primary incision for cuff placement and the actual 
cuff placement. Anatomical-surgical considerations are outlined in 
RGH document 78-2, "Design Guidelines: Relationships Between Operative 
Procedure and Configuration of a Prosthetic Urinary Sphincter." This 
review reflects information gathered from current literature, anatomy 
textbooks and discussions with the project surgeon, Dr. Ronald 
RabinOI.,i tz • 
In females there is only one location for the sphincter cuff; 
encircling the urethra, either at the bladder neck or the proximal 
urethra. The female urethra is accessed by a transverse suprapubic 
incision. 
In the male the two possible locations for the placement of 
the sphincter cuff are the bladder neck and the bulbous urethra. 
Placement at the bladder neck site typically requires a suprapubic 
incision. Placement at the bulbous urethra site requires a perineal 
incision. 
To satisfy the needs of a single configuration of the artificial 
sphincter at different placement sites and compatibility with different 
operating procedures, the following characteristics were identified as 
desirable. The complete prosthetic urinary sphincter should be as-
sembled, leak checked, functionally tested and sterilized pre-opera-
tively. The preferred cuff configuration should be sufficiently 
flexible and adaptable with regard to placement such that a large 
number of different sizes or configurational variants are ~ 
required. 
Other factors considered were the complications encountered when 
placing a sphincter device around the bladder neck ~ in the male. 
Furlow states that 'vesical neck cuff placement in patients with 
incontinence resulting from total prostatectomy is in my opinion 
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contraindicated.W He further states, -the risk of vesical neck erosion 
and of rectal wall injury with subsequent fistulization is high.-
There was an additional concern for reproductive status when placing 
the cuff at the bladder neck. Also, when placing the cuff around the 
bladder neck, injury may occur to the prostate and/or nerves associated 
with erection. One advantage of placing the cuff at the bladder neck 
is to prevent mixing of seminal fluid and urine, thereby insuring 
viable sperm. 
In considering a cuff configuration which is flexible and adapt-
able, with the least number of different sizes, we established designs 
using an adjustable balloon in the urinary sphincter cuff. After 
reviewing size tables for the AMS device and the Rosen prosthesis, a 
target was set to limit the number of cuffs to three sizes. 
Considering the difficulties encountered with placement of the 
cuff at the bladder neck in males and the need for limitation in 
variant sizes, we recommend that the placement of the prosthetic 
urinary sphincter be at the bladder neck in females and the bulbous 
urethra ~ males. 
7.2.3 PHYSIOLOGICAL-URODYNAMIC DESIGN CRITERIA 
The lower urinary tract consists of the bladder which is a 
storage organ for urine, the urethra which is a conduit through which 
urine can be excreted, and the bladder musculature which develops 
pressure to expel urine. In males, the urethra doubles as a channel 
for excretion of semen. The bladder expels urine from the body by 
contracting in response to appropriate stimulation. Voluntary con-
traction of the external sphincter (urethra) prevents and terminates 
micturation. 
Continence occurs by maintaining a relaxed bladder, an internal 
sphincter (bladder neck) pressure, and an external sphincter (posterior 
urethra and pelvic floor muscle) pressure. External sphincter pressure 
must be greater than bladder pressure to maintain continence. When 
any condition exists that allows bladder pressure to be greater than 
sphincter pressure, incontinence occurs. 
Incontinence or involuntary micturation occurs if there is damage 
to nerves supplying the bladder ana urethra, or to any motor areas of 
the brain. In addition, incontinence may occur due to alteration of 
normal anatomy (i.e. in males - prostatectomy and in females -
a change in intravesical angle). 
Urodynamics is the study of micturation. By studying the voiding 
process, by measuring pressures and length of the organs of the lower 
urinary tract, one can identify the parameters of continence and void-
ing. A urodynamic procedure called the urethral pressure profile 
identifies the pressure and length of the lower urinary tract in males 
and females. In this study, the urethral pressure profile was used to 
determine the applied pressure and location of the implanted prosthetic 
urinary sphincter system. 
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Urethral pressure profile allows determination of natural external sphincter pressures. These were used as guidelines for design pres-sures of the artificial sphincter system. Distance is measured in centimeters. Determination of distance allows identification of the location of the external and artificial urinary sphincter. Length of applied pressure is an important parameter and is defined as functional length. In considering the design of the cuff in the artificial urinary sphincter, the physiological pressures associated with continence are between 40 and 80 CmH20. The anatomical length of applied pressure should be between 2-4 cm. 
A list of questions were developed to help establish requirements for the amount of pressure needed to be appJ'ed to the urethra to cause continence, but not cause tissue damage. They are: 
(1) What is the amount of pressure needed to be transmitted through the urethra from the external sphincter cuff to 
cause continence pressure, but prevent compromise of blood flow to the urethral tissue? 
(2) 
(3) 
(4) 
What is the relationship of closure length to the amount 
of pressure necessary to cause cont.inence by the artificial 
urinary sphincter? 
What is the pressure that the art~ficial cuff prototype 
exerts on the urethra? 
How do cuff surface characteristics and ingrowth material/ location on the sphincter cuff affect pressure applied to the urethra due to the buildup of capsular tissue? 
(5) What are the venous and arterial capillary pressures in the 
urethra? 
(6) What morphological changes are associated with cuff pressure 
and pressures known to cause damage to the urethra? 
(7) What is the relationship between continence damage and 
continuous and intermittent applied pressures? 
(8) How does the elasticity of the urethra relate to trans-
mitted pressure? Is elasticity important? 
The results of research follow. Normal tissue pressure in solid subcutaneous tissu~ varies from 4.1 to 9.5 amn2o. Total tissue pressure is 13.6 amn2o. In a study of subcutaneous tissue, applied pressures of 64 amn20 did not cause ischemia. In addition, we know that arterial pressure is 20.4 amn20 (mean arterial pressure 149 amnfl and that venous outflow pressure is 6.8 amn2o. Thus, we have limite the applied pressure from the sphincter cuff to less than the mean 
arterial pressure in order to prevent ischemia. 
Any ingrowth material incorporated on the surface of the cuff affects the amount of capsular tissue around the urethra, causing 
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changes in elasticity and amount of pressure that can be transmitted. Elasticity of the urethra is important. Kaufman has determined that age of the patient and the number of operations performed on the 
urethra influence the amount of erosion (inelasticity) that will occur if an artificial sphincter is placed around the urethra. 
In summary, by studying natural continence structure, function, physiology of tissue pressures, elasticity and contracture, it is possible to identify a range of pressures and lengths used in the design of the artificial urinary sphincter. Performance specifications were varied according to new information acquired from bench studies. 
7.2.4 VALVE (GFE) PLACEMENT ilND CElllRACTERISTICS 
The valve and reservoir are a part of the urinary sphincter system which is supplied by the Parker Hannifin Corporation. The location of the reservoir-valve component depends on sex. In the female, the valve/bulb will be placed in the labia or surrounding skin foldS. In the male, the valve/bulb will be placed in the scrotum. There mayor may not be a need to remove one of the testicles. 
The desired characteristics of the valve/bulb are: 
The valve/bulb should be of a small size to allow manual 
compression of the valve and of the reservoir. 
The component must be located in an area to allow ease of 
access, but prevent inadvertent operation. 
Should contain the desired volume in the reservoir and hold the desired pressure at the valve to meet system performance 
specifications. 
7.3 PROTOTYPE J)ESIGN - RATIONALE 
A comparative study of A~!S, Rosen and other hydraulic sphincter system designs and literature survey of urodynamic parameters was performed at RGH (RGB 80-8) which led to preliminary performance requirements and subsequent prototype design. In addition, a study by plante and Susset showed parameters of the urinary tract in 10 
normal female subjects. These parameters are compared to the RGH design assumptions based on anatomy, physiology, surgical considera-tions and comparison to current sphincter designs. A brief rationale for the structure and function of the artificial sphincter follows. 
The cuff is a two-balloon system which has face-to-face cuff edges. This face-to-face geometry enhances the ability of the cuff to transmit applied pressure to the urethra. This configuration causes the urethral tube to be compressed in the efficient way of flattening instead of constriction. The two-balloon structure of this cuff is 
necessary to allow system pressure adjustment post-operatively or intraoperatively. The two-balloon system prevents particle contamina-tion of the valve/bulb system. By changing the volume of the second balloon (septum), the cuff size can be changed. This enables pressure 
reduction when complications occur due to uncontrollable buildup of 
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capsular tissue, and adjustment due to growth of the incontinent patient. Literature shows that incontinence devices have been im-planted in subjects whose age ranges from 8 to 80 years. 
The shape of the cuff influences continence function, therefore the faying surfaces of the two-balloon cuff should be slightly concave at rest. This allows maximum opening of the urethra to allow voiding. The width of the cuff should be 2 to 4 cm, which approximates func-tional length of the normal external sphincter. The longer the cuff surface is the more the pressure is dissipated evenly over the urethral tissue, thus preventing compromise of the circulatory system. 
Pressure is applied via compressing the pump-bulb (reservoir) 
component. The valve/bulb permits transferral of fluid into one balloon element of the cuff, causing a change of pressure on the 
urethra from 0 to 75 amB20. The press-to-release valve is designed to maintain pressures on the urethra of 75 amB~. If pressures in the abdominal cavity or in the urethra exceed 75 amB~O, the valve auto-matically releases to allow fluid to flow back ~nto the bulb. 
Another feature of this system is the self-sealing subcutaneous septum element, which is attached to the second balloon of the cuff. Post-operative adjustment of volume in the balloon enables the surgeon to decrease pressure to allow the patient to void in the event of abnormally high pressure. 
Initial hand layed-up pre-prototypes were made for evaluation in human cadaver and canine animal models. System design evolved through careful examination of anatomical, surgical and physiological consider-ations. 
7.4 PERFORMANCE SPECIFICATIONS 
7.4.1 SYSTEM 
System design parameters were developed by the sphincter team at Rochester General Hospital. Independent component and hydraulic fluid specifications were developed in the context of a functioning system. There are currently Seven components of the urinary sphincter system. They are: the valve-reservoir, cuff, septum, tubing, capa-citor, connectors, and fill fluid. Performance specifications for each component are discussed separately. 
7.4.2 PH VALVES 
RGH recommendations for valve characteristics were based on human factors analyses, natural external sphincter pressure, general engineering practices and information from the manufacturers of the P'1!R valve (PH). The valve specification (RGH 78-3) describes perform-ance requirements for the valve. Table 7-1 lists factors considered in the specification. 
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TABLE 7-1: FACTORS CONSIDERED IN PERFORMANCE SPECIFICATION 
Fluid media 
Operating temperature 
Functional temperature 
Storage temperature 
Sterilization pressure 
Free flow pressure 
Proof pressure 
Burst pressure 
Checked flow pressure 
Checked flow proof pressure 
Checked flow burst pressure 
Flow reseat pressure 
Internal leakage 
Manual defeat 
Manual defeat input requirements 
Manual defeat safety 
Inadvertent operation 
Shelf life 
Operating longevity 
Cyclic life 
Materials construction 
Materials traceability 
Material compatibility 
Configuration 
Surface 
Design interface 
Cleanliness 
sterility 
After assembly and testing of valves, performance specifications were reviewed by members of the sphincter team on March 22, 1979. A formal valve specification for the prosthetic urinary sphincter (PH-ETP5770020, revision A) was transmitted to NASA and RGH and only primary criteria are presented here. Major changes were the material from which the valve was fabricated. Initial change to titanium from 316SS becau~e of corrosion. The final change to polysulfone and MP-35 was made due to cost and availability of titanium. 
The design of the valve was changed due to flaws identified following testing of prototypes. Flaws were manual or inadvertent operation of the valve due to its elevated position, lack of spring tension Which closed the valve, and the shape of the closure plug that allowed leakage. A pressure offset was added by adjusting the valve spring to negate suction created by the elastic bulb wall. 
The pump-bulb is an integral part of the design of the valve. Thus, function of the bulb is covered in the valve specification. Key specifications follow: The pump-bulb (reservoir) contains fluid volume to deliver 4 cc. A residual volume of the pump-bulb shall not exceed 20%. The deformed shape of the pump-bulb when empty shall be compat-ible with its physiological location in the scrotum or labia. Thus, no 
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sharp cusps or angularities are allowed. The pump-bulb shall exhibit 
sufficient elasticity and wall thickness to promote fluid return from 
the cuff balloon. The elastic properties of the pump-bulb shall be 
consistent with the intended life of 100,000 cycles*. The pump-bulb 
shall be fabricated from medical grade silicone elastomer. Suitable 
documentation is provided to allow materials traceability. 
The performance specifications detailed requirements for accept-
ance trosts, format of results, test sequence, qualification tests, 
reporting methods, verification of analysis, and the timing of summary 
reports. 
Finally, this specification included descriptions of methods for 
identification of each valve, delivery sequence, packaging teChniques, 
labeling techniques, and method of shipment of valves between team 
members. 
7.4.3 TWO-BALLOON CUFF 
The initial cuff specification (RGB 79-7) for the prosthetic 
urinary sphincter developed at RGB describes general performance re-
quirements. 
A brief description of system operation and parameters follows. 
The cuff receives fluid from the valve/pump-bulb assembly. During 
operation, the urethra is maintained in a closed position by fluid 
pressure from the cuff. The fluid is permitted to exit from the 
balloon cuff, the urethra opens to permit voiding. The cuff has two 
chambers; one connected to the valve/pump-bulb assembly (active side), 
the other connected to the self-sealing septum element (passive side). 
Each balloon element of the two-chambered cuff is the same size. Cuff 
balloon volume is approximately 2 milliliters. The cuff material is 
compatible with fluids. The cuff should be compatible with tissue 
fluids, saline, blood. 
Parts of the original cuff specification are reproduced here: 
Functional characteristics - The cuff is intended to surround 
the female urethra at the bladder neck, or to surround the male 
urethra at the distal bulbous urethra. A range of modular sizes 
will be required for compatibility with varying anatomical 
dimensions. 
A) Temperature - The cuff shall be designed to operate during 
and after the temperatures listed below. 
1) Operating temperature - The cuff shall meet the speci-
fied performance requirement between the temperatures 
of 320 C to 44oC • 
* This has been changed from the original 50,000 cycles due to estimates 
of life requirements. 
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B) 
2) 
3) 
4) 
Functional temperature - The cuff shall function but 
not necessarily meet the performance requirements speci-
fied during extended exposure to temperatures outside 
the operating temperatures; that is, 150C to 50oC. 
Storage temperature - Cuff shall meet the performance 
requirements of this specification after extended ex-
posure to temperatures of -54oC to 550 C. 
Sterilization temperature - The cuff shall meet the 
performance requirements of this specification after 
exposure to the sterilization cycle of 1100C with 
steam (and sterilization solutions including ethylene 
oxide and alcohol).** The valve, bulb pump shall be 
capable of withstanding repeated sterilization cycles 
as follows: 
High speed instrument sterilization (flash) - 30 
minutes at 13200e and 30 PSI. 
Standard gravity sterilization - 30 minutes at 
1210C and 15 PSI. 
In normal use, three sterilization cycles may be 
encountered prior to implantation. 
Operating pressure - Operating pressure is that pressure 
supplied to one chamber of the cuff by squeezing the pump 
bulb. When fluid is forced into this chamber, intracuff 
pressures shall be increased to the range of 75-85 cmH20 
with instantaneous transient pressures of up to 150 cmH20. Transient pressures in the cuff will cause the valve to 
crack and fluid will return to the pump bulb until normal 
resting pressures between 75 and 85 amH20 are experienced. 
The fit of cuff to urethra of varying. diameters is obtained 
by adding fluid to the variable volume of the cuff through 
the self-sealing septum. Fluid is added to this portion of 
the cuff intraoperatively as required to obtain proper func-
tioning of the cuff. By adjusting the fluid volume in this 
portion of the cuff, it should be possible to obtain intra-
urethral pressures of 35 cmH20 or below when the valve is 
opened and fluid can exit to the pump bulb. Operational 
characteristics of the fully assembled system are described 
in more detail in the system performance specification. 
C) Response to transient pressures - Chamber 1 of the cuff is 
connected to a valve-pump bulb system which maintains 
pressure at 75 cmH20. This system will crack when pressure 
in the cuff exceeds 85 cmH20. 
, 
** Sterilization with ETO is not recommended. Cleaning with alcohol is 
not recommended. Exposure to these materials may be encountered and should 
be tolerated with damage to the cuff. 
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To prevent the valve from cracking and to reduce fluid flow 
out of the cuff in response to short term transient pressure 
increases, chamber 2 of the cuff shall provide more compli-
ance than chamber 1. In response to increasel; in surrounding 
pressure (in the range of 75 to 85 amffzO), chamber 2 shall 
be capable of deforming slightly to alternate pressure 
transmitted to chamber 1. 
An implanted cuff may experience surrounding pressures in 
excess of 100 cmH 20 for short durations when patients cough, 
sneeze, or engage in other activities which raise intra-
abdominal pressures. Under these conditions, some 
quantities of fluid may return to the pump bulb as the valve 
cracks to relieve pressure. With the removal of the 
transient intraabdominal pressure peak, intracuff pressures 
may, over a period of time, go to levels below 75 cmH20 or below levels sufficient to provide continence. In the 
interests of simplicity and high reliability, no mechanical 
provisions to forestall this pressure decay are provided. 
Patients may be required to re-inflate the cuff by discreet 
manipUlation of the pump bulb at periodic intervals follow-
ing bouts of coughing or sneezing. 
D) External leakage - Leakage from the cuff shall be zero 
when pressurized internally to 400 amff20. Leak tests shall be performed subsequent to acceptance testing of the self-
sealing septum. 
E) 
F) 
Flow - The cuff shall be capable of flow from both the up-
stream and downstream of 60 cc per minute at a differential 
pressure of 25 amff20 or less. 
Modular sizes - The cuff shall be available in a range of 
modular sizes. Provisional size ranges are shown in the 
table below. For all prototype tests and for animal trials, 
cuff width of 1.7 am and cuff length (nominal) of 8.0 am 
shall apply. Modular size requirements for clinical trials 
are to be determined • 
Width (am) A 
1.7 
2.0 
Nominal len th (cm) B 
6.0 
9.0 
8.0 
11.0 
Life - The cuff shall operate within the limits imposed by this 
specification during and after the longevity and cyclic require-
ments herein. 
A) Storage life - The cuff shall be capable of being stored in 
a controlled environment area for at least three years. 
B) Operating longevity - The cuff shall be capable of operation 
when implanted for 50 gears, consistent with cyclic testing 
as follows. 
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C) 
D) 
Cycle life - The cycle life test will be conducted on a 
closed sgstem which will include a valve, bulb-pump and a 
customer-furnished spIlincter cuff. The valve (closed 
system) shall be capable of 80,000 cycles of operation. A 
cycle is defined as pressurization of the sphincter cuff by 
squeezing the bulb, forcing approximately 4 cc fluid to the 
sphincter cuff, then relieving the pressure to the sphincter 
cuff by manually actuating the valve flowing approximately 4 
cc of fluid into the bulb. Alternatively, the cuff and the pump-bulb sgstem may be tested independently if (a) the joint which will be part of the system is also tested, and (b) this approach to testing is acceptable when presented to the F.D.A. in a Product Development Protocol (PDP). 
Environmental conditions - The cuff shall perform satis-factorily under the conditions expected to exist during the time of operation and be able to withstand, without damage 
or performance degradation, all environment conditions ex-pected to be encountered during test, storage, shipment, handling and normal operation in the body. 
Design and construction 
A) 
B) 
Configuration - With the exception of the balloon portions 
of the cuff, the cuff shall be fabricated from medical grade 
silicone rubber of low hardness to minimize erosion. The 
cuff should be molded in a circular or oval shape when at 
rest so that it will close normally after placement. The internal surface of the cuff will not require ingrowth 
material, but the outside surface or band of the cuff shall have provisions for suitable ingrowth material. 
Dimensions - The dimensions of the cuff shall be modular as 
shown below. Tubing connections to the valve-pump bulb 
assembly shall be Dow Corning 601-325. 
Inches 
mm 
ID OD 
0.104 
2.64 
0.192 
4.88 
C) proof pressure - The cuff shall meet the requirements of this specification after undergoing a proof pressure of 300 amHp (4.268 PSI) applied to (1) chamber 1, (2) chamber 2, and (3) both chambers simultaneously. 
D) Burst pressure - The valve-bulb pump shall withstand a burst pressure of 600 amH~ (8.538 PSI) without rup'ture. Burst pressures shall be applied using conditions described in C. 
E) Assembly bonding, molding and curing - All molding shall be performed using mold release agents which have been pre-
viously approved for implantable devices. 
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F) 
G) 
H) 
Adhesive bonding and curing methods and processes sball be 
suitably documented in process sbeets and sball be performed 
with sufficient inspection steps to insure process control 
~d process repeatability. 
i'be use of particulate powders (e.g. talc, cornstarcb, 
sodium bicarbonate, etc.) sball be avoided. 
Fluid compatibility - Tbe cuff sball be compatible with the 
following fluids: 
De-ionized and distilled l?ater 
MrL-P-2740lB nitrogen 
Isotonic saline solution 
Isotonic lactate ringers solution witb or witbout an 
isotonic radiograpbically opaque dye (e.g. Hypaque 25%) 
Human blood 
Lympbatic fluid or any other fluid that may be encoun-
tered wben being surgically implanted 
Actuation - Tbe cuff shall be capable wben secured of 
transmitting a pressure 75 + 10 cmff20 
- 0 cmff10 to the urethra. 
Pressurization sball occur by transfer of fluid from tbe 
pump bulb to cbamber 1 of the cuff. Transient overpressures 
sIlall result in fluid bleedback to the pump bulb. Resting 
pressure of the cuff with the bulb deflated sball be in the 
range 15-30 cmff20. 
Tbe fit of the surrounding cuff sball be adjusted intra-
operatively by tbe injection of suitable fluid into cbamber 
2 of the cuff. Intraoperative pressure measurements are 
required to verify tbis pressure and tbe pump bulb sbould be 
squeezed to insure fluid transfer into cbamber 1. Full 
functioning of eacb installed device should be verified 
intraoperatively. 
Tbe cuff sball be configured to fail Rsafe" (e.g. cuff 
failure does not result in pressure on the urethra). 
In the event of inadvertent malfunction of any element of 
the system, the cuff design sball permit deflation by a 
surgeon without laparotomy. 
Chamber volumes - Cuff cbamber 1 shall pressurize wben 
receiving 2.5 cc of fluid. The pump bulb sball contain 
fluid volume sufficient to deliver 4.0 + 0.0 cc 
when the cuff is palpated normally. 
the pressurized chamber 2 sball be: 
Width (am)/Length (am) 6.0 8.0 
1.7 TBD TBD 
2.0 X X 
7-13 
0.5 cc of fluid 
Tbe nominal volume of 
9.0 11.0 
X X 
TBD TBD 
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Materials and construction - The manufacturer shall provide 
information to Rochester General Hospital at the time of proposal 
as to the design of the proposed valve, the materials used, and 
the construction technique. 
Pressure parameters were determined: displacement of approxi-
mately 1 cc of fluid should cause pressures in the cuff balloon to 
change from 0 to 100 cmH;P. Cuff design should incorporate a 1:1 
pressure transmittance even in varying states of tissue elasticity of 
the urethra. Since tissue pressure is approximately 13 cmH;P, an 
applied pressure of 80 cmH~O should cause urethral closure and prevent 
passage of urine. An appl~ed pressure of approximately 80 cmH:p and a 
cuff width of 2 em insures that the applied pressure is dissipated over 
a large amount of tissue. 
An important aspect of the two-balloon cuff is the latch. The 
cuff latch should provide a simple, highly reliable mechanism to close 
the two balloons around the urethra. The purpose of a simplified 
latah is to: 
(1) Eliminate the requirement for sutures 
(2) Eliminate the need for speoial tools or instruments to aid 
in closing and seouring the cuff 
(3) Reduoe the time and complexity of the operative prooedure 
Desirable attributes of a latch mechanism include high reliabi-
lity, ease of closure, and low oost. 
Potential oandidates include meohanioal latches, wireform 
latches, elastio toggles, snaps, velcro tabs, imbedded magnets and 
sutures. Sutures have been successfully used in other systems (AMS), 
but are not preferred due to the ability of the suture to tear through 
silioone material. 
Finally, in an effort to determine performanoe specifications of 
the RGH urinary sphincter cuff, a oomparative study (RGH 80-12) of 
pressure volume characteristics of the In Vivo Metric cuff (nictating) 
was performed. Understanding the operation of this cuff enabled us to 
further develop our design. 
7.4.4 SEPTU~I ELEMENT 
The self-sealing septum was designed to be implanted subcu-
taneously to provide intraoperative and post-operative access. This 
allows adjustment of system pressure and size of the implanted sphinc-
ter cuff. The prototype (RGH) septum ,,,as fabricated from medical grade 
silicone elastomer (silasticf<) sheets, adilesive and tubing. A metal 
needlestop was made of 3/16 SS (POOS needlestop). All materials and 
assembly procedures met similar performance requirements required by 
other components of the system. The septa were assembled in a class 
100 laminar flow hood (GFE). All silicone adhesives were allowed at 
least a 48 hour cure. Following a two week curing period, the septa 
were ready for system assembly. Dacron velour ingrowth material used 
on the outside perimeter of the septa was clean and obtained directly 
from the manufacturer. 
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The self-sealing septum will be able to withstand at least 20 
penetrations with a 25 gauge septum point or regular cutting needle. 
During testing of silicone, sheet laminates which were used in con-
struction of the septa. 
Basic information about performance characteristics of the se1f-
sealing septum was initially derived from experience with septa used 
in gas chromatography. Septum point needles (perfektwrP) were recom-
mended for use in the self-sealing septum. 
Septum s],lecifications for phase 2B animal trials were developed 
from initial experience with theRGH self-sealing septum (Septum Pene-
tration Acceptan"e Tests, RGH 80-10) and those from the MEC se1f-
sealing septum. k'urther experience following phase 2B animal trials 
has led to fabricat;ion of a smaller size septum for use in clinical 
trials. 
7.4.5 TUBING/CONNECTORS/INTRADEVICE HYDRAULIC FLUID 
Tubing functions as a conduit that carries fluid between each 
component of the artificial urinary sphincter. Tubing is a crucial 
component and has been identified as a major area of failure in the 
AMS 762 urinary sphincter system. Tubing that was too long led to 
entanglement of itself and organs. Migration and rotation of system 
elements can occur if the tubing is too long. During closure of the 
surgical wound, cuts can be placed in the tubing which cause subsequent 
failure due to leakage. Rotation of system elements occurs when there 
is torque placed on system tubing during connection. 
Kinked tubing was a cause of failure in the AMS urinary sphincter 
system. Kinked tubing prevents movement of hydraulic fluid between 
components, thus subsequent failure of the urinary sphincter system. 
Kinking can be prevented by having the appropr.iate wall thickness to 
tubing diameter ratio. Tubing for all prototypes, animal trial and 
human systems, of a diameter of 0.104 ID x 0.192 OD (inches) was 
recommended. Availabilitg of other silicone tubing for prototype parts 
led to a mismatch of tubing. The second generation MEC-fabricated de-
vice used .062 ID x .0125 OD inch tubing. 
Tubing for implanted systems should be pre-cut in order to fit the 
size of the individual. The system was supplied with approximately 15 
cm of tubing at each component. Tubing connections should be made at 
the component and not at the mid-point of the tubing. This prevents 
inadvertent disconnection, allows ease of sizing and connection when 
implanting the system. Tubing was connected midway between components 
during animal trials. 
Consideration was given to the incorporation of radiopaque 
material onto or in the silicone elastomer. This would aid in post-
operative identification of system elements and prevent surgical 
intervention in order to identify malfunctioning components. This 
concept was discarded due to cost of adding opaquing material to the 
silicone elastomer, and changes in properties of the silicone elastomer. 
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Comlectors should be of a material that has adequate strength to 
prevent breaking and display corrosion resistance to biological fluids. 
Various connectors and design concepts were evaluated for use in the 
urinary sphincter system. Plastic and metal connectors used with the 
Rosen sphincter system were initially supplied by Heyer-Schulte. Use of 
plastic connectors was discontinued by Heyer-Schulte when they started 
breaking in half during use. In the Rosen system, Heyer-Schulte con-
nectors made of stainless steel and titanium were used for animal trial 
studies. A series of drawings elucidating various failsafe designs of 
connectors was developed by Brooks Tenney. These designs proved to be 
complex. Simple design of the Heyer-Schulte connector proved 
adequate. 
The hydraulic fill fluid used in the urinary sphincter system was 
a non-reactive, phYSiologic, particle-free saline. Various concentra-
tions of radiopaque material was added to this fluid until a concen-
tration of 2.4% Conray was identified to give adequate images upon x-
ray. Fill fluid should have osmOlality si.milar to serum. Physiologic 
sodium chloride (I.V. Travenol) with the addition of 2.4% Conray has a 
value of 400 mOsm, which is similar to normal serum which is approxi-
mately 300 mOsm. 
A potential problem is Ilgpersensitivity to the radiopaque com-
ponent of the fill fluid. There should be no tissue reaction (i.e. 
reactivity to radiopaque material) upon leakage. The fill fluid 
should be low enough viscosity to allow transmittance of pressure 
through narrow diameter openings of the tubing, valve and cuff. 
Studies to determine migration of components into and out of the 
hydraulic fill fluid were performed by analyzing the fill fluid follo~r­
ing implantation. This was to insure stability of fluid following 
implantation. Twenty separate analyses measuring electrolytes, 
triglycerides and other biologic components showed only a small change 
in movement of hydrogen ions and chloride ions. 
7.5 VENDOR SELECTION CRITERIA 
One of the primary goals of this contract was to manufacture and 
market the prosthetic urinary sphincter system. Since RGH has neither 
the ability or the desire to manufacture or market the prosthetic 
urinary sphincter, the decision was made at the beginning of the con-
tract to identify, make contact and involve potential manufacturers. 
A general outline for selection criteria for manufacturers for the 
urinary sphincter system was developed (RGH 78-2). The report presents 
subjective criteria that have been established to assist the process of 
screening and selecting a manufacturer for the urinary sphincter pros-
thesis. Criteria have been established without regard to order or 
relative weight. The list of 12 criteria appears in Table 7-2. 
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TABLE 7-2: VENDOR SELECTION CRITERIA 
1. Proven manufacturing capability for implantable prosthetic devices fabricated from medical grade silicone rubber. Candidate should cur-rently be manufacturing a silicone prosthesis. 
2. Proven marketing experience with prosthetic implant devices. Candi-dates should have primary marketing experience, should have an extended marketing sales and distribution net. 
3. Currently manufacturing one or more urological products, preferably should handle a line of urological products. 
4. TOp level management support invisibility. Urinary sphincter project should be clearly understood by top management and all of its ramifi-cations. The characteristics of the proposed device, its purpose and its expected timing for market introduction should be clearly under-stood at the top. 
5. Experience in requesting and obtaining F.D.A. approval for class 3 devices under Medical Device Amendment of 1976. The candidate should have successfully steered at least one new product through this process. 
6. Express willingness and ability to absorb the "front end" costs 
associated with new product development and, in particular, with devices of this type. 
7. Ability and willingness to pursue and exploit any potential patents which may arise from the joint development of this device. 
8. Experience in the cost effective development of a new implantable device through the timely use of an F.D.A Product Development Protocol (PDP). (This protocol permits development of a device and the collection of information necessary to develop the safety and effectiveness to evolve simultaneously.) 
9. Willingness to negotiate working arrangements with other organizations (e.g. Roahester General Hospital, NASA, Parker Hannifin) pursuant to the development and marketing of this device. 
10. Short run fabrication capability. Candidates should have and should be willing to make available, short run fabrication and development capability ~"hiah can be used in the development of the prototype devices in the development of alternative teChniques for final 
assembly and in the evaluation of alternative approaches to modular sizing or configurational alternatives. 
11. Proven reputation as a supplier of class 3 medical devices. The preferred candidate should be an established name readily recognized by medical, surgical and health care practitioners. 
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12. Proven ability to develop promotional software assoaiated with timely 
new produat introduation of deviaes of this type (ina1udes, but not 
limited to, experienae with film development, reprints, mediaa1 pub-
1iaations, data sheets, aonferenae partiaipation, and a gamut of 
advertising (ethiaa1) and promotional aativities appropriate to this 
deviae). 
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As of 9/76, 28 potential manufacturers were identified. All 
potential manufacturers were producers of medical products ranging 
from catheters, electronic devices, sutures, silicone elastomers, I.V. 
products, ostomy products, artificial organs, and artificial incon-
tinence devices for urinary sphincter. 
Two companies were selected from the list and contacts estab-
lished. These companies were Bowmedica (Division of Pfizer Company) 
and Wright-Dow Corning (subsidiary of Dow Corning Corporation). Talks 
with Bowmedica led to their interest in the project, but they showed 
lack of interest as a business venture. Talks with Robert Rylee and 
Frank Lewis of the Wright-Dow Corning Corporation in Arlington, 
Tennessee proved to be successful. Initial arrangements with Wright-
Dow Corning Corporation led to teaming with the Medical Products 
Division of the Dow Corning Corporation in Midland, Michigan. Work 
with Medical Products Division led to the fabrication of prototype 
cuff which was used in phase 2A of the animal trials. Subsequently, 
following the phase 2A animal trials, Dow Corning decided to drop out 
of the project due to business reasons. At this point, MEC was con-
tacted and teaming arrangements were made. Arrangements ~,ere made 
primarily between PH and MEC, with RGB as program coordinator. 
7.6 MARKET RESEtlRCB 
Discussion at RGB in 1978 and 1979 focused on the concern that 
the mUltiple etiologies of urinary incontinence might make demand 
forecasting for a prosthetic device more d.ifficult than forecasting 
the need for a prosthetic device with a more well-defined cause (e.g. 
mammary prosthesis, colostomy sphincter). 
It t~as apparent from the beginning ot: the program that a pros-
thesis manufacturer would need to develop some estimate of market 
size. Such a study requires an understanding of such factors as total 
market size, number of competitors, quality of competitors, qua1ity of 
competitive offerings, expected degree of market penetration, and time 
requirements for completion of clinical trials and F.D.A. approval. 
Based on initial discussions of these factors at RGH, the NASA, 
TU office in Washington, DC initiated a market research activity with 
the Technology Transfer and Market Research Section of the Illinois 
Institute of Technology Research Institute. The work led to the 
development of a report, nMarket Analysis of the Prosthetic Urinary 
Sphincter", IITRI project UB6046C58 (Contract NASA 2837). 
This study took into consideration the presence of existing 
devices currently in the marketplace (Scott prosthesis (AMS), Rosen 
prosthesis (Beyer-Schulte)), and the possible impact of other devices 
such as the Swenson prosthesis or electrical stimulation devices. 
Their report concluded with an estimate of approximately 275 
units (sales volume) during the initial five years of a clinical trial 
phase, with an increase to 650 units annually for five years following 
clinical trials. While all estimates and assumptions in a study of 
this nature are open to question and discussion, such information is 
helpful to business planners in marketing investment decisions. 
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Unfortunately these estimates of market size, coupled with a relatively long payback, proved to be of insufficient interest to Dow Corning, who ultimately elected not to pursue the development of this prosthesis. 
'l'his report shows there is a significant need for the artificial urinary sphincter and potential annual sales for the hydraulic sphincter prosthesis being developed at RGH for the first 10 years to be approximately 1,000 units. Since the establishment of MBC as the manufacturer and marketing agent for the prosthetic urinary sphincter, marketing and market research responsibilities are delegated to MBC. MBC is a proven manufacturer and markets mammary prostheses, penile prostheses and other urological devices. 
Market data indicates that device manufacturers may need patent protection to maintain an edge in this costly arena. 
7. 7 BIOMA'l'ERIAL SBLEC'l'ION AlW SPECIFICA'l'IONS 
7.7.1 LI'l'ERA'l'URE REVIEW 
In order to develop a better urinary sphincter device, a complete assessment of all materials used in biomedical devices was performed by reviewing the current literature. A list of biomaterials used in soft tissue, blood, electrical and dental applications in the human body was developed. In surveying the literature, many potential biomaterials were identified. 
7.7.2 SILICONE ELAS'l'OMERS 
Silicone elastomer material is currently being used by manufac-turers of prosthetic sphincters in associated devices, together with various "ingrowth" materials, such as dacron velour. Evaluating various materials allowed the RGH team to determine whether any mate-rial other than silicone elastomer had potential for improving the operation and biocompatibility of the artificial sphincter prosthesis, "Surface and Material Characteristics of the RGH/N~ Artificial Urinary Sphincter" (RGH 79-4). We conclude that silicone elastomers are well suited for this application. 
7.7.3 SURFACE CHARAC'l'ERIS'l'ICS 
An ideal implant would have a surface structure that would allow the organism to attach normal tissue to the implant at a molecular level. 'l'he chemistry of the surface would allow bonding, which leads to formation of a normal collagen matrix. Currently, there is no such material available, although commercially available ingrowth materials are well suited for use where fixation is required. 
'l'ISSUE 'l'OL~CE CONCEP'l'S 
Factors which must be considered when evaluating materials and surfaces include: 
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surface reaction 
thickness of capsule 
capsular blood flow after ingrowth 
infection 
degradation of polymer material 
After considering various materials such as teflon, dacron, PTFE, nylon, polyurethane and silastic, it was recommended that the silicone elastomer (silastiCR) be the material of choice. It exhibit,g proven biocompatibility and high tensile strength which was desirable for a long term implantation with a moving devi,!e. 
Potential problems associated with ,~,e USd of silicone elastomer were permeability and the absorption of blolo~ical components (such as lipids) through a thin membrane. Adsorpt:..:c .. ' of these biological com-ponents was shown to change the mater-ial ·",hysical and chemical properties. This is undesirable. 
To evaluate the potential problem of ~?sorbable lipids on or into silicone elastomer, a study was initiated (RGH 79-12), We determined that in 1964 the problem of absorption of lipidS and subsequent alter-ation of properties of silicone heart valves led to the development and formulation of silicone elastomer material in which either lipidS were not absorbed or absorption did not affect performance of the material. We determined that our concern was unnecessary. 
7.7.5 PH VALVE/BULB MATERIAL 
Valve - Prototype valves were made with sta1nless steel bodies, stainless steel springs, a sapphire ball and silicone elastomer diaphragm and casings. For specific details, please consult Valve Performance Specification. In phase 2, the valve was redesigned and used a flat disk instead of a sapphire ball to close the opening. The disk is made out of polysulfone, which rests on a silicone diaphragm. The valve body is made of polysulfone, the button is made of polysulfone, and springs are made or MP-35 alloy. 
Berore implementing material changes, RGH performed a literature review of engineering grade polysulfone (Udel polysulfone, PI700-MGll). Chemistry, physical properties and biocompatibility were reviewed (RGH 80-19). Experiments with polysulfone (valve at RGH) showed that this material could withstand standard autoclave sterilization. The 
use of polysulfone for valve components significantly decreased the cost of the valve and eliminated problems with availability of the titanium. 
Bulb - The bulb (reserv~ir) of the valve/bulb body is made or silicone elastomer. 
7.7.6 CUFF MATERIAL 
The urinary sphincter cuff was fabricated with various types of silicone elastomer. Pre-prototype and prototype cuffs were fabricated from silas tic stock sheeting, regular grade (500 series). The Dow Corning cuff, phase 2A animal trials, was fabricated using Dow Corning 
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MDF-008l elastomer silasticJl medical grade silicone tubing (BP), silastic medical grade rod, silastic medical adhesive type A. All 
materials are commercially available from the Dow Corning Corporation, except MDF-0081. Other silastic medical grade elastomers that were used are listed below: 
Q7-2178 medical grade elastomer Q7-2245 medical grade elastomer - dispersion 
Silicone sheeting was used for fabrication of the septa (500 series). 
For phase 2B animal trials, silicone elastomer that was used is listed as follows: 
MEC formulation 501 
RTV adhesive 508 
MEC 522 
Finally, ingrowth material which was used on the cuff element for phase 2A animal trials consisted of dacron velour from Medox. During the second phase 2B animal trials, velour ingrowth material was re-
moved from the urinary sphincter prosthesis. 
7.7.7 IMPLANT RETRIEVAL AND ANALYSIS 
Key factors for implant retrieval and analysis were identified to assess changes in materials of the explanted urinary sph:UlOter system. The assessment of material characteristics may allow pre-2iction of failure modes of silicone elastomer components, corrosion and material degradation which could lead to device failure or tissue toxicity. Methods for implant retrieval and analysis for devices used in animal trials are described in sections 8.12, 12 and the protocol appears in Appendix E. 
The RGB sphincter team recommends implant retrieval and analysis to identify changes in physical and Chemical properties of biomate-rials used in this device (RGB 80-21, -Recommendations for Post-Implant Retrieval and Analysis of Sphincter Systems in Human Clinical Trials n ). 
The amount of effort invested into implant retrieval and material analysis depends on current F.D.A. requirements and cost effectiveness as determined by the system fabricator. 
7.8 FABRICATION METHODS 
The goal of the project was to develop and fabricate a urinary sphincter system that could be mass produced using state-of-the-art 
molding and production teChniques. In order to insure this develop-
ment, a morphological approach using standard components was developed • 
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7.8.1 PRE-PRODUCTION 
Initial pre-prototype systems developed at RGH used a hand-layed up teohnique which oombined silioone sheets, adhesive and dipooating. These were used to develop system design. 
MOlding teohniques around aluminum mandrels were used to fabri-cate the Dow Corning ouff. A oylindrioal aluminum rod was cut to shape. In the center of the rod a wedge was cut. At the top and bottom edges of the wedge, at the oiroular portion of the rod there were sharp edges used to cut excess silioone material away from the cuff. The center of this mandrel was hollow, with holes that allowed a vacuum to be applied to the inner silicone sheeting. This caused the silioone sheeting to oollapse onto the inner surfaoe of the wedge. Another silicone sheet was then wrapped around the body of the oylinder and the silicone elastomer was cured. This formed the two-balloon aspeot of the ouff element. Holes were then cut into eaoh of these balloons where tubing was attached. The cuff was cheoked for leaks and any holes repaired. This procedure oould produoe a fair number 
of cuffs, approximately three to five per day. 
During the development of a prosthetio urinary sphincter, pre-prototypes and prototypes were fabricated using pre-produotion methods of hand layup and dipcoating. Examples of prostheses produoed by these teohniques can be seen in Figures 6-1 through 6-4. 
7.8.2 PRODUCTION 
For the cost effeotive produotion of urinary sphinoter prostheses, MEC has developed molding teohniques and molds to produce oomplex 
shapes required for the urinary sphincter prosthesis for both phase 2B animal trials and human olinical trials. These molds are cost in-tensive, but allow for mass produotion of sphinoter components. An example of a cuff produoed by these methods is sho<.n in Figure 6-7. Details on produotion molding teohniques are available from NEC. 
7.9 SYSTEM QUALIFICATION AND ACCEPTANCE TESTS 
Qualifioation and aooeptanoe tests were established to insure that performanoe requirements were met during every phase of pre-prototype, prototype and human olinical device development. Initially, qualifioation and aooeptanoe tests were performed by RGH on the cuff and septum elements. PH performed qualifioation and accept-anoe tests on the valve/bulb units. They oontinue to do so. 
7.9.1 FABRICATION AND MATERIALS VERIFICATION 
Qualifioation and acceptance tests verified the quality of fabri-oation and purity of materials, along with guaranteeing traoeability by maintaining appropriate documentation. Thes,~ procedures were developed in aocordanoe with standard engineering praotices. PH had the res-ponsibility of developing qualifioation, aooeptanoe test prooedures and parameters for the valve/bulb system element (PH 92003). RGH developed an aooeptanoe test for the PH valve/bulb whioh included examination of the produat, oheok of dooumentation, oleanliness, ability to be steri-
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lized at standard autoclave temperatures and pressures, hydraulic 
functional tests that included cyclic pressure tests up to 100 cycles 
at pressures of 60 cmH20. A proof pressure test was performed to a 
pressure of 300 cmH 20 for one minute and subsequent leakage was 
determined. 
Qualification and acceptance tests continued at RGH through phase 
2A animal trials which used the Dow Corning cuff, RGH septa and PH 
valve. Pre- and post-acceptance test data sheets were developed. Ten 
valves l~ere sent to RGH for use and evaluation, for use during proto-
type testing and phase 2A animal trials. Of these 10 valves, two 
failed; one because of non-functioning valve (no seal) and one because 
of internal leakage. MEC performed qualification tests on systems 
fabricated for phase 2B animal trials. RGH continued to perform 
acceptance tests. 
7.9.2 QUALIFICATION AND LIFE CYCLE TESTS 
Life cycle tests were performed on individual components of the 
pre-prototype and prototype device (phase 2A). Life cycle tests on 
valves were performed at PH. 
The artificial urinary sphincter may be implanted in subjects 
for a maximum period of up to 80 years. Assuming that the device will 
be cycled at least 6 times a day, 365 days a year for 80 years, the 
device must tdthstand at least 175,200 cycles. Assuming that the 
average length of implantation would be 40 years, we chose a cycle 
test length of 100,000 cycles for the prototypes. Quality provisions 
as stated in cuff specifications appear in Table 7-3. 
Results: 
The pre-prototype fabricated at RGH underwent a total of 104,160 
cycles, with an operating pressure of greater than 100 cmH20. This 
was determined to be the maximum pressure delivered to the cuff by 
squeezing the bulb unit. Results of cyclic pressure testing of the 
pre-prototype cuffs appear in RGH 79-9. Set-up is shown in Figure 7-1. 
Qualification and life ~1cle tests for the Dow Corning prototgpe 
EEE!. appear in RGH 79-9. Vi~ual exam was performed. Fabrication 
quality and material integrity were checked. Volume was determined to 
be approximately 1.8 cc for each balloon cuff, and associated changes 
in the dimensions of the cuff were recorded as a function of varying 
pressures. The cuff was inspected for changes in material properties 
(i.e. stretch) and leakage after applying a pressure of 680 cmH20. These prototype cuffs were cycled in excess of 128,000 cycles, with 
pressures ranging from 0 to 1.~0 cmH :p. Four of the seven prototype 
cuffs that were received for q~alif2cation and cyclic testing were 
implanted. In addition, they wei:e used for in vivo studies of pressure 
in the canine model. These tests showed that the cuff functioned as 
designed and caused pressure to be transmitted to the urethra on a 1:1 
ratio (RGH 80-13). The final 12 animal trial cuffs were received from 
DC and underwent similar evaluation. 
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TABLE 7-3: QUALITY PROVISIONS - CUFF SPECIFICATION (RGH 79-5) 
Quality Provisions 
The quality of the cuff shall be ascertained through the following tests: (1) qualification tests, ,'2) sample, and (3) acceptance tests. 
1) Qualification tests - Qualification testing Shall be con-ducted by the manufacturer to assure that the cuff is 
capable of meeting the performance requirements defined by (a) testing and (b) analysis or inspection. 
A) Selection of test specimens - Two cuffs shall be sub-jected to the tests specified herein. These cuffs 
shall be selected from the first lot of cuffs manu-factured and shall be representative of production hardware. 
B) Notification of testing - The manufacturer shall 
notify Rochester General Hospital representatives 
within five working days prior to the initiation of qualification testing. 
C) Test sequence - The qualification cuffs shall be sub-jected to and pass the following tests in the sequence 
specified herein. 
Qualification test sequence 
Sterilization - cycle 1 
Sterilization - cycle 2 
Penetration test self-sealing septum 
Acceptance test - cuff 
Storage temperature 
Cycle test 20,000 cycles 
cycle test 40,000 cycles 
Cycle test 60,000 cycles 
Cycle test 80,000 cycles 
Burst pressure 
Cyaletest (continue at option of manufacturer) 
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Septum qualification, life cycle and acceptance tests: In order 
to simulate the environment of the sphincter cuff, silicone sheeting 
laminate was constructed and placed into the outlet of a saline I.V. 
bag. Pressure on the bag was elevated to 300 cmH20. 
In addition, commercially available silicone gas chromatography 
septa were evaluated. The purpose of the test was to determine the 
number of repetitive penetrations which can be tolerated by commer-
cially available septa without leakage. Various factors to be con-
sidered are: 
the type of the septum 
needle size and type 
magnitude of fluid pressure behind the pressurized septum 
Tests were carried out against back pressures of 102, 204 and 408 
cmH20, respectively. Four needle gauges; Stylex regular medical grade point needles 18, 20, 22 and 25 gauge were used. A needle was placed 
on a syringe and the system was punctured repeatedly. 
The results (RGH 80-10) sho,~ that the septa can withstand 60 
penetrations using a septum point needle and 50 penetrations from a 
regular medical grade point needle. The results of this test show it 
is advantageous to use a septum point needle. 
A similar report by the John Hopkins Applied Physics Laboratory 
(RGH 80-9) shows a septum integrity testing report using 0.062 inch 
thick non-reinforced medical grade silastic sheeting (same thickness 
used in the RGH septum). Recommendations from the report similar to 
those identified at RGH are: 
The septum should be punctured smoothly and perpendicular 
to the plane of the septum. 
The needle should not be moved while in the septum. 
Use a sharp pointed needle, withdraw needle only when 
pressure is zero in the system, since higher pressures 
cause leakage from the system. 
Back pressure on the septum material enhances sealing 
because it forces the material to close together. 
Summary - qualification and life cycle tests: 
RGH was responsible for septum qualification and acceptance tests 
during pre-prototype, prototype and phase 2A animal trials. 
During phase 2B animal trials, ~C assumed fabrication, qualifi-
cation, acceptance and life cycle testing responsibilities for septa. 
MEC has similar experience using a self-sealing septum developed for 
mammary prostheses which they manufacture and market. 
For the phase 2B animal trials and for human clinical trials, 
qualification tests and life cycle tests are the responsibility of the 
system manufacturer. PH is responsible for the valve/bulb unit and MEC 
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is responsible for all silicone components of the sphincter system. 
Recommended bench test protocols (RGH 81-4) were forwarded to MEC. Currently, life cycle tests of the system fabricated by MEC have under-gone in excess of 2,000,000 cycles to date. This greatly exceeds the life cycles necessary for a functioning implant. 
7.9.3 BURST-PRESSURE TESTS 
Burst pressure tests were performed to simulate possible high pressure due to falling or striking of the urinary sphincter system inadvertently by the patient. During cyclic test procedures, con-sideration of pressure spikes were evaluated. Pressure spikes have been shown to reach 160 cm, with a time base of approximately 0.2 seconds. We determined that loss of pressure could be eliminated by constant manual compression of the bulb unit. Any method of system design to prevent the bleeding back of fluid from these transient pressure spikes was eliminated from consideration. A burst pressure test was performed by elevating intradevice pressure to 600 cmH20 and holding for one minute. This is in accordance with performance speci-fication 3.4.4 (RGH 79-7). The component was checked for leakage following this procedure. During the cyclic test procedure, six proto-type cuffs were placed under maximum pressure of 530 cmH20 in order to see if the system would burst. None of the systems failed. Results appear with life cycle tests. 
ACCEPTANCE TESTS 
RGH established acceptance protocols and data sheets based 
on criteria shown in Table 7-4 (Section 5.2, RGH 79-5). 
Summary - Acceptance procedures were performed for pre-prototypes, prototypes (phase 2A and 2B). Recommendations for human clinical trials device acceptance tests (RGH 80-4) have been forwarded to MEC. Table 7-5 shows a representative 
acceptance test data sheet from Phase 2B animal trials. 
7-27 
. .... 
~', 
I, 
,I 
r t 
Ii ,. 
(i, 
" 
.' 
I 
1\ 
\ 
'. 
i 
r 
J 
J 
J 
I 
I 
[ 
J 
J 
J 
T 
J 
I 
T 
TABLE 7-4: ACCEPTANCE TEST CRITERIA 
Acceptance tests - Each cuff shall be tested and shall meet the 
requirements of the paragraphs listed herein. All testing shall be 
conducted at an ambient and fluid temperature of lS.GoC to 37.8oC. 
The fluid shall: 
A) Penetration test, septum 
B) Sterilization cycling 
C) 100 cycles of operation 
D) Internal leakage at 50 amH 20 
E) Examination of product 
F) Proof pressure 
G) External leakage 
H) Cleanliness verification 
A test data sheet shall accompany each cuff and shall be identi-
fied to its appropriate cuff by serial number. Where applicable, 
actual test values shall be recorded rather than pass/fail nota-
tion. Cuffs which are not suitable for human implantation shall 
be clearly identified. 
1) ~ - The following data shall accompany each cuff 
upon shipment: (a) test certifications, (b) lot iden-
tification. The following test data shall be maintained 
by the manufacturer for three years after shipment: 
(a) acceptance test data, (b) material and process 
certifications. 
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TABLE 7-5: RGH PRE- AND POST ACCEPTANCE TEST DATA SHBET 
SYSTBM NUMBER: 
1.0 BXAMINATION OF PRODUCT: 
1.1 Dimensions 
1.2 Data: qualification/acceptance tests 1.3 Label information: 
Part number 
Valve number 
Date packaged 
Date received 1.4 Inspection macro/micro/blacklight 
2.0 STBRILIZATION CYCLE: 
Reason 
3.0 SYSTEM ACCBPTANCB TEST: 
Pre-implant preparation: 
Fill/assemble 0.9% saline (0.45 micron) Control 
Saline lot number 
Cycle test 10 times 
Conforms ____ _ 
Clean 
TecPJlician's initials 
Date: 
Steam sterilize (filled, immersed in saline) 
4.0 IMPLANTATION: 
Dog #: 
Functional test 10 times Observe for leaks 
Tubing modification 
Pass/fail ____ _ 
Yes/no 
Yes/no 
5.0 POST-IMPLANT ACCBPTANCE! TEST: 
DWR 
4/19/82 
Refill system saline. Operate 10 times. Reseat pressure. _-",--"""","~X Leakage, operate, allow to stand 1/2 hour ~_~ ____ amffzO/min Indicate storage, parts returned to PH, MBC, teardown. 
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7 .10 SUPPORTING STUDIES 
During the initial phase of this study, a number of supporting 
studies were performed to address speoifio areas of oonoern. In some 
oases these peripheral aotivities had interesting side benefits, as 
desoribed in the following paragraphs. Areas which were studied 
inolude: ingrowth materials, latoh design and materials, non-
invasive system visualization. 
7.10.1 TEXTURED vs SMOOTH DEVICE SURFACE 
Ingrowth biomaterials were evaluated. Speoifioally, the effeot 
of having an ingrowth or textured surfaoe adhered to the implant. In 
addition, the teohnique of texturing of silioone elastomer by ion beam 
and transfer oasting was reviewed. The resultant texturing of the sur-
faoe led to enhanoed devioe fixation. Fixation prevents migration of 
oomponents of the sphinoter system. Initial experiments determined 
whether the devioe should have ingrowth material and what the approp-
riate types of ingrowth material should be. 
A pilot study was performed using mook miniature oomponents made 
from silioone elastomer, silioone elastomer oomponents with daoron 
ingrowth material, and a third group, silioone elastomer oomponents 
with proplast. This unpublished study showed that daoron is more 
flexible than proplast (oarbon and silicone oomposite). This study 
led to an understanding of the histology of devioe/tissue interfaoe of 
various surfaoes. 
Another independent study, whioh used an ion beam to texture 
silioone elastomer, was performed by Weigand (NASA TM-78851). It r~as 
determined that this experimental texturing of silicone, whioh altered 
the surfaoe ohemistry, was still in the preliminary stages and not 
applicable to the first phase development of the artifioial sphinoter 
devioe. It is reoommended that it be oonsidered for future silioone-
based artifioial implants in order to enhanoe surfaoe oharaoteristios, 
whioh may minimize foreign body reaotion to the implant. 
A disadvantage of having textured surfaoes on the implant is an 
inoreased potential for oontamination. Thus, an increased diffioulty 
in oleaning and sterilizing the sphinoter system. While a smooth 
surfaoe may allow oomponent migration during the initial healing phase, 
the smooth surfaoe may be oleaned more effectively, thereby eliminating 
tissue reaotion from oontaminating partioles w~d bacteria. Seotion 6 
details the looation of ingrowth material on urinary sphincter systems. 
7.10.2 LATCH DESIGN AND MATERIllLS 
In searohing for an appropriate latoh design, velcro w,d magnets 
were examined as possiblie solutions. A review of literature on the 
use of vel oro as an implantable material was performed. In addition, 
oomponent materials of vel oro were identified. These oonsisted of 
polyurethane and nylon material. We determined that veloro was not 
suitable for implantation and use as a latoh material on the artifioial 
urinary sphinoter. The reason was that both polyurethane and nylon 
used in vel oro are non-medioal grade. In addition, the polyurethane 
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backing of this material is biodegradable. n~he Evaluation of Velcro 
as an Implantable Materialn (RGB 80-15) puts to bed the idea of velcro 
as a latch mechanism. 
~he use of implantable magnets as a potential latch mechanism was 
considered. A magnetic stoma cap has been introduced using samarium 
cobalt magnets. ~his concept was evaluated. It was determined that 
these magnets are expensive, provide a difficult molding problem; and 
complicate the simple design of our system. ~herefore, the idea of 
using magnets as a latch was eliminated from consideration. Current 
latch mechanism is detailed in section 6. 
7.10.3 NON-INVASIVE (IN VIVO) S!!'S~EM VISUALIZA~ION 
Studies were made to identify the best t,ray to allow visualization 
of the implanted system. Visualization would be necessary in the case 
of malfunction or non-related abdominal surgery. The use of contrast 
material on the silicone material surface r~as entertained (i.e. 
tantalum dots or contrast media in the rubber). ~hese approaches were 
discarded since either of the processes were costly and placing the 
contrast material in the rubber grossly affected its physical and 
chemical properties, making it unsuitable for our application. 
Serial x-rays were used to determine the final concentration of 
the contrast media (ConraJR) that was needed to provide visualization. 
~he final concentration of 2.4% conraJR was determined to be suitable. 
Finally, the use of ultrasound to identify the system was dis-
cussed with Dr. Borg, Radiologist, Rochester General Hospital. In his 
opinion, sensitive ultrasound techniques would be able to distinctly 
identify the artificial urinary sphincter system, including very small 
tubing components. Use of ultrasound would eliminate radiopaque media 
that has caused allergic reactions in some instances. 
We elected to use radiopaquing material instead of depending on 
ultrasound. ~he availability of highly sensitive ultrasound equipment 
is limited to major hospitals. This may change in the future and allow 
elimination of radiocontrast media. 
7.11 SUMMAR!!' 
Design guidelines and system specifications ~~abled the develop-
ment of an artificial urinary sphincter. A rev"iew of results with 
comparison to original technical objective follows: 
The design of the urinary sphincter system allows for a mznzmum 
of surgery for implantation by excluding the bladder neck as a site. 
The design has been simplified to allow post-operative access to 
adjust the size and pressures without surgery. 
~he two-balloon cuff, which is a key element. of this system, 
allor~s for maximum reliability without contamination of the highly 
sensitive PTR valve. 
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The use of silicone elastomer materials meets the requirement of 
use of proven compatible materials. 
Rigorous guidelines for implanting the urinarg sphincter device 
at the bulbous urethra (male) and the bladder neck (female), along with 
recommended technical training of surgeons at RGH, meets the require-
ment of no detrimental effect on sexual activitg. A bg-product of im-
proving incontinence of the subject is that this usuallg increases 
sexual response and activitg. 
A modular design eliminates the need for having different com-
ponents for use in males and females. 
Consideration was given to mechanical and hgdraulic designs. 
A mechanical design bg Swenson was reviewed and found unsatisfactory. 
It was bulky and did not function smoothly. 
Redesign of the valve occurred during the second and third year 
of this contract to minimize compression drift. An additional system 
component, a capacitor element, was introduced to minimize compression 
drift by providing a greater volume. 
Maximum flexibility of connecting tubing was insured by using 
high performance (HP) silicone material. A studg of the diameter to 
wall thickness of tubing shows that the proper ratio will prevent 
kinked tubing in human clinical trial stUdies. Prevention of other 
problems associated with tubing, such as twists, may be eliminated by 
addition of colored lines on the tubing. Proper tubing alignment may 
vent rotation of system components after implantation. 
Throughout the development of prototypes and operating systems, 
manufacturability has been a keg concern. Design criteria were always 
formulated with direction towards current production molding techniques. 
The system is not filled intraoperatively. Thus, the problem of 
blood contamination has been eliminated. In addition, tubing plugs 
are used to prevent contamination of hydraulic intradevice fluid prior 
to connections which are made intraoperatively. 
Simple assembly procedure during implantation is insured; since 
there are only two tubing connections to make during implantation. 
The procedure of implanting the prosthetic device takes a total time of 
15 minutes if no other surgical difficulties are encountered. 
Minimum cuff size and modular cuffs will be used. We have deter-
mined that three modular cuff sizes will cover the tdde range of 
urethral sizes seen in both males and females. Evidence for ranges of 
sizes which will produce appropriate pressure to the urethra have been 
determined experimentally. 
The requirement for minimum actuator size has been met. The human 
factors studies described in RGH 78-1 show that the actuator is of ap-
propriate size in that any smaller will not allow the human subject to 
successfully operate this prosthesis. 
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It is the intent of the RGH sphincter team that this section 
briefly review key studies that led to the successful design of an 
artificial urinary sphincter system. A complete listing of bench 
studies and appropriate documentation appears in section 22. 
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8. ANIMllL TRIALS (PHASE 2A) 
8.1 OBJECTIVES 
8.2 EXPERIMENTAL DESIGN 
8.3 DEVELOPING INCONTINENCE IN THE ANIMllL MODEL 
8.4 EXPERIENCE WITH DOW CORNING CORPORATION 
MEDICAL PRODUCTS DIVISION 
8.5 TISSUE TOLERANCE STUDIES 
8.6 EXPERIMENTAL PROTOCOL - PHASE 2A ANIMllL TRIALS 
8.7 CONFIGURATION OF TRE SPHINCTER PROSTHESIS 
8.8 SURGICAL PROCEDURE 
8.9 CLINICAL OBSERVATIONS AND DATA 
8.10 PRESSURE STUDIES - PHASE 2A 
8.ll FUNCTIONAL TEST OBSERVATIONS 
8.12 POST-IMPLANT ANALYSIS AND TEARDOWN 
8.13 CONCLUSIONS AND RECOMMENDATIONS 
8.1 OBJECTIVES 
The purpose of the phase 2A animal trials for the urinary 
sphincter device is to test the functional characteristics of a system 
fabricated by Parker Hannifin, Dow Corning and Rochester General Hos-
pital and assembled at Rochester General Hospital, and to assess the 
performance of the implanted system in canines. 
8.2 EXPERIMENTAL DESIGN 
The female mongrel dog was ohosen as an animal model to evaluate 
the urinary sphincter system beoause of its anatomy, ease of acoess 
for urodynamio studies, and availability. The animal trial protoool 
appears in Appendix A. Animal studies were begun on June 9, 1980 and 
ended February 10, 1981. 
The experiment was designed to test the artificial sphinoter 
system in six dogs, Subjects were conditioned for 30 days prior to 
implanting the sphincter system. There was a 14-day post-operative 
healing period. On day 15 the system was funotion tested and 
urodynam.io studies were performed. The six animals were divided 
into two groups. One group was funotion tested for 45 days following 
healing. The seoond group was tested for 90 days following healing. 
Th~ ~xperimental design appears in Table 8-1. 
TABLE 8-1: EXPERIMENTAL PROTOCOL (PHASE 2A) 
Subjects Total Observation Days 
(excl uding post-op healing) 
Group 1 3 90 
Group 2 3 45 
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8.3 DEVELOPING INCONTINENCE IN THE ANIMAL MODEL 
In order to develop a representative model of human incontinence, 
efforts were undertaken to develop incontinence in the dog. A review 
of the world literature showed only one paper in which the authors 
created incontinence in dogs. Dackiewicz and Berson in their paper, 
·Results of Own Experiences in Treatment of Incontinence of Urine in 
Dogs·, (16th Congress of International Society of Urology in 1973), 
describe creating incontinence by removing the muscular layer from 
the posterior urethra at a distance of 2.5 to 3 cm down from the 
lower border of the prostate. The results of their experiments were 
permanent. 
In discussions of this technique and examination of our female 
canine subjects, it was determined that this method could cause 
extensive damage, preventing appropriate evaluation of the urinary 
sphincter device. A modification of this surgical technique was 
performed by Dr. Ronald Rabinowitz on three test subjects. In the 
first test subject, the urethra was split to the mid-part -- up to 
5 em length of the urethra from the external meatus -- using scissors. 
This proved unsatisfactory since the dog was still continent for urine 
and there was extensive bleeding. In the next two test subjects, the 
external urethra was split to a distance of 5 cm. In addition, a Y-V 
plasty was performed on the bladder to remove the internal sphincter 
mechanism at the detrusor muscle or bladder neck area. Again, this 
proved unsatisfactory. Following three unsuccessful attempts to 
create an incontinent animal, we re-evaluated our requirements. 
We believe that the surgical construction of an incontinent test 
subject is unnecessary in order to successfully evaluate the pros-
thetic urinary sphincter. 
8.4 EXPERIENCE WorTH DOW CORNING CORPORATION MEDICAL PRODUCTS DIVISION 
A suitable manufacturer was needed to develop and fabricate a 
urinary sphincter system of biocompatible material. Evaluation 
criteria for potential implant fabricators were established. These 
criteria were used to screen potential candidates. The Do~' Corning 
Corporation was contacted and appeared to be a suitable candidate. 
An initial meeting was initiated with Wright-Dow Corning in 
November of 1978 to explore working relationships and to meet with 
Frank Lewis, Technical Director, Robert Rylee, President, and Chris 
Sidebottham, Designer. Dr. Howard Harrison and J,B. Tenney, represent-
ing Rochester General Hospital, participated in a meeting with Robert 
Rylee, President of Wright-Dow Corning, on February 8 & 9, 1979. 
Topics of discussion were prototype development, lab testing, animal 
trials, and human clinical trials. A program structure was outlined 
and the prosthesis was discussed with emphasis on the quantity 
necessary for animal and cliaical trials. In April of 1979, a joint 
meeting was held at DOI~ Corning Medical Products Division in Midland, 
Michigan. Wright-Dow Coraing is an orthopedic subsidiary of Dow 
Corning, whereas Dow Corning Medical Products Division is the silicone 
manufacturing and fabrication unit of the Dow Corning Corporation. 
Dow Corning developed detailed drawings of the cuff component from 
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dimensions provided by Rochester General Hospital. At this meeting. 
the complete study was discussed and activities for fabrication, animal 
studies, F.D.A. and clinical trials were reviewed and coordinated. 
Discussion included patent considerations. From April 1979 to May 
1980, teaming arrangements were finalized. 
The urinary sphincter cuff prototypes were developed and fabri-
cated by Dow Corning. Jim Vallender of the Medical Products Division 
fabricated cuff devices using hand layup techniques around an aluminum 
mandrel. Mr. David Rogers of Rochester General Hospital visited Dow 
Corning to review fabrication techniques and to provide technical 
support. Dow Corning provided cuffs for cycle testing, in vitro pres-
sure studies, and for the phase 2A implants in the first six dogs. 
Following their participation in the first six animal studies, 
Dow Corning Medical Products Division elected to drop out of the 
study for business considerations. 
8.5 TISSUE TOLERANCE STUDIES 
After selection of the appropriate materials for the urinary 
sphincter system, a study was performed using mock devices and 
material (i.e. silicone elastomer and dacron ingrowth material) on 
tissue tolerance in rats. This study determined the amount of 
collagen buildup and foreign body response to any foreign material 
which appears in biologic tissue. Results of the study comparing 
silicone surfaces to that of dacron and proplast showed that the 
silicone surface is essentially non-reactive, causing minimal 
isolation or encapsulation. Dacron was shown to be an appropriate 
ingrowth material, although over time itself becomes encapsulated or 
isolated. Proplast is an appropriate ingrowth material, but did not 
display the flexibility needed for a hydraulic implant. Details of 
this study are available in the report, "Evaluation of Ingrowth 
Materials· (RGH 79-4B). 
8.6 EXPERIMENTAL PROTOCOL - PHASE 2A ANIMAL TRIALS 
The experiment (six subjects) was designed to evaluate the 
urinary sphincter system over two time intervals. The first group 
was designed to have the sphincter device implanted for a period of 
90 days, and the second group for a period of 45 days. The actual 
time implanted ranged from 56 to 246 days. A summary of the experi-
mental design and device data appears in Table 8-2. 
The complete experimental protocol appears in Appendix A. 
8.7 CONFIGURATION OF THE SPHINCTER PROSTHESIS 
Configuration of the initial six prosthetic sphincter systems 
was selected after reviewing the literature. Drawings and photo-
graphs of the AMS device were considered. Results from the implanta-
tion of the AMS device, along with the experience of other investi-
gators such as Rosen and Kaufman, were taken into consideration. 
Studies of the anatomy of the lower urinary tract and consideration 
of the urodynamics and pressures necessary to cause continence were 
8-3 
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used to select device configuration. Pre-prototypes were developed 
and fabricated at Rochester General Hospital and the Parker Hannifin 
Corporation in order to understand the system elements. Detailed 
descriptions of this development and bench studies appear in section 7. 
The final configuration is shown in Figure 8-1. These drawings reflect 
evolving knowledge of fabrication and manufacturing techniques and take 
into consideration the need for manufacturing by cost effective molding 
techniques. 
As shown in Figure 8-1, the device consists of a two-balloon cuff, 
one which is connected to a pump-bulb/valve system. The bulb is 
spherical. The other balloon is connected to a subcutaneous septum 
element which allows access to the balloon to adjust volume and pres-
sure of the sphincter system. The two balloons are isolated to prevent 
particulate contamination of the valve system. 
8.8 SURGICAL PROCEDURE 
A brief description of the surgical procedure follows. The dog 
is anesthetized with sodium pentobarbital. The operative site is pre-
pared by shaving hair and antiseptically washing the site with alcohol 
and Betadine. The sterile procedure is preceded by a urethral pressure 
profile of the normal urethra. The bladder mayor may not be filled 
with saline to aid in identification. 
In the female canine subject a lower midline incision is made 
just anterior to the pubis using Surgistat electrocautery to cut tissue 
and coagulate bleeders. The bladder is located and the urethra identi-
fied. Next, a careful dissection of the tissue around the urethra and 
between the urethra and vagina is conducted. 
Isolation of a 2 to 3 em segment is performed by using a blunt 
dissection. The cuff tab is then fed through the opening between the 
urethra and the vagina using forceps. The cuff should be positioned so 
that the tubing leads exit the cuff balloons towards the anterior of 
the dog. The cuff component is then latched and rotated so that the 
latch is between the urethra and the vagina and the tubing leads are 
parallel to the urethra. The septum is then placed SUbcutaneously on 
the left side of the dog and the valve-bulb reservoir is placed subcu-
taneously on the right side of the dog. Figure 8-2 demonstrates the 
position of components prior to subcutaneous placement. System 
operation is checked after tubing connectors have been installed. The 
midline incision is closed using interrupted sutures and skin staples. 
Immediately post-operatively, a urethral pressure profile is per-
formed to determine the anatomical location of the cuff for reference 
in subsequent studies and to determine that the pressure exerted on the 
urethra from the artificial sphincter cuff is nominal. Operative time 
is recorded. The uncomplicated procedure of implanting this sphincter 
system taI(es approximately 15 minutes from opening to wound closure. 
8.9 CLINICAL OBSERVATIONS AND DATA 
Cuff placement: To minimize concerns with the problems 
associated with the device implantation, such as contamination, damage 
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to the device from sutures and scissors and possibly misconnections, 
the system was designed as a righthanded system; meaning that when the 
cuff $s implanted, the latch will enter underneath or between the 
urethra and the vagina with the tubing leads exiting to the top or 
anterior of the dog. 
Septum placement: During these six trials, tubing leads from the 
cuff to the septum were evaluated in several positions. These varia-
tions were based on the need to place the septum for ease of access 
and the bulb for ease of palpation. Long tubing runs were required 
when the septum was placed on the ribcage. These runs required sub-
cutaneous tunneling which caused edema and delayed healing. In one 
case, the septum was able to migrate inside its subcutaneous pocket. 
In humans, low anterior placement of the septum is recommended. 
This placement, coupled with device fixation -- through the use of 
ingrowth material when required -- is expected to eliminate problems 
with septum positioning. 
Ingrowth and fixation: In one instance, tissue adhered to the 
device surface with a related increase in fibrotic tissue. In all 
others, the capsule material was very thin and non-reactive (reflect-
ing previous experience with silicone elastomers). In one subject, an 
8 mm ingrowth disk was placed on the bottom of the bulb reservoir in 
order to secure this component to the surrounding tissue. Placement 
of this disk was ineffective in providing increased support and 
fixation. 
Problems: Iv all six dogs, there was no major problem with 
device implantation. The time of implantation is minimal, i.e. 
15-20 minutes. Two concerns arise during device implantation; proper 
placement and careful closure. Proper placement of the components in 
subcutaneous pockets and closure of these pockets minimizes migration 
of subcutaneous components. Potential damage is associated with the 
closing of the incision with needle and suture. Care mu:" Je taken 
not to damage or nick any of the silicone material which may result 
in subsequent tear and failure of the functioning prosthesis. 
Recommended procedural changes: It is recommended for the next 
series of dogs that the septum-side pressure be adjusted to less than 
the set point pressure immediately post-op. The lac}: of fixation of 
the ingrowth disk on the bulb shows that this is not necessary. The 
type of stitch to close the midline should be a mattress and should be 
interrupted. Finally, the self-sealing septum should have tabs on the 
top to indicate Which side is up and to aid in subsequent penetration 
with a needle. 
In two subjects, th~ tubing to the septum-side balloon was kinked. 
In one case the tubing was too long. The twisting and rotation of the 
septum element in its subcutaneous pocket was the probable cause of 
the second kink. 
Changes in the surgical protocol were identified. We will not 
rinse the 'abdominal cavity with Ancef or Betadine sinceth1:S inay 
irritate. We will not adjust the device pressure intraoperatively, 
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but will wait to adjust post-operatively. The final consideration is 
that there will be no inspection of the bladder or urethra with a 
cystoscope prior to implantation since this leads to undue delay of 
the surgical procedure and has proven to be unnecessary since most 
dogs have normal lower urinary tracts. 
Two important factors are: (1) administration of antibiotics 
(I.V. push), and (2) wound care to prevent infection or wound opening. 
Wounds should be rinsed with Betadine or hydrogen peroxide for the 
first three post-operative days. As previously noted, implant time 
was about 15-20 minutes and ranged from 60 to 20 minutes as experience 
increased and the need for photographic documentation decreased. 
Clinical observations: Care of the animal subjects was performed 
according to the protocol in Appendix A. Daily clinical observations 
and weekly laboratory tests were performed to assess and monitor the 
status of the dogs and the body's reaction to the implant. Appendices 
C-l through C-6 describe these findings. 
8.10 PRESSURE STUDIES - PHASE 2A 
To verify design pressure and to determine physiologic parameters 
of the lower urinary tract (u:r:ethra) Idth the presence of the implanted 
sphincter, urethral pressure profiles were performed. The urethral 
pressure profile (VPP) allows mapping of pressure versus distance for 
the bladder and urethra; monitoring of applied pressures both from the 
valve-controlled balloon side and the septum balloon side. Knowledge 
gained from the VPP permits determination of pressures and aids in 
decision making on whether to adjust the pressure in the passive side 
of the system. In addition, the combined pressure measurement of the 
septum balloon side and the VPP allows determination of operating 
characteristics of the hydraulic sphincter system. A report on con-
tinence testing on dogs with the hydraulic urinary sphincter by ureth-
ral pressure profiling and urine flow observation appears in report 
RGH 81-2. 
The urethral pressure profile measures pressure caused by the 
bladder and the urethral lumen (sphincters) by inserting a catheter 
of known diameter into the bladder via the external urethral opening, 
infusing saline or water at a constant rate, and withdrawing the 
catheter at a known rate (em per minute). Gas (C02 ) may also be used. A tracing is produced by recording both pressure (in cmH20) and distance along the urethra. 
Method - VPP: H~ profilimetry was used to determine the VPP 
for our canine subjects. The catheter is a modified 10 Fr pediatric 
feeding tube. Modifications include plugging of the end hole with 
silicone elastomer, rounding the tip and placing 4 outflow holes 0.5 
em from the tip and 900 apart from each other. Centimeter markings 
are placed on the length of the catheter. The catheter and the pres-
sure system are assembled and zeroed with the infusion pump on the 
"on" position. The flow rate is 9.89 cc per minute. The technician 
Idthdraws the catheter at a rate of 1 em per second. Normal VPP's are 
obtained one week before implant surgery, immediately post-operatively, 
and every two weeks thereafter until the animal is sacrificed. Pre-
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sacrifice, the final UPP is performed before the sphincter system is removed. 
In addition to evaluating the artificial sphincter system by 
measuring pressures between the two cuff balloons of the cuff element, a cuff opening pressure test was performed in two subjects by filling the bladder through the profile catheter with the sphincter system in the closed position. This test more approximates the normal physio-logic response to a full and distended bladder and demonstrates that the sphincter cuff will allow the subject to maintain continence until the set point pressure is exceeded. In test subject #1, the bladder was filled to an approximate volume of 390 cc; the bladder pressure 
measured between 75 and 88 amH;!J. At this pressure, cuff valve pres-sure was overcome and squirts of fluid were observed exiting around the catheter. In dog #2, the bladder was filled with a fluid volume of approximately 200 cc at which point the pressure in the bladder was 37 CmH20. The subject became incontinent (appearance of drops of urine). At the pressure of 61 amH;fJ, there r,ras a constant flow of water from the urethra, indicating that the dog was no longer continent and the set point was overcome. Studies of this nature allowed us to determine bladder pressures at which the cuff could be overcome. 
Results of the pressure measurements in each of the six dogs over the post-implant period are summarized in Table 8-3 and can be com-pared to the pressures for the second phase in Table 11-2. Detailed statistical analysis of these pressures for each dog and the combined animal trials appears in report RGB 81-2. 
Before reviewing the results of the intraluminal pressures for the first six dogs, the data for the pressure set point of the Parker Hannifin valve is presented in Table 8-4. All pressures were determined before and after implantation in the animal subject and pressures r,rare determined from between 10 and 100 cycles, 100 cycles pre-acceptance test and 10 cycles post-acceptance test. The mean reset pressure for the six valves is 78.5 !10.8. The mean leakage rate for this series of valves is -0.453 ! 0.876. 
During the study all septum side pressures were adjusted to the active side pressures. Since this passive pressure was adjusted to the same pressure as the valve pressure, the open system intraluminal pressures for this series of six ranged from 40 to 115 amH20 with a mean of 79 ! 36, and a median pressure of 68 amH:P. With the system closed, the active pressure as measured from the bench studies pre-
and post-implant was 71 to 100 amH:P with a mean pressure of 78 ! 10 CmH40, and a median pressure of 75 amH20. The corresponding intra-lum2nal pressure for the six dogs with the system in the closed state 
ranged from 72 to 148 amH20 with a mean value of 111 ! 38 amHfJ, and a median value of 102 amH20. Note the differences in open and closed values for the operating spIlincter system. 
To compare the artificial sphincter with the dog's natural ex-ternal sphincter system, the peak pressure was determined from the profile for the external sphincter in all six dogs. The range of the external sphincter pressures was 66 to 112 amH20, the mean value was 89! 23 amH20, and the median value was 85 amH20. This comparison 
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shows that our artificial sphincter system was in the range of pres-
sures that caused natural closure, although on the slightly high end. 
Passive pressures were not recorded during the actual animal trials. 
The artificial urinary sphincter was implanted in dogs to cause 
continence by exerting a pressure on the urethra that approximates 
external sphincter pressure. The normal external sphincter pressure 
of this series of six dogs was approximately 85 amHjO. The open system 
intraluminal pressure measured approximately 68 amH20, whereas the 
closed system intraluminal pressure measured 102 amH20. These results 
show that the artificial sphincter system produces the desired pres-
sures on the urethra and, with a full bladder, prevents urine flow 
(continence) • 
8.11 FUNCTIONAL TEST OBSERVATIONS 
Urine flow observations made after implantation consist of com-
paring flow patterns of urine (normal pre-implantation patterns) 
(low pressure, high volume) with flow patterns when the implanted 
device is in the open or closed cuff positions. Patterns of urine 
flow with the cuff in the closed position should either show no flow 
or have a high pressure, low volume stream with straining and multiple 
voidings present. In phase 2A trials, the sphincter system was closed 
between 8 AM and 5 PM during the day and left open overnight. This 
time interval was abosen to insure normal voiding and to prevent 
possibility of kidney damage due to reflux. 
Urine flow was observed for such characteristics as straining, 
flow pressure, and flow volume. 
Definitions for the urine flow studies are as follows: 
Success Pattern significantly different than normal flow and 
meeting criteria of continence. 
Failure No difference between normal or that of open cuff 
voiding pattern. 
Questionable - Pattern mixed or no daily observation for comparison of 
open voiding pattern. 
During the 9-hour closed period, the cuff was opened and closed 
three times, once at 8 AM, once at 12 noon and once at 5 PM daily, 
excluding weekends. Results of these observations appear in Table 
8-5. The number of days tested and hours that the device was 
either open or closed appears in Table 8-6. The total number of 
functional tests (times which urine was observed with the cuff open, 
then closed) is 530 (100%). The number of failures is 213 or 40%. 
Failures are when there is no difference in the voiding pattern open 
versus with the device closed. Combining success with the results of 
the questionable or ambiguous observations shows that for 321 times 
(60%) when the cuff was closed the urine flow was interrupted or the 
dog was continent, the dog had to strain to void, or a high pressure, 
low volume stream was present, indicating that the cuff was function-
ing. 
Results for this phase of the animal studies allowed development 
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of the "Guide to Continence" and the daily observation format sheet 
for the second phase of the animal studies. In addition, confidence 
gained from the results of pressure data allowed us to close the system 
for the majority of the observation time, allowing the system to be 
open only during flow observation studies. This situation is more 
normal or representative of expected conditions of use in human trials. 
8.12 POST-IMPLANT ANALYSIS AND TEARDOWN 
Following removal of the artificial sphincter device from the 
six test subjects, fill fluid was removed and analyzed for physio-
logic compounds. The sphincter system was then refilled with 0.9% 
saline (I.V. Travenol) and cycle tested 10 times to determine 
reseat pressure. The system was pressure tested for internal 
leakage for 3 minutes. The system was emptied of all saline 
solution and shipped to the Biomedical Products Division of the 
Parker Hannifin Corporation for analysis, pressure studies and 
teardown. TeardoMl of the first valve (subject #2) was performed on 
site at Rochester General Hospital by David Rogers (RGH) and Elmer 
Eddins (PH) to determine the appropriate procedure. 
8.13 CONCLUSIONS AND RECOMMENDATIONS 
In reviewing the urodynamic studies and the functional test ob-
servations in which 60% continence was achieved, it can be stated that 
the artificial urinary sphincter system performs successfully in 
applying desired pressure of approximately 75 cmff20 to the urethra 
and causes continence. 
It was recommended that the devices being fabricated by Medical 
Engineering Corporation incorporate several design changes. Changing 
the bulb configuration, incorporating an attenuator, eliminating the 
random valve leakage problem, and adding ingrowth material in the 
additional series of 10 animal subjects (phase 2B) should allow a 
successful evaluation of this artificial urinary sphincter prosthesis. 
Overall, there is no significant pathology induced by the presence 
of the artificial sphincter system in these six animals. Histological 
results are described in section 12. 
Table 8-7 compresses the findings of this phase into 25 basic 
questions which provide a useful -- thbugh subjective -- overall sum-
mary of device performance. 
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TABLE 8-2: SUMMARY; EXPERIMENTAL DESIGN AND DEVICE DATA (PHASE 2A) 
Planned Actual 
Experimental Experimental 
Implant Period Period 
Dog Date Device (days) (days) 
1 Tara 6/9/80 PH ss prototype 2 > 90 246 
DC cuff prototype #3 
RGH septum, lot 1 
2 Marni 7/21/80 PH tit. spring 10 90 85 
DC cuff prototype #4 
RGH septum, lot 1 
3 Vera 9/4/80 PH tit. spring 9 90 103 
DC prototype #5 
RGH septum, lot 1 
4 Diane 10/14/80 PH #5 45 59 
DC ATC #1 
RGH septum, #1 
5 Sue 11/11/80 PH #4 45 63 
DC ATC #2 
RGH septum #1 
6 Pat 12/16/80 PH #6 45 56 
DC ATC #4 
RGH septum, #1 
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3 VERA 
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TABLE 8-3: 
-, --, ....., -., ..., ~ 
MEASURED RANGL JF PEAK PRESSURES - PHASE 2A 
(em H20) (Resting urethra pressure 20-30) 
(;'1>£1'1 - S"lSrcJ4 (!L~S£,() -SYSre-J-{ NATURAL EXTERNAL 
ACTIVE INTRALUMINAL • ACTIVE INTRALUMINAL SPHINCTER 
( Preop 27-95 
I \ ' 
, . . 
'-.., . l , , 
':i" 
*\' \ 
' • I 
, I··V ' 
{ f" I :-
i I · , . . . ! , . , v 
Hedian / Range Median / Range Median / Range , 
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0 (56-61 ) 40-132 100 (85-102) 71-146 (85) 58-101 i 
0 (77) 30-159 71 (130) 111I-16? (6]\ ---
0 (80) 71-156 75 (91) 74-177 (81) 60-83 
0 (100 ) 82-224 75 (153) 132-254 (104 ) 83-104 
0 (71 ) 68-109 72 (95) 71-122 (125 ) 96-143 
, 
0 (53) 41-102 79 (88) 68-109 (101) 71-109 I 
0 40-115 71-100 72-148 oo.:n2 
0 79 + 36 78 + 10 111 + 38 89 + 23 
0 68 - 75 - 102 - 85 -
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TABLE 8-4: SET POINT PRESSURE (PARKER HANNIFIN BULB-VALVE) 
Reseat (set pt) Leakage Rate 
Dog # PH valve # Pressure (CmH2O) (CmH20/sec) 
1 SS# prototype 100 -0.0 
2 10 70.8 -0.0175 
3 09 74.8 (vertical) -2.2 
91 (horizontal) 
4 05 74.7 -0.0 
5 04 72.0 -0.49 
6 06 78.9 -0.015 
x 78.5 + 10.8 x -0.453 ;. 0.876 
All pressures determined with valve in a working sphincter 
system. 
Each valve/bulb cycled 100 times pre-implant as acceptance and 
qualification tests. Set-point pressure was determined at each 
cycle. 
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TABLE 8-5: SUMMARY OF DAILY URINE FLOW/CONTINENCE OBSERVATIONS FOLLOWING CUFF CLOSING-OPENING 
(PHASE 2A) 
---------- Functional Tests ---------------------
Total Failure Success Questionable 
# % # % # % # % 
251 100 1120 47.8 58 23.1 73 29.1 
37 100 1 13 35 17 45.9 7 18.9 
96 100 45 46.8 22 22.9 33 34.4 
41 100 15 36.6 8 19.5 18 43.9 
57 100 6 10.5 12 21 39 68.4 
48 100 14 29.2 9 18.75 25 52.1 
530 100 1213 40 126 24 195 36 
combined = 60% 
Comments 
UPP - overall successful in evaluating the effect of the de-
vice. Added fluid to septum to increase pressure. 
Function testing did not begin because of high pressure on 
urethra and unable to void even when the device was open. 
After post-op adjustment on days 9, 21 - UPP; blood and pro-
tein r.ere seen in urine. Blood was visible after inserting 
catheter tip. Start functional testing day 30 post-healing 
(+ 14d) when dog was able to void freely. 
Appears more positive results with system when septum fluid 
removed. This may be due to more displacement of the fluid; 
therefore, the urethra from its plane of normal functioning. 
UPP agree with the above finding. Morphology of tracings UPP 
have shown cuff ~ay appear with 2 peaks and in female dogs 
external sphincter may be main continence mechanism. In-
creased success in functional testing with increase in urine 
pH and protein. 
UPP - note high pressures with edema. 
15/48 - times urine present in ca~e after closing the cuff, 
which relates to small amounts or no voiding at 3 daily func-
tional test observ5tions. High % of questionable (52) due to 
no voiding when cuff was open but compared to when cuff was 
open and voiding, there appears to be an effect from the 
cuff. Functional test -- appears more influence of cuff on 
urine flow when closed pressures of 95 cmU20 or greater. 
i 
l~ 
*'--~ :.~ 
"""' .......... ll·.. ;;,.:...;;s:--:-~-~":- -'- " 
.,:- ~_r_""-'~' • _,_~_-= __ _.:'~~~ __ .::~ __________ ~" ___ _ 
I:t' II!!~ 
.c. 
'. 
~ 
. '11> 
! I f1~ ~.:::..:::.~~ C~::.:..; ~l L_.:._-~·"J' ~...:-~.~ c.: __ "':;"'-l , c. __ ~' __ t: ... ,.:.:.\ 
" 
, t ~ .::-_-1 
I 
C""":-::·1 
. , s-- ) ,. : J C . J ,- -.~J ~ ~ ~ • 
....... ., 
.~ ~ 
; 
TABLE 8-6: PATTERNS OF DAILY DEVICE USE (OPEN/CLOSED) - PHASE 2A 
i -i 
., 
, 
Co 
I 
.... 
... 
i 
.~ 
Dog 
1 
2 
3 
4 
5 
6 
Totals 
Days 
Implanted 
246 
85 
103 
59 
63 
56 
612 
---
Days Function Tested 
(available days in period) 
121 
20/44 
43/60 
15 
23 
24 
246/--
--_._---- ~-.-- .. -
- -
l.;;;,;...:;,,----" . ~~_"'""""-;:;.;o.=:...;.--~ 
Average Time Open Daily Average Time Closed Daily i 
ihours) (hours) .-C;.< 
! 
18 6 
I 
16.9 6.9 + 1.4 
, 
17.6 6.4 + 2 
16.8 + 1.8 6.Q5 + 1.7 
16.9 + 1.8 7.08 + 1.8 
, 
16.4 7.6 I 
I x=17.1+0.5 x = 6.82 + 0.56 
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TABLE 8-7: 
SUMf.IARY -USD EIXPEIRIlmNTAL REISULTS - PHASEJ 2A 
(1) Cuff pressure (am H2O) 
(2) Days post-op survival (% of planned) 
(3) Midline difficulties encountered? 
( 4) Reservoir pocket problems? 
(5) Post-operative edema? (excessive) 
(6) Urethral stricture as evidenced at L'PP 
or sacrifice? 
(7) Was subject totally/partially continent 
some period during test? 
(8) Device function demonstrated 
convincingl y? 
(9) Device related death? 
(10) Did cuff rotate? 
(11) Did cuff latch open in vivo? 
(12) Did any element (septum, reservoir, 
capacitor) rotate in vivo? 
(13) Did any element of device fail in vivo? 
(14) EIvidence of infection around cuff? 
(15) EIvidence of infection or hemorrhage 
around septum? 
(16) EIvidence of infection or hemorrhage 
around reservoir? 
(17) EIvidence of necrosis, ischemia, 
hemorrhage under cuff on urethra? 
(18) Was bladder thickened? 
(19) EIvidence of inflammatory or foreign body 
reaction around cuff? 
(20) Subject generally healthy at sacrit-ice? 
(21) Device functioning at time of 
sacrifice? 
(22) Device pressure too high at sacrifice? 
(23) Did subject have weight loss? 
(24) Did reservoir fold in capsule or tubing 
or tubing curl or twist? 
(25) Did dog have e,ridence of urinary tract 
infection at any time during experiment? 
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FIGURE 8-l: URINARY SPHINCTER 
SYSTEM (INITIAL 6 
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9. ANIMAL TRIALS (PHASE 2B) 
9.1 OBJECTIVES 
9.2 EXPERIMENTAL PROTOCOL 
9.3 ROLE OF MEDICAL ENGINEERING CORPORATION 
9.4 PRE-OPERATIVE CONDITIONING 
9.5 SURGICAL IMPLANTATION 
9.6 POST-OPERATIVE TESTS 
9.7 URODYNAMIC STUDIES - URETHRAL PRESSURE PROFILE 
9.8 SEMI-QUANTITATIVE CONTINENCE ASSESSMENT 
9.9 POST-MORTEM EXAM 
9.10 POST-OPERATIVE RESULTS 
9.11 CLINICAL SUMMARY 
9.12 LABORATORY RESULTS 
9.13 HISTOLOGY 
9.14 PRESSURE TEST DATA 
9.15 SPHINCTER - FUNCTIONAL TESTS AND OBSERVATIONS 
9.16 CONCLUSIONS 
9.1 OBJECTIVES 
The purpose of the second phase (2B) of animal trials was to 
continue studies begun in Phase 2A using a modified prosthesis in 
which all elements were fabricated by one manufacturer (Medical 
Engineering Corporation), reflecting changes and improvements stemming 
from Phase 2A. In this set of trials, the intent was to have a com-
pleted prosthesis assembled, tested and shipped by the manufacturer. 
The functioning system would then be sterilized and implanted under 
conditions which most closely duplicate those which would be encoun-
tered with a marketable device. 
This phase was begun iIl July 1982 and was completed in March 
1983. Two devices were implanted on each operating day. 
9.2 EXPERIMENTAL PROTOCOL 
The experimental protocol was modified to assess the intradevice 
pressures on both sides of the device by using a double septum system 
in the first four dogs. In these dogs, multiple urethral pressure 
profiles wer~ performed in order to determine intra urethral pressure. 
In dogs 5 through 11, a device with a single septum on the passive 
side was implanted. It was determined in the first four subjects that 
the pressure was similar to or equal to those obtained on the bench for 
the active side pressure. In the last six subjects, passive pressure 
was measured and urethral pressure profiles were performed at implant, 
at sacrifice, and one or two times equally spaced throughout the func-
tional t.est period. Table 9-1 summarizes the experimental protocol • 
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Table 9-1: EXPERIMENTAL PROTOCOL (PHASE 2B) 
Total Observation Days 
Subjects (excluding lJOst-oQhealing) 
Group 1 4 64 
(double seQta) 
Group 2 3 96 
(single septum) 
Group 3 3 64 
(single septum) 
The experimental protocol which describes cuff pressures and indicates 
the times of profiles and functional tests appears in Appendix A. A 
more detailed experimental timetable is givelJ in Table 9-2. 
9.3 EXPERIENCE WITH MEDICAL ENGINEERING CORPORATION 
Teaming arrangements were established with RGH, MEC, and Parker 
Hannifin, with PH taking the lead in business and system coordination. 
Meetings were held to communicate the physiology, anatomy of the lower 
urinary tract, and to describe the system configuration. All sphincter 
components were fabricated, assembled, bench tested; then shipped un-
sterilized to RGH. Once received at RGH the devices were ins~eJted, 
sterilized and implanted in test animals. Explant of the devices 
occurred at sacrifice, at which time the devices were rinsed with 
Isopropyl alcohol, packed in styrofoam containers and shipped to MEC 
for teardown and post-implant pressure tests. 
9.4 PRE-OPERATIVE CONDITIONING 
Each test subject was held for a period of two to four weeks for 
observation of clinical status, stabilization of diet and behavior. 
Dogs with happy, moderately aggressive behavior were chosen. Dogs 
were vaccinated with canine distemper, hepatitis, leptospira and 
licterohemorrhatia bacteria vaccine (Fort Dodf/e). A routine physical 
exam, Betadine bath and antihelminthics (EVIC") were given. Dog diet 
was Big Red Choif/ supplemented with PrimeR. Water was given ad lib. 
A pre-implant urethral pressure profile was performed and blood was 
drawn for establishment of pre-op chemistry and hematologg values. A 
routine urinalysis was performed to make sure that the urine was free 
of bacteria. Routine voiding habits were observed and recorded. 
Food was restricted 24 hours prior to surgery. One gram of 
Keflin or Ancef was given I.M., 12 to 24 hours pre-op. Immediately 
pre-op, blood samples were drawn for a chemistry profile and CBC, 
differential and red cell morphology. One gram of KeflinR was ad-
ministered intramuscularly. The dog was .lnesthetized using sodium 
pentobarbital (60 mg/every 10 kg body Weight .r.p.) and anesthesia was 
maintained by I.V. supplements. Immediately before implanting the 
prosthetic sphincter system, an I.V. push of one gram Keflin was given 
to elevate the tissue concentration of antibiotic (shown to be 
effective when implanting prosthetic hips). 
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9.5 SURGICAL IMPLANTATION 
The device was implanted by placing the urinary sphincter cuff 
around the urethra with satellite components in subcutaneous positions. 
A complete description of the surgical procedure is given in section 
7. Surgical procedures were recorded photographically and written 
reports of each procedure were prepared. A slide-tape summary of key 
steps in the surgical procedure was developed for use by NASA-MSFC and 
by fmc. A photograph of key positioning of cuff element is shown in 
Figure 9-1. 
9.6 POST-OPERATIVE ~ 
Immediately post-op, a urethal pressure profile is performed 
using Browne UD-4 equipment. During the first seven post-operative 
days, one gram of Ancef or Kefzol is given per day (I.M.). Wounds are 
11ashed with Betadine for three to four days and carefully inspected in 
the morning and afternoon to monitor integrity. For two days imme-
diately following surgery, diet is supplemented with milk and moist 
Chow to enhance immediate post-op nutritional status. Diet is returned 
to normal diet at day 3. The dog's activity usually returns to normal 
24 hours after surgery, at whiCh time the dog is allowed to return to 
the dog run. During the post-operative period, special attention is 
given to the dog's voiding characteristics. The device was not 
"activated" tor a period of 21 days following implantation to allow 
for healing and stabilization of capsular material. A standard format 
for observing and recording voiding observations was developed. It was 
used throughout the experimentai period to record urine flow and device 
functional test observations. Laboratory tests (blood analysis; 
routine chemistry and hematology parameters, urinalysis) were per-
formed weekly for the first month following implantation; bi-monthly 
thereafter unless clinical management called for reassessment. 
9.7 URODYNAMIC STUDIES = URETHRAL PRESSURE PROFILE 
Immediately before the sphincter cuff was implanted, a urethral 
pressure profile (UPP) was developed in test subjects. This data 
allows comparison of resting urethra to pressure profiles following the 
implantation of the device. UPP was performed at two week intervals 
following implantation for the first six subjects. In the second 10 
subjects, UPP was performed at two week intervals (first four subjects) 
and at three equally spaced intervals during the experimental period 
(last six subjects). All urethral pressure profiles were performed and 
reported according to terminology set by the International Continence 
Society. UPP was performed to assess the normal external sphincter of 
the canine subject, the applied pressure and the location of the arti-
ficial sphincter system. 
In these ten animal subjects (prototype 2), urethral closure 
pressure profiles were performed using Browne urodynamic equipment 
(UD-4 with standard membrane catheter). Current studies show minor 
differences in pressures obtained by H20 and CO2 urodynamics; we 
assume that values are generally comparable. Press~e was reported 
in amH20 and distance in centimeters. Data provided by UPP includes 
normal resting urethral pressure, normal bladder pressure and the 
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range of the open and closed sphincter pressure. A tgpical profile 
obtained bg this method is shown in Figure 9-2. 
Intradevice pressure for the operating sphincter sgstem was ob-
tained through the septa. The first four dogs had double septa sgs-
tems to allow measurement of valve pressure. Figure 9-3 shows the 
position of septa and reservoir prior to subcutaneous placement. 
Final implant position is indicated in Figure 9-4. The transmitted 
pressure obtained via urethral closure pressure (UCPP) can be compared 
to the applied pressure from the artificial sphincter sgstem. Set 
point pressure data provided bg MEC appears in Table 9-3. Variabilitg 
in leakage rate is a problem. RGH has recommended that preciSion be 
improved. 
9.8 SEMI-QUANTITA2'IVE CONTINENCE ASSESSMENT 
Functional test observations were performed on a Mondag through 
Fridag dailg basis. The dog was allowed to enter the dog run, the 
device status was checked (open or closed), at which time the device 
was closed and the dog allowed to void. Urine flow pattern was ob-
served; straining, low volume-high pressure flow, or high volume-low 
pressure flow. The device was then opened and the dog allowed to void. 
The flow pattern was determined. This procedure was repeated two or 
three times dailg. These results were compared to standard criteria. 
Success occurred when the device was closed and the dog could 
not void -- or voided with great amount of straining as compared to a 
normal flow with the sgstem open. Ambiguous results were when the 
dog voided successfulg, but no open device configuration flow was 
recorded. Failure occurred when the device was closed and the dog 
voided easilg with no straining or interruption of the urine stream, 
when compared to the normal voiding. 
Observations of urine present in the dog's cage were made prior 
to allowing the dog into the cage. Results were either positive or 
negative, positive meaning that the dog was continent (did overcome 
device pressure) during the observation period with the device closed, 
negative meaning that the dog voided (overcame device or device not 
working). 
9.9 fS!§:£. ~10RTJ!]M EXAl1 
A complete post-mortem exam was performed on all test subjects. 
Microscopic tissue observations were recorded. All major organs were 
sampled for histologg and evidence of silicosis. The lower urinarg 
tract was removed with kidnegs, ureters, bladder, urethra and device 
components intact in capsular tissue. A careful dissection ,>'as per-
formed following removal of these organs from the dog. Segments of 
tissue were sampled and submitted for histological assessment of 
capsular material, especiallg the area directlg under the cuff. 
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9.10 POST-OPERATIVE RESULTS 
Of the 16 animal subjects implanted with a prosthetic urinary 
sphincter, two subjects experienced opening of the midline due to 
suture failure and one experienced excessive edema at the midline for 
a period of seven days. The incidence of complications appear in 
Table 9-4. Specific details are contained in case histories contained 
in Appendix C. Some complications are: device migration and rotation 
occurred in 37.5% of the test subjects, post-operative edema greater 
than expected occurred in 25% of the test subjects, kinks or folds in 
the tubing or reservoir element of this device occurred in 31% of 
the test subjects, along with capacitor bond line failure in one 
device. 
9.11 CLINICllL SUMMARY 
In all canine test subjects, behavior immediately following the 
post-operative healing period and throughout the experiment was ex-
cellent, except at times of urinary tract infection, which were in-
frequent. Behavior returned to normal upon adequate antibiotic 
therapy. Subject 4, a small beagle, exhibited failure to thrive and 
inability to overcome device pressure even when the device was inacti-
vated. This subject died of kidney failure due to retention and 
reflux of urine. This was the only test subject in which the device 
was related to death. All anima.ls were fed the normal test diet of 
Chow and maintained their weight throughout the experiment. 
9.12 LABORATORY RESULTS 
Chemistry values throughout the experimental period for all test 
subjects were within the normal range, except when correlated with 
the clinical condition of tissue damage. These values returned to 
normal upon healing. 
Hematological values for all test subjects were normal, with an 
occasional shift to the left of the white cell differential when a 
urinary tract infection was present. 
Urinalysis was performed at two week intervals on all test sub-
jects. Samples were obtained through the urodynamic catheter imme-
diately preceding the pressure profile. There was evidence of small 
amounts (2-10) P.BC's. Small amounts of WBC's, along with few epi-
thelial cells and evidence of blood in the urine. This is believed to 
be due to straining and to erosion from repeated insertion of the 
urodynamic catheter. Evidence of small amounts of protein in all the 
subjects' urine indicated small subacute chronic urinary tract infec-
tions which are common in dogs. 
The dogs' urinalyses are more normal in the last eight test sub-
jects of the two experimental groups due to decrease in passive cuff 
pressure. This allows less straining and retention to occur. In 
addition, in the last six test subjects, pressure profiles were per-
formed at three equal intervals during the experimental period, in 
contrast to every two weeks in the first 10 animal subjects. This 
decrease in urodynamic pressure profiles (and introduction of the 
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catheter) caused a reduction in erosion and infection in the animal model. Results were: incidence of infection (62.5%), thickened bladder (37.5%), evidence of change in morphology of kidney (18.8%), urethral stricture related to prosthesis, repeated profilimetry (leading to erosion and subsequent inflammation) scarring leading to 
stricture (75%). 
9.13 HISTOLOGY 
A complete autopsy was performed on all animals. Tissue sections were taken from major abdominal and thoracic organs and found to be normal. Histological sections of the lower urinary tract show pathologic changes in only the cases in which the device caused 
obstruction, kidney damage and subsequent death. There were slight changes in kidney morphology in 18.8% of the test subjects. Foreign body reaction occurred in only 18.8% of the test subjects and appeared mostly in the capacitor or septum elements. 
Bvidence for pressure changes under the sphincter cuff in the urethra, such as dilatation and hemorrhage, along with erosion due to the chronic infection and pressure profiling, occurred in 43% of test subjects. The sections of bladder tissue showed a thickened and 
chronic inflammation in 37.5% of test subjects. This is related to retention in 6% and infection in the remaining 31%. Overall, capsular tissue was non-reactive. 
Following assessment of all program results, n9 significant pathology was associated with the implantation of the prosthetic 
urinary sphincter device in these animals. 
9.14 PRBSSURE '!.!!!§f ~ 
The major criteria for evaluation of the sphincter device is determination of interdevice pressures and intraluminal urethral pressure profiles (uPP). Pressure test data for the device in the closed configuration and in the open configuration appear in Table 9-3. Ranges in intraluminal pressure are given. Increases in intr.a-luminal pressures greater than applied sphincter pressure are due to conditions such as infection or irritation due to repeated profilimetry. 
The active pressure (applied system pressure) for all 16 test 
subjects was approximately 79 cmH20. The passive pressure in the first 8 test subjects was adjusted to be equal that of the active pressure of approximately 60-80 amH ~, and in the last 8 test sub-jects the pressure fit philosophy was varied so that the passive (septum) cuff pressure allowed an open intraluminal pressure less than 40 amH20 (bladder and resting urethral pressure). 
In order to void the dog must elevate bladder pressure greater than the applied sphincter pressure either in the closed or open con-figuration. Since I~e wanted the dogs to void normally with the device in the open configuration, adjustment in the passive side pressure was made so that the resting urethral pressure under the sphincter cuff was less than bladder pressure. With an active closed pressure of 79 
cmH20, the intraluminal pressure varied from 68 to 254 amH20, at 
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cmHZ'. the intraluminal pressure varied from 68 to 254 cmHZ'. at 
which time the passive pressure varied from -43 to 92 cmH20 (all 16 
test subjects). 
With the device in the open configuration, the active pressure 
is assumed to be a and was measured to be 0-30 cmH20 in the double-
septum systems (prototype ~). The pressure of 30 cmHZ' resulted from 
an overfilling of the reservoir active side (dcg #4 of prototype 2), 
resulting in inability to decrease pressure, obstruction and death. 
The illtraluminal pressure ,.,hen the device was in ';he open configuration 
measured 40 to 183 cmH20. Th'u passive pressure measured -66 to 42 cmH20. The above pressures show that the designed artificial 
sphincter functioned to cause continence as demonstrated by the ureth-
ral pressure profile and positive urine flow continence tests. Minor 
pressure peaks appear on the major peak associated with the sphincter 
cuff (urethral pressure profile). These peaks are the rigid cuff 
edges. These edges lead to increased erosion due to insertion of the 
catheter and, at one or two times throughout the pressure measurements, 
the technician was unable to insert the catheter due to the resistance 
of cuff edges. 
Correlation with histology shows that even though the pressures 
up to 254 cmH20 were observed intraluminally (from applied pressures 
of 80 cmH 0), histology shows only evidence of dilatation of blood 
vessels w~ich is considered non-pathologic. The urethral pressure 
profile is a relative measure of pressure in the lumen and depends on 
lumen to catheter size ratio and buildup of fibrotic tissue. This may 
contract and cause a pressure intraluminally which is greater than the 
actual applied pressure of the artificial urinary sphincter syst.em. 
Intradevice pressure measurements confirm that the applied pressures 
from our system are within specified limits; less than 100 cmH20. 
This increase in intraluminal pressure may be minimized by ob-
serving a longer inactivation pe:ciod in human subjects. In our test 
subjects, a 2 to ., week healing period was allowed. plans for human 
clinical trials should include a 6 week healing period during which 
time no pressure is applied to the urethra. 
In order to verify the placement and location of the prosthetic 
urinary sphincter in our canine test subjects, fluoroscopy was per-
formed on one of the test subjects in the prototype 2 group. Fluoros-
copy demonstrates device position, the artificial sphincter cuff in 
place around the urethra, and the capacitor valve-bulb, tubing and 
connectors. Fluoroscopic results are on file at RGH. 
9.15 SPHINCTER = FONCTIONAL TESTS AND OBSERVATIONS 
Evaluation of the function of the prosthetic urinary sphincter 
was based upon observations of urine flow and cage continence and on 
urethral pressure profile data. Continence (closing the sphincter 
device and watching the animal void) was observed and compared to 
normal urine flow. Urethral pressure profiles, with the prosthesis in 
the open and closed configuration were made. Results show a positive 
test result in 60% of the first six subjects (phase zq) and 87% of 
the last 10 test subjects (phase 2B) for a total positive continence 
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test of 80%. A positive test of continence was defined to occur when 
the closed device causes: (1) no flow, (2) interrupted pulsating flow, 
or (3) high pressure-low volume stream, or significantly different 
than normal flow. 
Cage continence testing gave minimum indication of device func-
tion since most dogs' behavior was adapted to voiding in the pit. 
Since animal subjects can void and overcome the device, much cage 
continence testing was negative. 
9.16 CONCLUSIONS 
Following implantation of the prosthetic urinary sphincter 
system in the canine test subjects, subjective assessment showed that 
the device affected urine flow ncontinencen 80% of the time. Pressure 
test studies show that, with an applied presure of approximately 
80 amH20, the intraluminal pressures varied between 64 and 254 amH~. Histology of the urethra under the sphincter cuff with these pressures 
showed no pathologic response. Slight dilatation of submucosal blood 
vessels was observed. Only in one case, in which the device active 
pressure side was overfilled and test subject which exhibited failure 
to thrive, did the device cause death due to obstruction. Table 9-4 
provides a summary of experimental results for Phase 2B. 
Limitations in the animal model preclude absolute identification 
of the ability of the device to maintain continence. Thi,s is due to 
the animal's inability to communicate, common urinary tract infections 
due to repeated profiling for urodynamic assessment, and inability to 
create an incontinent animal model without totally disrupting normal 
morphology of tissue in the area of the device function. The model 
does allow determination of system operating pressure, device func-
tion, and assessment of tissue tolerance to the prosthetic urinary 
sphincter device. Our findings show that the device functions as 
designed without introducing pathologic changes in the tissue sur-
rounding the device and that -- with exceptions as noted -- test 
subjects maintained normal health and behavior during the experimental 
period. 
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CUFF PRESSURE(CM H2O) 
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IMPLANT DATE 
PRESSURE lWJUST DATB 
PRESS. PROF #1 DATE 
PRESS. PROP' #2 DATE 
PRESS. PROF 03 DATE 
EXPLANT DATB 
FUNCT.. PEST PERIOD 
PLANNED TIME IMPLANT 
ACTUAL TIME IMPLANT 
c·· J 
USD 01 
80.15 
-0.08699 
7/15/82 
2-4PH 
8/16/82 
8/26/82 
9/2/82 
9/17/82 
9/17/82 
43 DAY 
64 DAY 
64 DAY 
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TABLE 9-2: DETAILED EXPERIJ.1ENT PROTOCOL - URINARY SPHINCTER SYSTEH 
-------
USD tl2 USD H3 USD 04 USD 1/5 USD //6 USD 07 
84.8 81.0 78.8 86.4 78.6 75.5 
-0.0263 -0.0561 -0.0582 -0.0522 -0.0695 -0.0543 
7/15/82 9/2/82 9/2/82 9/16/82 9/16/82 9/21/82 
2-4PM 2:30-4:30 2:30-4:30 2-4PM 2-4PH 2-4PH 
8/11/82 9/23/82 9/23/82 10/7/82 10/7/82 10/14/82 
8/26/82 10/12/82 10/11/82 10/27/82 10/27/82 11/2/82 
9/2/82 11/19/82 N/A 11/19/82 11/19/82 11/24/82 
9/17/82 N/A N/A 12/14/82 12/14/82 12/21/82 
9/17/82 11/19/82 10/11/82 12/14/82 12/14/82 12/21/82 
43 DAY 43 DAY 43 DAY 75 D11Y 75 DAY 75 DAY 
64 DAY 64 DAY 64 DAY 96 DAY 96 DAY 96 DAY 
64 DAY 75 DAY 39 DAY 89 DAY 89 DAY 91. DAY 
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9/21/82 11/30/82 11/30/82 1/19/83 
2-4Pl·I 2-4Pf.I 2-4PM 1:30-3:30 pJ.] 
10/12/82 N/A 12/21/82 2/9/83 
11/2/82 N/A 1/11/83 3/1/83 
11/24/82 N/A 2/7/83 3/22/83 
N/A N/A N/A N/A 
11/24/82 12/4/82 2/7/83 3/22/83 
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TABLE 9-3: SET POINT PRESSURE (PH VALVE) 
Valve Pressure Leakage Rate 
System Number* (cmH20) (cmH20/min. ) 
1 80.15 -0.08699 
2 84.8 -0.0263 
3 81.0 -0.0661 
4 78.8 -0.0582 
5 86.4 -0.0522 
6 78.6 -0.0695 
7 75.5 -0.0643 
8 77.0 -0.0810 
10 74.3 -0.0898 
11 76.8 -0.1457 
x 79.34 0.07401 
s 3.89 0.03124 
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" Sf»tMARy - USD EXPERIMENTAL RBSULTS 
'J' i. J\l' 
-~- .. -
PHASE 2B 
(1) Cuff pressure (CmH2O) 
(2) Days post-op survival (% of planned) 
(3) Midline difficulties encountered? 
(4) Reservoir pocket problems? 
(5) Post-operative edema? (excessive) 
(6) Urethral stricture as evidenced at OPP 
or sacrifice? 
(7) Was subject totally/partially continent 
some period during test? 
(8) Device function demonstrated 
convincingly? 
(9) Device related death? 
(10) Did cuff rotate? 
(11) Did cuff latch open in vivo? 
(12) Did any element (septum, reservoir, 
, \ 
capacitor) rotate in vivo? 
(13) Did any element of device fail in vivo? 
( 14) Evidence of infection around cuff? I' j, 
;1 (15) Evidence of infeotion or hemorrhage 
around septum? 
(16) Evidenoe of infection or hemorrhage 
around reservoir? 
I' 
" i 
,,' 
'j I, 
(17) Evidence of necrosis, ischemia, 
hemorrhage under cuff on urethra? 
(18) Was bladder thickened? 
1 , 
i: 
I 
(19) Evidence of inflammatory or foreign body 
reaction around cuff? ! , 
; (20) Subject generally healthy at sacrifice? 
(21) Device funotioning at time of 
sacrifice? 
(22) Device pressure too high at sacrifice? 
(23) Did subject have weight loss? 
(24) Did reservoir fold in capsule or tubing 
~ or tubing curl or twist? (25) Did dog have evidence of urinary tract infection at any time during experiment? 
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FIGURE 9-3: EXTERNAL POSITIONING OF DOUBLE SEPTA SYSTEM USED IN 1st FOUR SUBJECTS (PHASE 2B) . 
SEPTA ATTACHED TO ACTIVE AND PASSIVE BALLOONS ALLOW MEASUREMENTS OF SYSTEM PRESSURES IN VIVO 
'--- ----'" ~~ --- ~ --
'~ 'O 
0;0 
;015 
-oz 
Xl:> 
Or. 
3"0 G>>' ~~ 
"'0 
X 
l. 
ORIGINAL PAG~ 
COLOR PHOTOGRAPH 
-
,
 
-
=
-
c , 
~-
- ! 
" r I.. 
~ 0, 
i 
J 
~ 
I 
n" I 
1 
T 
1 
,I 
J 
J 
J 
J 
I 
J 
I 
-'- ] 
" 
J 
I 
1 
[I 
I 
.....-
~""-"'.-
10. BVOLUTIONARY CHANGES 
Purpose: 
During the course of the development and animal trials experimentation using the urinary sphincter device, several changes were made in the various protocols for different phases. Generally, changes were only made in response to specific, well-defined problems. These changes were made following discussion between key members of the team. Changes of primary interest were those made in: 
Pre-prototype development, bench test and supporting studies Prototype system and component development Pressure tests of inter- and intradevice pressure Concepts of the animal model 
Animal trials phase A 
placement 
Sterilization teahniques 
Surgical procedure 
Configuration of prosthesis 
Animal trials phase B 
Clinical trials. 
The sequence in Which these changes evolved -- together with primary reasons for the change -- is shown in Tables 10-1 and 10-2. 
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TABLE 10-1: MAJOR EVOLUTIONARY CHANGES - PRE-PROTOTYPES 
Problems Fabrication Pressure Tests 
.. Too stiff " Hand layup " Thick balloon walls 
o Non conforming " Dipped led to eleva ted 
• Asymmetrical balloons inrerdevice pressure 
" Latch ties 
" ft!ock septum 
t:.._. __ ~ 
• :~ 
"-'_.,, , I r;~ • .j "~ 
Remarks 
e Need thinner wall 
thickness 
• Need faying (face 
to face compressing ) 
balloons 
" Add functional hand 
layed up septum 
----------------------- rSame as RGH pre-prototype 
--------------------------
------------------
m Cuff fabrication " Cuff fabrication 
technique resolved by DC 
" Need connectors design 
" Tubing mismatch " Connectors isolated 
.. Valve design change from Rosen device 
" Specifications need 
firming up 
" Ingrowth 
" Added rods as latch 
" Valve design change 
from 55, titanium 
to polysulfon," 
I 
I 
" Hand lay up using 
an aluminum mandrel 
and vacuum solves 
fabrication problem 
of cuff 
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TABLE 10-2: MAJOR EVOLUTIONARY CHANGES - ANIPIAL TRIALS 
Problems Sterilization Prosthesis Surgical Procedure Remarks 
Tubing too long. Pre-filled prior PH stainless steel Per protocol Dog lived 246 days 
Tubing through to sterilization valve 2 post-implant. 
midl~ne. DC prototype 3 Shorten tubing. 
RGH septum 
Switch to PH 10 Tubing placed thru Introduce vito C to 
titanium spring tunnel, not mid- combat urinary 
DC prototype 4 line. infections .. 
T'~o latch rods 
00 
":;0 PH 9 No longer rinse May be irrit:ant or 
"tJj§ 
02 DC prototype !;i implantation or ineffective vs 
OJ;> Ingrowth on bulb site with high Iv/tissue 
;01"" Betadine or concentration of 
rO"tJ antibiotic. antibiotic. c:> J>G) Start IV bol us. Eliminate ingrm-lth 
eM on bulb. 
<w 
PH 5 
1st AT cuff-DC 
with ingrowth 
PH 4 Vito C ineffective, 
DC 2 stop treatment. 
Midline opened Change to PH 6 Use mattress stitch Next series -
8d, closed, unfilled DC 4 to close skin. adjust septa 
resolved. sterilization Add tabs to septa Adjust device pres- pressure less 
top next sure post-op. than set point 
iteration. of valve. 
H20 urodynamic 
measurement used 
this series. 
.--. 
"" " -... ~- -- ~ ~::::: ~-:-:--. _ _ ~-.L'" 
i'~.·. . .. ····c· .. ·c--·· -,--" ~ . , . 
j " ! ~ [---;-? ~~--=~~ 
'I 
-' 
.'>.. j~ " 
,-~, ~'-=-'.ol ~---.~ 
• 
Table 10-2 (cont'a) 
:ubject* Component:. Placement Problems Sterilization 
1B Reservoir in groin. Septum flippea. Unfillea 
Double septum, one Valve button 
each side of down, 1/4 fold 
midline. reservoir. 
Tubing too long-
curl. 
i 2B 1/4 fold 
reservoir. 
Flipped septum. 
Tubing too long. 
3B 
4B Failed to detect 
overfillea 
reservoir. 
i 
f 5B 
, 
i 6B Flipped septum 
i 
! 
., 
i' it 7B Component migra 
tion. I' 
" Capacitor bond 
I line break. 
i 
: 
: 
t ~: 
i 
: I: 
I 
BB Component 
migration ! 
9B Reservoir placed 
on ribs 
lOB Tubing curl 
near capaci tor 
and septum. 
.. Tubing curl and 
knot at septum 
i 
I 
, 
" 
,~ L_. ~ .. 
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* Two systems 
c ----1 r:: __ ---, i ~C -, J r- -J ~' .~--~ ~ ~ 
(1,2) (3,4) imp1antea on same aay. 
Prosthesis Surgical Procedure Remarks 
NEC fabricated Institute alcohol Immediate post-op 
Double septa prep followed by pressure check 
Red cell shaped Betadine scrub interdevice and 
reservoir urethral 
Adaea capacitor 
C02 urodynamic 
measurements used 
this series. 
More care in pres-
sure measurements. 
Fill around stent. 
More aggressive 
decompression. 
Failure to thrive. 
Single septa Reduced time Decrease occurrence 
of pressure tests. 
Recommend UP 
printed on top 
septum, line 
printed on tubing 
to prevent twist 
"hen connected. 
Sharp cuff edge Pressure peaks at 
cuff edges con-
sistently noted, 
smooth shape for 
clinicals. 
Leave more tubing 
at: capacitor 
connection. 
suture subcutaneous 
°9 pockets closed • 
. . 
-.:J (" 0::; 
~:sa ;ilF 
,~ ~ 
~GlJ Recommend elliptical CfiifJ shape to reservoir ;1= 1\1iI as 1st recommended 
by RGH. 
Proper tubing diam. 
to wall thickness 
to prevent kinks • 
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11. SUMMARY: PRESSURE STUDIES/FUNCTIONM TESTS - PHASE 2B 
11.1 
11.2 
PRESSURE STUDIES 
FUNCTIONM TEST OBSERVATIONS 
11.1 PRESSURE STUDIES 
This section summarizes results from the pressure studies. 
Results of pressure stUdies of Phase 2A are discussed in section 8 and 
will not be repeated here. During the course of this program, approxi-
mately 45 separate experiments were performed to measure in vivo device 
pressures -- and pressures in the urethra -- using techniques described 
previously. The volume of data collected is large and conditions which 
were evaluated vargo For these reasons, presentation of raw data is 
impractical and summarization r.equires some patience on the part of the 
reader. 
Pressure measurements ,"ere made in the following locations: 
Active cuff (two septum systems only) 
Passive cuff (single septum system) 
Intraluminal pressures 
System pressurized (closed) 
System unpressurized (open) 
In measuring pressures within the active and passive cuff, traces in-
dicate pressure versus time. For measurements of intraluminal pressure 
made using a membrane catheter (Browne Urodynamic equipment), traces 
measure pressure versus distance from external meatus (outer opening of 
the urethra). 
Bench pressure values were provided with each device based on the 
measurements by MEC. These values apply only to the active cuff. 
Following implantation, RGH measured these pressures in vivo for the 
first four devices which featured a double septum. 
Intradevice pressures were measured in the active cuff only for 
the first four subjects, while measurements for the passive side were 
made f9r all 10 subjects. Intraluminal pressures were measured in all 
10 subjects. Intradevice pressures provide a measure of the absolute 
pressure seen by an elastic hydraulic system. Intraluminal pressures 
provide a relative measure of intra urethral pressure. In many cases, 
understanding of pressure data is dependent n9t only on the magnitUde 
of peak values obtained, but on the general shape of the pressure time 
curve. It is helpful to be familiar with raw data in order to fully 
evaluate system performance. After this caveat, we have grouped pres-
sure data from the study into Tables 11-1 and 11-2. Table 11-1 shows 
pressures for the first four subjects (two septum system). Table 
entries reflect the summarization of multiple readings taken across the 
duration of the experiment. Table entries define the range in which 
observations occurred during the study. 
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The occurrence of high intraluminal pressures does not necessarily suggest that blood supply to the urethra has been compromised. These pressures occurred only as the catheter was being withdrawn. The pressures do, however, confirm the presence of a hig1l pressure zone created by the cuff. 
Table 11-1 illustrates intradevice pressures in the initial four subjects. With the system in the open configuration, the active pres-sures measured in the range of 0-30 cmB20. Pressures greater than o measured with the system in the open configuration are du: to over-filling in one case and due to pressure caused by capsule ,'on traction or due to tightness of the skin over the area in which the ~ompQnent was placed. In the open configuration, the passive pressures measured (-)12 to 42. These were set to 0 or below immediately post-,~peratively (healing period) and adjusted upward to create an opposing pressure at the pressure fit. The intraluminal pressures always measured higher than the pressures imposed by either side of the sphincter cuff. This is thought to be due to pressure created by the physical presence of the cuff and the relative pressure seen by the increase of tissue mass between the normal urethral tissue and the sphincter cuff. 
With the system in the closed configuration, the active pressure for the first four subjects varied around the bench pressure. For 
system 1, the measured active pressure ranged from 73-93 cmB20 and showed a variance of +9 and -14%. For system 2, the active pressure 
ranged from 58-92 cmB~ and varied -15% from the recorded bench pres-sure. In systems 3 and 4, measured bench pressures were within ;!:10% of the set point determined from bench measurements. Combined passive pressure measurements ranged from 27-73 cmB~. Intraluminal pressures with the device in the closed configuration ranged from 119-150 cmB20. These values greatly exceed pressure that could be caused by the sphincter cuff. An indication of closing (the capability of the normal external sphincter to cause continence) is measured by a parameter 
called urethral closure pressure. This was calculated for our sphinc-ter system. The cuff UCP ranged from 50 to greater than 150 cmB20. Urethral closure pressure is defined as the closed maximum pressure 
minus the resting urethral pressure. These pressures greatly exceeded normal external sphincter urethral closure pressures which are generally about 80 cmB20 for an anesthetized subject. 
For the first four animals in which active, passive and intra-luminal pressures were measured during the urethral pressure profile, measured pressures reflect the proper functioning of the urinary sphincter system. Expected levels of transmitted pressures to the lumen were experienced. Elevated pressures are explained by tissue reaction to repeated urethral pressure profile which denudes the mucosa from the urethra. The tissue reaction can also come from causes asso-ciate~ with urinary tract infections which are a recurring problem in dogs,. 
The last six subjects had a single septum attached to the passive balloon of the occluding cuff. Active pressure was not measured and is assumed to be the bench value determined by MEC. Measured ranges for peak pressures (cmB20) for the single septum configuration appear in Table 11-2. The ranges indicate the initial pressures to the final 
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pressures over the experimental period. Regardless of the pressure in the passive side (sometimes adjusted greater than 0), the trend is to observe an increase in intraluminal and passive side pressure corres-ponding to the encapsulation·and build-up of fibrotic tissue between the intercuff surfaces and the urethra. The increase in intraluminal pressure occurred near the mid-point of the experimental period in subjects in which the passive pressure was approximately zero. In subjects in which the passive pressure was negative during the healing period, there was a slight buildup followed by a decrease to approxi-mately normal operating pressures. Recall that intraluminal pressure is an artifactual pressure since the presence of the catheter causes pressures which vary depending on the diameter of the lumen at the point being measured. For subjects 6 through 11 with the system in the open configuration, the active pressure is assumed to be O. Passive pressures measured (-)66 to 25 amHZO. The intraluminal peak pressure measured 40-135 cmff20 and showed a·very small, but sharp peak present at the distal edge of the cuff which usually measured 150 cmH20. 
With the system in the closed configuration, the active pressure is assumed to be that of the bench pressure which ranged from 74-86 
cmH?O. Passive pressures measured (-)43 to 59 cmH20. These pressures reflect post-operative and pressure fit volume adjustments to the passive side. This permitted, for the last two subjects, a very low closure pressure which allowed lower intraluminal pressures. The intraluminal pressure peaks with the system in the closed configuration measured 88 to greater than 150 cmH ZO' signiZicantly higher than the open configuration pressure values. 
Cuff urethral closure pressures for these six subjects measured between 38 150 WitIl an average value of 120. Normal external 
sphincter l~ethral closure pressure for one subject measured 132 when the dog was anesthetized. 
In comparing closed intraluminal pressures to open intraluminal pressures, one sees that the urinary sphincter system caused a large change in pressure by which continence was obtained. Observation of elevated proximal and distal peaks, which reflect pOSitions of proximal and distal cuff edges, shows that the cuff shape needs to be adjusted to be more rounded and flexible. 
To evaluate the success of the prosthesis in relation to pressure measurements, 20 questions were posed for four periods during the time thesystem was implanted. These periods are immediately post-op or at surgery, at the time of the pressure fit (21 day healing period), pressure profiles during the experimental period, and pressures taken at sacrifice. The results of these questions appear in Table 11-3, Summary of Pressure Observations. 
Table 11-3 indicates that the prosthesis causes continence or partial continenqe ~n most cases at least part of the time. These are 
subjective observations based on instances when the urine flow can be observed with the device first in the open position and then in the closed position. Demonstration of effect of the sphincter system must cause changes in the urine flow and voiding pattern. Details of this subjective assessment are described elsewhere. The actively regulated 
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cuff seems to perform its function appropriately (questions 3,G,15), 
but the prosthesis as a system needs improvement in reliability (10%) 
and care for pressure adjustment (50%). 
Results from pressure studies indicate that the hydraulic sphinc-
ter system performed as designed by operating at pressures indicated. 
The presence of the cuff element around the urethra caused an elevation 
of pressure. The presence of the catheter in the lumen caused varying 
increases in pressure seen by the system and in the urethral pressure 
profile. Due to its presence these values ranged from 0-30 amH~, 
indicating that the urethral pressure profile measurement is inaeed 
artifactual. Even though it is a relative measure of pressure, the 
profile technique indicates that the system functions to increase 
intraurethral pressure and influences the stream and voiding pattern 
of dogs (who may not wish to be continent). 
11.2 FUNCTIONAL ~ OBSERVATIONS 
The purpose of functional test observations is three-fold; (1) to 
manipulate the device and note any inoperative states or failure modes, 
(2) to demonstrate that the functioning device causes continence or a 
non-functioning device causes either continence or incontinence but no 
pathophysiology, (3) a device in an open configuration allows normal 
voiding. 
In order to establish uniform reporting and understanding of 
descriptors used in the observation notes, the wGuide1ines to Contin-
ence- document was developed. A few terms will be repeated here. 
Success (animal trials) - Success is when the occluding device 
causes changes in normal voiding pattern and causes either 
continence or allows voiding at prescribed times. 
Failure - Failure is when there is either a mechanical or hydraulic 
malfunction of the device. No difference when compared with 
normal voiding pattern when device is closed or device will not 
open to allow voiding. 
Continence - Voiding at a time or place that is socially acceptable 
(in humans). For animal subjects, continence is defined as 
voiding only when the device is open; not voiding any other 
time during the observation period when the device is closed. 
It should be noted as in humans that the system is designed so 
that if adequate pressure is applied to the bladder, voiding 
will occur due to drop in system pressure. 
Voiding - To evacuate urine. 
Sphincter, open - Balloon cuff open, allowing urine to pass, the 
reservoir is full and pillowy. 
Sphincter, closed - Balloon cuff closed, not allowing urine to pass, 
the reservoir is flat or slightly pillowy. 
Passive - Description of the self-sealing septum which is a sealed 
subcutaneous elastic device that allows penetration with 
a needle to fill one or both sides of the cuff. 
Active - Either refers to the reservoir component or fluid storage 
area to r~hich fluid returns when the cuff is open; used as a 
pump when compressed to push fluid into one side of the cuff. 
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In performing the functional tests tmd observations, it is im-
portant to understand that the animal has no desire for the successful 
operation of this device and, in fact, usually is an unwilling subject 
and is capable of self-inflicted injury. 
During the experimental period, the animal was observed for con-
tinence by determining whether there was urine in the animal's cage 
following device closure. These are denoted as cage observations. 
The device was closed 23 out of 24 hours a day when conditions allowed 
the device to be tested. During these functional device days, func-
tional test observ'ations were recorded. Spontaneous evacuations (or 
continence) which give evidence that the sphincter device is operating 
as designed are indicated under spontaneous observations. Both results 
for cage continence and spontaneous testing appear in Table 11-4 and 
are reported as numbers and percentages of total observations. 
Results for Phase 2A appear in section 8 and are not repeated here. 
In reviewing the results of continence cage observations and 
spontaneous functional test observations, one must be aware that there 
are four states of observation that can occur during the observation 
of device function. The first is total continence, in which the device 
is known to be closed and no voiding occurs in either the cage or at 
the immediate time of observation. Pe~tial continence for cage obser-
vations is when there is only a medium to small amount of urine in the 
cage (as compared to when the device is left in the open configuration) 
and the device is in a closed or partially closed state. For func-
tional test observations, partial continence is when the device is 
closed and only a minimal amount of urine flows when there is a high 
voiding pressure (strain to overcome). Both are judged as successes. 
Incontinence for cage observations is when the device is closed and 
there are large amounts of urine in the cage. For functional test 
observations, incontinence (failure) is when the device is closed and 
urine is easily voided at the time of urination with no straining to 
overcome. The final state at which observations can occur is one of 
no flow, when the device is either open or closed configuration and 
there is either no flow or attempt to void. This state of no flow was 
defined as guestionable in Phase 2A. 
Remarks describing the individual events of continence a~d device 
status appear with the numerical results of each dog in Table 11-4. 
Results are as follows: The total number of cage observations is 673. 
On the average, there were 67 observations per dog. Dogs were cage 
continent 5% of the time, partially continent 1%, incontinent 29% of 
the time. A no flow state occurred in cage observations 65% of the 
time. 
The total number of spontaneous functional test observations was 
381. The number of times there was total continence is 20%, partial 
continence is 17%, incontinence is 6%, and a no flow state is 57%. 
Partial or total continence occurred 37% of the time for spontaneous 
functional test observations and 6% of the time for cage continence 
observations. We conclude that the device affects urine flow and 
effectively causes obstruction of urine flow at times when the device 
is olosed. 
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TABLE 11-1: MEASURED RANGE OF PEAK PRESSURES (cmH20) DOUBLE SEPTUM 
N 
N 
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ACTIVE 
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INTR~~~~INAl PASSIVE 
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1 o - 30 107 - lSO 
2 0-7 SO - 183 
3 3 - 17 93 - lS2 
4 o - 20 >lSO 
( ) = Bench Measurement 
83 119 - 251 47 - 70 90 - 183 
32 - 42 75 (85) lSO - 197 37 - 92 140 - 146 
(-) 12 
- 34 84.S (81) 145 - lS2 27 - 49 l1S - 132 
8 - 25 78 (85) ) lSO 40 - 73 > 150 - 50 
UCP = closed maximum-resting urethral pressure (urethral closing pressure) 
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11-3 SUNNARY OF PRESSURE OBSERVATInNS USD PHASE 2B 
. ,-~, .. -, 
(1) r"as prosthesis pressure/function tested at 
time of implantation? 
(2) Follol'ling surger~ did active cuff (1st 4) 
~T SURGERY operate Idthin + 10% of bench value? 
(3) Did the passive cuff respond t'lhen the 
active cuff t\o'"as closed? 
(4) Did pressure traces suggest possibility 
of overfilling? 
(5) r'las active cuff still operating I.,ithin 
+10% of bench values (1st 4)? 
AT PRESSURE FIT (6) Did data indicate a high pressure zone of 
POST-21 DAY continence? 
HEALING (7) Did pressures appear to be too high from 
an2: cause? 
(8) r"as :"luid added to/removed from passive 
001101... •• cuff? 
(9) r"as there evidence to indicate device 
malfunction? 
(10) r"as fluid added to passive cuff? 
AT CPP AND (11) r"as fluid removed from passive cuff? 
FUNCTIONAL (12) r"as there evidence to indicate device 
TEST OBSERVATION malfunction? 
PERIOD (13) [vas there evidence of overfilling (1st 4)? 
(14) Had subject been totally or partially 
continent at anr-1 time during this Der iod? 
(15) rvas active cuff still operating within 
+10% bench values (1st 4)? 
(16) r"as there evidence of device malfunction 
prior to sacrifice? 
(17) Did device still demonstrate pressure 
AT SACRIFICE change in response to open-close cycles? 
(18) fvas there evidence of a high pressure 
continence zone created bl! the cuff? 
(19) Did intraluminal pressure under cuff (in 
the zone of) exceed 100 cmH20? 
(20) rvas there evidence of overfilling (1st 4)? 
YES 
TorA rE EACII DOG: NO 
* Change pressure fit philosophy 
~ 
1 
N 
1m 
N" 
NN 
N +9% 
-14% 
Y 
Y 
N 
N 
N 
N 
N 
N cap 
contract 
Y 
l>Jissing 
NEC 
N 
Y 
Y 
Y 
{>Jissing 
{>JEC 
7 
8 
*** Reservoir placement - skin tension - prevent flol'lback 
N/ A Not appli cable 
~.~ ... 
>-' ::-~ ,-" w-· 
"' 
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~ 
2" 
N 
Nf.I 
NIl 
NIl 
N 
Y 
Y 
Y 
N 
N 
N 
N 
Y 
+6 
Y 
Missing 
MEC 
N 
Y 
Y 
Y 
N 
-34 
8 
8 
~ ~ ~ ~ 
TEST SUBJECT 
, 4 5 6 7 
Y Y Y Y Y 
Y Y NN Nf.I NN 
Y Y Y Y Y 
N*** N Nil NN Nf.! 
Y Y Nil Nil Nt-J 
Y Y Y Y Y 
Y Y Y Y Y 
N N N Y Y 
-0.5 repair 
N N N N Y 
kink 
N N N N N 
N Y N N N 
N N N N N 
N Y Nil Nt.] NI'] 
active 
Y Y Y Y Y 
Y NJ.! NH NJ.1 Nf.J 
N N N N N 
Y NH Y Y Y 
Y Y Y Y Y 
strict. 
Y Nf.J Y Y Y 
N Nf.J NH NJ.1 Nt-J 
11 9 8 9 10 
9 6 6 5 4 
~ 1=3 
8 9 10 11 
" 
Y Y Y 
N/ol Nil Nt-J Nr.! 
Y Y Y Y 
Nr.! NJ.J Nil Nf.1 
Nf.I Nf.I Nil NN 
Y NIA Y Y 
Y NIA Y Y 
N NIA Y N 
N NIA N N 
N NIA N Y 
O.lcc 
N NIA N N 
N NIA N N 
Nt-J lIN NJ.J Nf.1 
Y NIA Y Y 
Nt, NJ.J Nf.J Nf.J 
N NIA N N 
Y NIA Y Y 
Y NIA Y Y 
Y NIA Y Y 
Nf.J NJ.1 NN NN 
8 NIA 9 9 
6 NIA 5 5 
~--~~-ij 
TOTAL 
~.; YES 
80 
100 
100 
a 
50 
100 
100 
40 
10 
10 
10 
0 
50 
100 
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• 
0 
100 
100 
100 
0 
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** - Catheter presence may cause too high artifact pressure 
NM Not measured 
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DOG TOTAL C 
1 1 44 1 (2) 
I 
• 
<=-'- ! 
CAGE (%) 
P I 
0(0) 3( 
~'i 
NF 
~,l 
j 
TOTAL 
7) 40 ( 91)'* 40 
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TABLE 11-4: CONTINENCE/FUNCTIONAL TEST OBSERVATIONS (PHASE 2B) 
SPONTANEOUS URINE F'LoroJ (%) 
C P I NF CONt·IENT 
11 ( 27) lOr 25) 0 19(48) This dog , .. as a very good test: sub jeet. TilC're ["ere very defi-
nitive continence test observations. Post-op pressure was 
reduced to less than 100 immediately follol"ing implant, but 
profile pressures (intraluminal) allTlays were> 100, usually 
> 150 throuqhout the experimental period • 
2 66 0(0) a (0) 2( 3) 64( 97)* 50 10( 20) O( 0) O( 0) 40(80) This dog t.,ras a very good test subject, but there t"as evidenci 1  hh I nrM I nml I f 1  1 f J*1  I lor  I f OJ I Dr OJ 1 I a I" u a . 'l'a e 
! 
i 
1 , 
: Ii 
'i 11! 
f~ ! 
~ ,~ 
r1 
1 : 
I 
L , : 
; 
I ii 
I 
'[I 
N 
N , 
'" 
3 74 0(0) 
4 28 0(0) 
5 88 6 (7) 
6 83 2 (2) 
7 84 0(0) 
;Il~r ~-_~ , .o,: __ :.,,='-----=:~ 
0(0) 74(100) O( 0) 
0(0) O( 0) 28(100) 
a (0) lS( 17) 67 ( 76) 
1(1) 11 ( 13) 69 ( 84) 
0(0) 28 ( 33) 56 ( 67) 
27 O( 0) 2( 7) 1 ( 4) 24(89) 
3 3(100) O( 0) O( 0) o ( 0) 
63 6( 9) 11 ( 17) 12 ( 19) 34(54) 
37 11 ( 30) 9( 24) 1( 3) 16 (43) 
47 8( 17) 3( 7) 5 ( 10) 31 (66) 
.,c:",::;;, "',,,,,..,,.-"-----
of blood in the urine throughout the experimental period, 
indicating urethral erosion, above and beyond damage caused 
due to profiling. Pressures in the device Ivere normal. The 
passive side lvas 32 Cm1i20. Intraluminal pressure Ivas allvays 
> 140 l'lhen closed and open usually was around 100 cmH 20' 
Extremely hyperactive dog follo\"ing the implantation. 
Virtually n~ positive continence test results were observed. 
The dog alb'dlls voided in its cage. 
This dog was a purebred subject I"ho could not overcome the 
pressure of the implanted device. Even t'Ii th adjustments, the 
active side appeared to be overfilled and pressures t'lere 
alt.,ays "> 150 cmH2O. The cuff led to obstruction and subse-
quent kidney failure and death. Nore aggressive treatment of 
this E!2.tient t"ould have been beneflcial. 
This test subject all"ays overcame the system during voiding, 
although there is some evidence that the closed device did 
influence the urine stream. 
This animal subject I'l'as an excellent model, providing 
numerous continence observations. During the healing period 
there Ivas no sign of straining. Closed, the device caused 
changes in the urine stream and sometimes continence. Open, 
the stream l'l'aS 101" volume and flol"ed normally. Observations 
of increased retention due to irritated urethra and inflamrns 
tion follOI'ling t"ere observed. Recovery period t"ith reduced 
00 
"'::<1 
.,,15 
.02 0;;::. 
::0.-
pressure t"as noted. 
This dog I"as a good test subject. There I.,as edeIIB T'lhich led 
to clumping of components and subsequent inoperation of the 
lOy 
C;;:. 
;r:.~ 
.... m ~£.?l 
device until a re-op repositioned components. Intraurethral 
pressures l'l'ere slightly high in this dog even in the open 
configuration which is evidenced by interruption of the 
stre!'lm_ o9casional~_ !'!....h.e!!_th~_ device l!TaS ,?p"~n. 
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Table 11-4 (cont'd) 
DOG TOTAL 
8 61 
10 80 
11 65 
TOTAL 673 
CAGE (<;OJ SPONTANEOUS URINE FLOI'I (%) 
C P I NT' TOTAL C P I 0(0) 0(0) 21 ( 34) 40 ( 66) 34 2( 6) 6( 18) O( 0) 
24(30) 3(4) 16 ( 20) 37( 46) 42 12 (28) 15( 36) O( 0) 
1 ( 1) 1 (1) 28 ( 44) 35 ( 54) 38 14 (37) 10 ( 26) 2( 5) 
34( 5) 5 (1) 198 ( 29) 436 ( 65) 381 77 (20) 66 ( 17) 21( 6) 
NF - No flot'l or attempt to void 
C - Continence l!li th device closed 
I - Incontinence '!lith device closed 
P - Partial continence l!lith device closed (strain to overcome) 
* - Dog voided routinely in pit 
[~~ .>=~=",-,-~-"----,-=- ~. ..,.-.~, , . 
NF 
26(76) 
15 (36) 
12(32) 
217 (57) 
CONl.JENT 
Very ski ttish test subject in t1hich intra urethral pressures 
IIrere VerI,' high. 
This dog w'as an excel !'mt test subject I.;hieh experienced 
closed pressures > 150. stricture occurred as in most of the other dogs ,,,hich caused difficulty inserting the pro-filing catheter. Probable damage occurred as visible blood 
on the mucosa at sacrifice in most dogs. 
This dog I ... as a good animal model l>7hich provided some con-tinence observations. The dog Il'as condi tioned tot"ards the 
r 
end of the experimental period to void only ,~hen the observeJ
I .. as ·not '!latchinq. 
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12. POST-MORTB~! EXAMINATION: 
Teohnique: 
The animal was prepared by removing food 24 hours before saorifioe. 
Immediately prior to saorifioe, the animal was anesthetized. Blood samples 
were taken. Devioe funotion was verified by performing intradevioe pres-
sure measurements (through the passive septum) and urethral pressure pro-
files. Euthanasia was performed by administering Sleep-Away (lO'lG Isopropyl 
aloohol, 30'lG pentobarbital sodium). 
The devioe waf.; removed, with the surrounding oapsular tissue and lower 
urinary traot, anf plaoed on a disseotion table. Careful disseotion was 
required to avoid destruotion of the devioe due to adherent tissue. Onoe 
the devioe was removed, dissection was continued to remove the devioe from 
the oapsular material. 
Serial photographs provided dooumentation of oapsular thiokness, 
devioe defeots, material disooloration and fluid oharaoteristios. Faotors 
oonsidered in assessing devioe function and changes were: relative pOSition 
of each oomponent versus position when implanted, oapsule thiokness, mate-
rial stress points or thinning, position of latoh and ouff in relation to 
original implant position, defeots in bond lines, fluid ooloration or 
evidenoe of preoipitation, position of urethra in the ouff, and thiokness 
of urethral wall. 
The isolated devioe was rinsed with Isopropyl aloohol (99'lG), plaoed in 
a plastio oontainer, and sent to Medioal Engineering Corporation for post-
implant analysis and pressure testing. Fill fluid was not removed. 
Maorosoopio Tissue Observations: 
During disseotion, the ureters, bladder and urethra were removed from 
the abdominal oavity. Organs were inspeoted for pathology, suoh as infaro-
tion, oonstriotion due to adhesions, lesions, inflamed lymph nodes, edema, 
or other abnormalities. Onoe the devioe was removed, the bladder and 
urethra were split. The walls (bladder and urethra) were examined for 
thiokness (overall), evidenoe of hemorrhage or ohanges in the musoularis, 
lamina propria and ohanges suoh as erosion and inflammation of the muoosa. 
Following examination, all organs and lower urinary traot tissue were plaoed 
into lO'lG Formalin for fixation and subsequent histology. The devioe-tissue 
interfaoe was oultured to identify infeotion. 
Miorosoopio Tissue Observations: 
Histologioal examination was performed by Dr. Z. Tomkiewioz, Chief 
Pathologist at Roohester General Hospital. Results of these examinations 
appear in Seotion 13. Analysis was performed on fluid taken from prostheses 
from the first two subjeots. There were no signifioant findings. At this 
point, analysis lias disoontinued. 
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13. HISTOLOGICAL RZSUbTS 
,-
This section describes the histological studies which were performed 
at the end of each period of observation on a test animal. All histo-
logical stUdies were performed by the Department of Pathology at RGH under 
the direction of Dr. Zygmunt Tomkiewicz, Chief of Pathology. 
At the end of each experimental period (phase 2A and 2B), an autopsy 
of the thoracic and abdom.i.nal cavities was performed on each dog. Gross 
observations on abdominal and thoracic organs; and a detailed study of the 
urinary sphincter cuff and lower urinary tract were made and recorded. The 
urinary sphincter system was removed intact with surrounding capsular 
tissue and lower urinary tract organs, washed with saline and removed from 
the tissue. The bladder and urethra were then dissected in order to 
examine the walls and internal mucosa. The device was rinsed with 99% 
Isopropyl alcohol, allowed to dry and placed in a plastic container or 
pouch. This pouch was shipped to Medical Engineering Corporation for 
teardown analysis. Numerous topographically labeled sections,as depicted 
in Figure 13-1, were taken. Microscopic slides were examined for any 
abnormality and specific histopathology criteria appear below. 
(1) Urethra 
A. Epithelium is examined for changes in architecture, cellular 
population, and injury including ulceration. 
B. 
C. 
D. 
Muscularis is examined for hypertrophy, atrophy, and other 
associated changes such as fibrosis and infiltrates. 
Serosa is examined for fibrosis and inflammation. 
Other observations 
(2) Prosthesis-Tissue Interface 
(3) 
E. Foreign body reaction in any of the capsular material. 
F. 
G. 
H. 
I. 
The thickness of the capsule is determined as an indication of 
reaction. 
Tissue is examined for evidence of erosion. 
Capsular tissue is examined for infiltrates and/or bacteria as 
an indication of infection. 
Tissue is examined for specific amorphous refractile globules 
which may indicate tissue contamination from the silicone 
material. 
Post-Mortem Tissue - Organs 
J. All organs were examined for: tissue architecture 
K. Infil trates 
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L. Normal cellular population 
M. Evidence of injury, acute or chronic 
N. Fibrosis 
The results of the histologic studies are recorded in Tables 13A-l through 
6 and 13B-l through 11 that appear in Appendix D. 13A corresponds to 
histology from the experimental group phase zq, 13B corresponds to experi-
mental animals from phase 2B. A summary table, 13-12, contains conclusions 
in a tabular form. 
In phase zq (13A-l through 6), the device was different than the prosthesis 
diagrammed in Figure 13-1 by the absence of the attenuator and the second 
septum (drum)*. This system for the first six experimental dogs was a 
device fabricated by R.G.H. (septum), Dow Corning (cuff) and Parker 
Hannifin (valve-bulb). In the second phase of animal trials, the pros-
thesis fabricated by ~redical Engineering Corporation (MEC) was employed. 
Summary: 
overall,histology shows that the implantation and function of the 
urinary sphincter system did not cause significant pathology or harm to 
the animal test subject. 
The exceptions are: one subject in Phase 2B died of obstruction due 
to overfilling of the device and of inherently poor biological condition 
associated with this animal. Some bladder thickening and urethral erosion 
occurred because of repeated urodynamic measurements (mechanical) and 
subsequent infection from introducing the UPP catheter at routine intervals. 
The animals' response to a foreign implant was to form a capsule to 
isolate it. Our concern was that no foreign body response (adverse reaction) 
occurred. Minimum tissue reaction (inert capsular material) was present at 
device/tissue interface in all test subjects but one. 
Another area of concern was changes to the urethra under the cuff in 
response to applied pressure. Figure 13-1 shows a section of urethra taken 
at the midportion of the cuff. The thin, non-reactive cuff capsule can be 
seen (A); dilated vein (B) in muscularis which is a non-pathologic response 
to pressure; slightly thickened submucosa (e); normal (D); and thinned 
mucosa (E). All changes are non-pathologic. 
* 
The term "drum" was used by pathology to describe the septum. 
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TABLE 13-12: 511Mfo!ARY OF HISTr;~y RESULTS - PHASES 2A & 28 N - non significant 
S - significant 
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ii' 
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Su~j_ect: 
Phase 2A 
I Inf. 
2 1m. 
3 Inf. 
4 
5 inf. 
6 
Subtotal % 
significant 
Phase 2B 
1 
2 
3 
4 
5 
6 
7 
8 
9 
IO 
II 
Subtotal % 
sianificant 
Total Z 
significant 
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FIGURE 13-1: HISTOLOGIC SECTION OF URETHRA UNDER MID-CUFF. THE THIN, NON-REACTIVE CUFF CAPSULE CAN BE SEEN (A); 
DILATED VEIN IN MUSCULARIS (B); SLIGHTLY THICKENED SUBMUCOSA (C); NORMAL (D); THINNED MUCOSA (E). 
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14. RECOMMENDED CHANGES (PROSTHESIS) FOR HUMAN CLINICllL TRIllLS 
As a result of the final phase of animal trials (Pllase 2B), a series 
of recommendations for changes were proposed to Medical Engineering 
Corporation. These changes were reviewed at a program meeting in Racine, 
filisconsin in November 1982. At this time, the case history of each test 
subject was reviewed based on detailed daily records, post mortem findings, 
a review of photographic records during implant, and explant surgery. 
Recommended changes to the prosthesis focused on: 
Changes to the cuff: 
Cuff 
Fluid reservoir 
Valve 
Septum 
Connectors and tubing 
Increase the bend radius at the corner of the cuff's internal 
cross-section. 
Reduce wall thickness consistent with life cycle test require-
ments. The objective of this change is to increase the elastic 
compliance of the cuff. 
Avoid all abrupt corners or sharp angles. 
Fluid reservoir changes: 
Increase wall thickness of the bulb to provide internal suction 
capability. 
Return to the ellipsoidal shape recommended at the beginning of 
the study. 
Valve changes: 
Adjust the valve's spring to compensate for elastic properties 
of the fluid reservoir and the reconfigured cuff. The assembled 
system should be adjusted so that activation of the upset 
mechanism always results in fluid return to the reservoir without 
dependence on gravi ty. 
Reduce the range on valve checkpoints and on valve leakage rates • 
Septum changes: 
Reduce septum diameter. 
Reduce septum thickness. 
Reduce corner radii on the septum cross-section to obtain a more 
molded, physiologic shape. 
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Connector and tubing changes: 
Increase the ratio of tubing wall thickness to diameter to increase resistance to kinking. 
Employ standard connectors, preferably made from the same 
material as the valve bodg. 
Reconfigure tubing end caps which should be made of hard molded plastic compatible with grasping bg forceps. 
In reviewing these changes with MEC, specific details of recommended dimensional changes were provided, together with photographic records in support of the reoommendations. Currentlg, these changes are being incor-porated in the prosthesis design bg M&C. 
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J2..:... CLINICAL TRIALS 
15.1 
15.2 
15.3 
15.4 
PATIENT SELECTION CRITERIA 
OPERATING PROTOCOL (RECOMMENDED) - MALE, FEMALE 
F.D.A CONSIDERATIONS 
INVESTIGATIVE TEAM - CRITERIA/SELECTION 
Following the positive results obtained with two phases of animal 
trials, it is appropriate to pursue investigation into human patients. 
This task is t.ne responsibility of the device manufacturer who must meet 
conditions imposed by the FoD.A. in order to market a prosthesis. We have 
developed numerous criteria to aid the manufacturer with this task. 
15.1 PATIENT SELECTION CRITERIA 
Patient selection criteria have been outlined by numerous inves-
tigators (e.g. Scott rANS device) and "Surgery of Female Incontinence" 
by Stanton and Tanagho, 1980). Indications for use of a prosthetic 
spl)incter system are post-prostatectomy incontinence, stress incontin-
ence where other operations and modes of management have failed, 
epispadias, incontinence after urethral replacement by bladder flap 
reconstruction, neurogenic bladder secondary to meningomyelocele, 
spinal cord injury, mUltiple sclerosis, sacroagenesis, spinal cord 
tumors and other incontinence secondary to operative procedures. 
Before patients are considered for implantation with an artificial 
sphincter, a pre-op evaluation should be performed using urofluorometry 
to determine flow rates in order to rule out obstructive uropathy. 
Cystometry should exclude the presence of detrusor hypereflexia and/or 
the ability to have medical control of lower urinary tract using ENG. 
Urethral pressure profile should demonstrate intraurethral pressures. 
Other tests for a complete urodynamic work-up include: residual urine, 
sphincter ENG, pressure flow study, urinalysis and culture to insure 
that the urine is free of bacterial growth, panendoscopy (pre- and 
post-operatively to rule out other pathology) and estimates of sphinc-
ter cuff size requirements (prior to surgery). 
A urodynamic questionnaire should be completed by each prospective 
patient at the first visit. This data mag be computerized for inves-
tigations and tabulation of follow-up data. 
For the initial clinical trials, groups of patients should be 
selected at designated medical centers. Patients should be motivated, 
understand the advantages and disadvantages of an artificial urinary 
sphincter, have manual dexterity, and be capable of communicating 
effectively with the research staff. Bach patient should undergo 
teach.ing, preferably from the surgeon, about the artificial sphincter 
implant. Teaching may consist of slide-tape or video presentations. 
Xt is recommended that any patients with urinary sphincters wear 
appropriate medical identification bracelets or jewelry. 
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15.2 OPERATING PROTOCOL (RECOMMENDED) :: MALE, FEMALE 
Specific guidelines for selection of the procedure according to the type of incontinence are given by Furlow. 
For males - Males will be placed in the lithotomy position. A perineal incision will be made, isolating and identifying the bulbous urethra. Dissection will be performed isolating the bulbous urethra. The artificial sphincter cuff is placed around the bulbous urethra. A blunt dissection rrill be performed from the incision into the testes rrhere the bulb-valve will be guided and placed. Blunt dissection through the skin will be performed to place the self-sealing subcu-taneous septum element of the system. All system components will be connected via tubing and a system check will be performed by operating the artificial sphincter. 
For the female a suprapubic inc~s~on is used. The bladder shall be isolated and retracted, identifying the urethra. A stent may be inserted into the vagina to aid in identification and dissection. Blunt dissection will be performed, carefully separating the urethra from the vagina. The artificial sphincter cuff will be placed around the urethra and latched. Tubing exits at the top of the bladder. After the cuff has been rotated to its normal position, the bulb-valve is placed via a conduit into the labium. The self-sealing septum element is placed in a non-obtrusive subcutaneous position. Position-ing of the valve-bulb and septum should be considered pre-operatively. Sites should be marked so that skin folds and other anatomical bends are taken into consideration. The literature in this area is extensive. RGH will provide consultation to MEC as required. 
15.3 F.D.A. 90NSIDERATIONS 
MEC, as system fabricator, will assume responsibility for meeting F.D.A. requirements. It is proposed that the IDE and 5101( be submitted for the urinary sphincter device. RGH will supply necessary informa-tion and data to allow MEC to meet the documentation requirements of the F.D.A. 
15.4 INVESTIGATIVE TEAM - CRITERIA/SELECTION 
The investigative team should consist of a multi-institutional team in which RGH will not be the primary investigator. The principal surgeon at RGH is a pediatric urologist and handles too few cases for a timely clinical development phase. Discussions with MEC indicate that they prefer to select their own investigative team. 
The initial number of implants envisioned for human clinical trials to meet F.D.A. approval may be a low estimate. Instead of 20, as indicated in the contract work statement, perhaps 100 patients are required for F.D.A. approval to market this device. Criteria for an investigator are: Background, surgical experience and interest in 
urologic problems; execution of an investigator agreement form; com-pletion of surgical training (consisting of a slide-tape or videotape teaching session, hands-on experimental implantation in an animal sub-ject or implanting with one of the co-investigating surgeons in a human patient. 
At the present time, MEC is developing detailed plans for clinical investigations • 
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16. RESULTS 
This section provides a brief subjective assessment of program per-
formance with regard to stated objectives. Detailed results of technical 
tests and physiological tests have been provided elsewhere in the report. 
In general, we believe that the program has been successful in effecting a 
transfer of valve technology into the biomedical field. Table 16 sum-
marizes performance by phase: 
TABLE 16: SUBJECTIVE ASSESSMENT: PERFORMANCE BY PHASE 
Phase 
1. Bench studies 
2. Animal studies 
3. Clinical trials 
Assessment 
Successful. Pre-prototypes and prototypes 
demonstrated performance in repeated tests. 
Successful. Work occurred in 2 stages. 
Initial trials with prototype hardware. 
Final trials with improved hardware and new 
manufacturing source. 
Not completed. Ongoing. Responsibility for 
this work has been transferred; together with 
relevant technical data, to the device manu-
facturer, Medical Engineering Corporation, 
Racine, Wisconsin. 
Since the initiation of this study, the valve manufacturer, Parker 
Hannifin Corporation, Irvine, California, has formed a medical products 
division. One of the products offered by this division is the valve used 
in the urinary sphincter. This valve also has applications in other 
prosthetic sphincters and these applications are being pursued. 
The device manufacturer, Medical Engineering Corporation, Racine, 
Wisconsin, has recently been acquired by the Bristol-Myers Corporation. 
MEC will continue to manufacture a wide range of silicone rubber pros-
theses under its new management structure. 
MEC and PH have negotiated business teaming arrangements relative to 
the use of the PH valve in the urinary sphincter system. They have agreed 
that, based on MEC's experience with implantable prosthetic devices, that 
MEC will lead activities in the clinical trials phase and in subsequent 
F.D.A. approval activities. 
In October 1983, MEC suspended accelerated testing on valves and 
system components after 521,000 test cycles. This greatly exceeds require-
ments developed at the beginning of this program and is indicative of the 
effort being applied to device development. 
Based on the work currently underway and on the results of this 
program as contained in this report, we believe that a successful transfer 
of valve technology to a biomedical application has occurred. The ultimate 
success of the prosthesis in humans remains to be demonstrated • 
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17. CONCLUSIONS 
In developing conclusions for a program spanning more than five years, 
it is convenient to group them into the categories shown below. Some of 
the conclusions drawn are based on hard evidence, while others reflect com-
posite subjective judgements reflecting our experience • 
Overall system performance 
Device function 
Animal models 
Intraoperative fill procedures 
Operative protocols 
Post-operative observations 
preparation for clinical trials 
Overall system performance: 
Implanted prosthetic urinary sphincters are effective in creating 
continence in human subjects and in animal mOdels. 
Pressures transmitted by the cuff to the urethra can be maintained 
within specified limits based on careful design of the prosthesis 
as modified by non-invasive techniques in vivo. 
Appropriate tests on key elements of a prosthetic urinary 
sphincter can verify performance through any reasonable and 
prudent number of specified cycles. Each proposed design for 
the cuff element of the RGH prosthetic urinary sphincter was 
successfully tested to or beyond the specified number of cycles. 
System testing of a completely assembled device should be 
deferred until a final system configuration has been determined. 
Performance of the device without histological damage or without 
unacceptable histological change has been verified by in vivo 
testing. The proposed configuration is ready to begin clinical 
trials in selected subjects. 
No mechanical malfunctions of a type which would be injurious to 
an animal or a human subject were encountered. Latch mechanism 
failures, as reported, result in a non-functioning system. These 
failures can be eliminated by appropriate design modifications 
(already completed in the design) and by attention to technique 
during implantation. 
The urinary sphincter system, as modified by specific recommenda-
tions to the selected vendor, is considered to be ready for human 
clinical trials in properly selected patients. 
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Device function: 
The USD prosthesis creates continence in canine subjects when 
properly placed. The prosthesis performs well within specified 
limits. When problems were encountered, the reasons for these 
problems were understood and were resolved. 
The device is well tolerated by tissue, as verified by tests both 
in canine subjects and in rat models during the early stages of 
the program. 
Where fixation is required for the septum or the bulb-valve, 
several appropriate fixation materials can be used with assurance. 
In the region of the urethra surrounded by the sphincter cuff 
some thickening and physiologic change may be encountered, but 
these changes are not pathologic. 
The septum configuration used during in vivo tests on animals was 
larger than the corresponding device used in humans and it per-
formed successfully. Proposed modifications to the septum for 
use in human trials are expected to produce an improved cosmetic 
result with no loss in function. 
The bulb-valve configuration is easily palpated beneath the skin 
in animal models. Some migration of this device occurred in 
canine subjects. This can be resolved through the use of fixa-
tion material. The size and shape of both the fluid reservoir 
and the valve body are compatible with subcutaneous palpation 
that the small volume of fluid required to activate the cuff 
prevents positive feedback to the operator, requiring judgement 
and experience on the part of the operator. This is not expected 
to be a problem in human subjects. 
With the exception of one subject, no health or management 
problems were encountered which are directly attributable to mal-
function of the system with regard to its ability to open and 
close. In the one case where an adverse reaction was encountered, 
contributing factors are understood and should not preclude prog-
ress into a human clinical phase. 
Animal model: 
Canine subjects tolerate the urinary incontinence prosthesis 
well. They provide a practical, though far from ideal, model 
for prosthesis development. 
Verification of the device in animals can be ambiguous since the 
test subjects are not incontinent. With determination they can 
apply sustained pressure to succeed in voiding. The difficulties 
encountered as a consequence can only be overcome by careful 
daily observations. 
The creation of a controlled model for an incontinent animal is 
not considered to be a practical approach in studies of this 
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nature. Several attempts were made to create an incontinent 
canine subject by a range of surgical techniques. None were 
successful. This approach is not recommended for subsequent 
investigators. 
There are few instances in the available literature indicating 
animal experience with a urinary sphincter prosthesis. This is 
probably due to the difficulties associated with constant monitor-
ing and to concern over possible problems with reflux and at-
tendant kidney damage. Subsequent investigators who employ canine 
subjects for similar prosthesis testing should consider the selec-
tion criteria developed during this study. In general, female 
subjects are preferred based on anatomic considerations, ease of 
surgery, and convenience in subsequent monitoring of device 
performance. 
Operative protocol: 
The operative protocol employed to place the urinary sphincter 
prosthesis in animals (and human subjects) is relatively simple 
and requires little time. 
In vivo testing was limited to female subjects. Placement is 
relatively straightforward due to the size and position of the 
urethra. This situation is expected to apply in human patients. 
Placement in males is more difficult as a consequence of urethral 
length and configuration. Some development of an appropriate 
protocol for placement in human males will be required. Place-
ment of the septum may vary both in canine subjects and irl human 
subjects based on convenience, ease of access, and desired cos-
metic results. Consideration should be given to the use of 
fixation tabs or ingrowth material to prevent migration of the 
septum. ~'he use of fixation sutures or any element of this 
prosthesis is not recommended due to possibilities for damage. 
The use of fixation material as an aid to placement of the bulb-
valve and fluid reservoir is optional based on the surgeon's 
judgement and experience. While no adverse consequences are 
expected as a consequence of using ingrowth material, some 
thickening may be encountered which is undesirable in the scrotal 
or labial areas used to place this §lement of the prosthesis. 
Intraoperative fill procedure: 
Intraoperative placement of clean sterile fluid is recommended. 
Initial implants employed pre-operative fill prior to steriliza-
tion of the prosthesis. This teChnique, while acceptable, is 
considered less flexible than intraoperative filling. The use 
of an assistant to fill a pre-sterilized device is the preferred 
technique. 
All elements of the device should be filled and tapped to remove 
all air bubbles. We employed saline containing 1.4% Conray, a 
radiopaque tag material. This level, determined experimentally, 
is considered to be the minimum amount which will be visible 
during subsequent fluoroscopic examinations. 
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Fluid should be introduoed using a syringe with a Millipore 
filter. 
Follol~ing positioning of the ouff around the urethra, shod clamps 
should be removed and fluid should be allowed to run out of the 
ouff in order to obtain an equilibrium position around the 
urethra. Care is required on the part of the surgeon and 
assistants to prevent overfilling the devioe. There is evidenoe 
to indioate that underfilling is the preferred teohnique. 
Reported experienoe with the AMS urinary sphinoter (Model 742) 
indioates that an underfilled ouff should be implanted and per-
mitted to heal for a 6-week interval prior to aotivation. This 
approach is recommended. 
Post-operative observations: 
The response of oanine subjeots to the urinary sphinoter pros-
thesis varies, but in general it appears to have little impaot on 
health, appetite, and disposition. Multiparous females make good 
subjeots and are well suited to post-operative examination and 
testing. 
Post-operative tests with urethral profiling equipment provide 
a good picture of device performanoe. These tests, however, are 
a oontinuing cause of irritation and possible infection. Routine 
use of these tests is not required. Daily observations of devioe 
performanoe are often ambiguous sinoe a healthy animal oan over-
come the cuff with effort and since a properly funotioning device 
can be opened by action on the part of the test subjeot. In spite 
of these souroes of ambiguity, careful daily observations oan 
verify device performance. 
Preparation for clinical trials: 
Based on the incorporation of reoommended ohanges, this.prosthesis is 
suitable for use in clinical trials. Key steps include tbe following: 
Selection of partioipants and institutions 
Identifioation of a principal investigator or investigative 
ooordinator 
Coordination with appropriate Human Experimentation Committees 
Development of a suitable experimental protoool 
Establishment of an integrated approaoh to data oolleotion 
and analysis 
Identifioation of patient soreening oriteria 
Provisions for informed oonsent, pre-op oounseling and other 
patient considerations (i.e. oost considerations) 
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Initiation of activities leading to approval bg the FDA 
Development of a coordinated marketing plan 
Consideration must be given to the number (and dimensions) of device 
sizes required to serve the market. RGH will provide recommendations 
on device size requirements to ~C. Recommendations concerning pro-
tocol development have been submitted previouslg. 
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18. RECO~NDATIONS 
Recommendations stemming from this studg mag be grouped in three 
general categories: 
A. Recommended changes to the prosthesis for human clinical trials 
B. Recommendations for surgical placement in humans 
C. Recommendations for the human clinical development phase 
These recommendations have been transmitted to MEC, PH and to NASA-MSFC 
previouslg. In most cases, theg are alreadg being incorporated into 
ongoing activities. These recommendations are brieflg summarized as 
follows: 
A. Recommended changes to the prosthesis 
Most of these recommendations were reviewed with HEC, Racine in 
November 1982 at which time the rationale for each change was 
presented and supported with slides. Areas for change (not listed 
in order of importance) were: 
1. Septum configuration 
2. Tubing end caps 
3. Cuff reconfiguration 
4. Valve changes 
5. Fluid reservoir configuration 
Fixation tabs 
Septum configuration 
The septum configuration used for animal studies is felt to be 
excessivelg large; incompatible with subcutaneous placement in 
,human subjects. Recommendations for reduction of both diameter 
and thickness to approximatelg 50% of current size were made to 
HEC. Ingrowth tabs are also recommended to promote fixation. 
Tubing end caps 
To plug the ends of tubing leads for various components of this 
sgstem, rigid plastic end caps are recommended. These caps 
prevent the introduction of particulate contamination, prevent 
fluid loss subsequent to filling and aid in device placement. 
Round or "bullet-nosed" caps are helpful when the tubing is 
being drawn through subcutaneous tunnels. 
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B. 
Cuff reconfiguration 
The occlusive cuff for the urethra should be reconfigured to 
provide additional compliance, a more natural opening for 
urethral passage, larger radii of curvature where the urethra 
enters and exits the cuff, and an overall design reconfiguration 
to an improved molded shape whiab reflects physiologic considera-
tions. 
Valve changes 
Changes are required in the valve to compensate for any increased 
stiffness of the fluid reservoir and in the decreased stiffness 
of the cuff. Close coordination between PH and MEC is essential 
to insure that the assembled system functions within specified 
limits and that the opening in the valve permits a sufficient 
fluid return from the cuff to allow flow through the urethra. 
Variability of abeck pressure should be addressed. 
Fluid reservoir configuration 
The spherical fluid reservoir used in the animal trial phase 
should be replaced with an elongated, ellipsoidal reservoir with 
the same internal volume. Drawings and sketches developed by MEC 
have been reviewed at RGH and reflect an improved configuration. 
Fixation tabs 
Use of fixation tabs made of ingrowth material is optional with 
this device. They should be included with the prosthesis con-
figured in such a way as to permit easy removal by the surgeon if 
they are not required. A small amount of ingrowth material is 
satisfactory in any location and should not exceed O.5mm x O.5mm. 
Recommendations for surgical placement in humans 
A single low anterior incision is suitable for placement in females 
and should be sufficient for placing all elements of the syst.em. 
Techniques for placing the prosthesis in males should be evolved by 
participating clinical investigators. 
C. Recommendations for human clinical trials 
The manufacturer, MEC, should proceed with work appropriate to 
beginning human clinical trials with a modified prosthesis. 
An investigative team should include representatives from several 
participating institutions to insure a balanced study. 
We recommend that procedures developed for use in the human phase 
permit a period of inactivation to occur, allowing the device to heal 
in place before regular periodic pressurization is begun. 
18-2 
~ oi/;, J ~.: 
I' , 
!~ 
q 
" 
" 
" 
;,1 
'J 
f 
r 
i 
i 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
if 
,{I) 
I 
Screening criteria for patient selection should be developed and 
agreed to bg all participants prior to the start of a clinical phase. 
The purpose of such criteria should be to insure an evaluation of the 
prosthesis which is compromised bg other complicating factors. 
In general, we recommend that M8C initiate a full-scale clinical 
development activitg oriented toward ear1g F.D.A. approval of this 
prosthesis. 
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19. NEW TECHNOLOGY 
Under the New Technology Clause of this contract, periodic reports 
were required on new technology. In general, these reports were negative, 
however tlfo reportable items were disclosed. 
In 1981, RGH disclosed a concept for a two-chamber cuff. One version 
of a double-chambered cuff had been shown in the original RGH proposal to 
NASA. A variant of this design was disclosed following the development of 
several pre-prototypes (hand layups). An invention disclosure was submitted 
to NASA-MSFC and a decision to file (N~-MSFC) was announced in November 
1981. 
Following a series of meetings Idth NASA and with other members of the 
Program Team, NASA made a decision to file and, in October 1982, a patent 
was issued. 
In 1982, a second disclosure was made for an occlusive cuff to be usea 
in the sw:gical construction of a continent ileostomy. This device Ifas a 
variant of previous cuff designs modified for compatibility with a specific 
surgical procedure. The proposed device did not emplog a pressure regulat-
ing valve. Following internal discussions within NASA-MSFC it was decided 
that the disclosure did not constitute new technology and that NASA would 
not file for a patent on this device. 
No additional inventions or other elements of reportable new 
technology were encountered during this study. 
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21. REFERENCES 
During the course of this study, RGH monitored the medical literature 
on a oontinuing basis. Papers and reports of interest to program personnel 
were obtained and oiroulated for review. A wide range of topics were sur-
veyed -- from surgioal procedures to urodynamic studies. Consequently, the 
volume of reference material is large. Older papers are sometimes less 
helpful and newer survey papers often roll-up the experienoe of previous 
investigators. Consequently, we have eleoted to oite only a few of the 
referenoes we found to be most helpful. 
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inoontinence. Two are: (A) "The Study and Control of Bladder-Urethral 
Funotion", The Inoontinence Reporter 1(3): 1973, 1(6): 1976, 1(7): 1978, 
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5. Brooklehurst JC: Differential Diagnosis of Urinary Incontinence. 
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1978. 
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Shawer M, Brown M, Sutherhurst: Comparative Examination of 
Female Urethral Pressure Profiles Measured by C02 and H20 
Infusion Techniques. Br. J. Urol. 55:326, 1983. 
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22. KEY REPORTS AND TECHNICAL DOCUMENTS 
In the course of this program, RGH prepared a number of freestanding reports, analyses, test protocols and specifications. This section sum-marizes this work. Typically, reports were numbered sequentially during the year in which they occurred (e.g., 80-3: third report in 1980). In several cases, the testing performed by RGH on prototype configurations has been performed by the manufacturer using improved hardware and more sophis-ticated test equipment. We believe that requirements for documented testing required by the FJ).A., coupled with the manufacturer's detailed knowledge of the prosthesis will insure adequate testing for a safe and effective prosthesis. 
The summary which follows demonstrates the breadth of testing per-formed or managed by RGH in support of program objectives. 
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URINllRY SPHINCTER PROSTHESIS 
DOCUMENT LIST 
SYSTEM .DESIGN & SPECIFICATION 
Document # 
RGH 78-la 
RGH 78-lb 
RGH 78-2 
RGH 78-3 
pH 92003 
RGH 79-2 
RGH 79-3 
RGH 79-5 
RGH 79-6 
RGH 79-7 
RGH 79-8 
RGH 79-13 
RGH 80-2 
RGH 80-3 
RGH 80-4 
RGH 80-5 
RGH 80-6 
RGH 80-7 
RGH 80-8 
9/78 
9/78 
9/78 
9/78 
2/79 
6/79 
9/14/79 
2/12/79 
1979 
2/5/79 
5/79 
12/79 
System Design - Cadaver Studies 
Valve-Bulb Design Characteristics - Human Fit 
of Me-dels 
Design Guidelines: Operative Procedure and 
Configuration - USD 
Valve Specification: Urinary Sphincter Prosthesis 
PH Acceptance Test 
PH Valve/Bulb Acceptance Test - RGH and Data Sheet 
Review of component Dimensions of the Artificial 
Urinary Sphincter System 
Question-Answer: Effects of Cuff Pressure 
(literature - physiology data) 
Summary of Design Characteristics: Urethra 
Occlusive Cuff (with literature and sketches: 
detailed) 
Cuff Specification - Prosthetic Urinary Sphincte. 
Septum Specification - USD 
RGH Septum Design 
RGH Protocol - Particle Size Analysis 
component Acceptance Test 
System Acceptance Test 
Cleaning Protocol RGH P005 Needle Stop 
Quality Control Protocol Bacteria Contamination 
System - Material Handling, Sterilization and 
Clean Room Procedures 
Comparative Study - System Design versus 
Current Devices Found in Literature 
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Document # 
RGH 80-9 8/80 
RGH 80-10a 
RGH 80-10b 
RGH 80-11 
RGH 80-21 
RGH 80-22 
RGH 80-23 
RGH 80-24 12/80 
RGH 82-1 2/82 
PH E92003 
PH P~ID Series 8000 
RGH 82-2 
Title 
Septum Test Report Johns Hopkins (PH-IPIP) 
RGH Septum Penetration Test - GG septa 
RGH Septum Penetration Acceptance Test 
Post Implant Teardow.n Analysis - PH Valve 
Post Implant Analysis Recommendations for 
Clinical Trials 
System Drawings/Component Drawings Urinary 
Sphincter Prosthesis (sent to MEC) 
Recommendations for a Coordinated Approach to 
Release of Information on the USD Prosthesis 
Results and Disposition List, PH Prototype Valves 
Phase 2A Animal Trials 
Patent Application Letter to J.H. Beumer, NASA 
Drawings Valve/Bulb and 
Prosthetic Pressure Control Valve Illustration 
MEC USD System and Component Drawin~s 
UATERIAL CRITERIA AND SELECTION 
RGH 79-1 
RGH 79-12 
RGH 79-4A 
RGH 79-4B 
RGH 79-10 
RGH 80-
RGH 80-15 
RGH 80-18 
9/79 
4/79 
7/79 
6/79 
9/80 
10/80 
Literature Survey of Biocompatible Materials 
Effects of Absorbable Lipids On and Into 
Silicone Elastomer (SilastiaR): Decision to 
Pursue Investigation as a Potential Problem 
Surface and Uaterial Characteristics of the 
RGH-NASA Artificial Urinary Sphincter 
Evaluation of Ingrowth Materials 
Fill Methods/Packaging Techniques USD (Table ) 
Letter from J. Vallender (DC), Silicone Materials 
used in Sphincter (transmitted to D. Sanders, 
MEC) 
The Evaluation of Velcro as an Implantable 
Material 
Letter from E. Eddins, UDEC Polysulfone 
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Document U 
RGH 80-19 
RGH 80-
RGH 80-20 
RGH 82-3 
12/80 
1980 
Title 
Evaluation by Literature Review of Polysulfone 
Multiple Requests for Literature on Materials, 
Material Standards, Device(s), and Costs. 
Study of Permeability of Thin Silicone Elastomer 
Membranes 
RGH-MEC-PH Explant Analysis and Device Disposal 
Protocol 
CONSTRUCTION/~NUFACTURER - VENDOR SELECTION 
RGH 78-2 10/78 
IITRIUH6046C58 2/79 
RGH 79-10 8/79 
RGH 79-.rl 5/79 
RGH 80- 5/80 
Vendor Selection Criteria 
Market Analysis of the Prosthetic Urinary Sphincter 
Preliminary Evaluation of Dow Corning Prototype 
Cuff 
Selected Bibliography for Urinary Incontinence 
and Mechanical Devloes used for its Control 
Letter, Steve Wirtz, Vendor List 
BENCH TESTING - DEVICE (VALVE/CUFF/SEPTUM/SYSTEM) 
RGH 79-9 2/79 
RGH 80-13 9/80 
RGH 81-4 
ANI~ STUDIES 
RGH 80-9 
RGH 80-13 9/80 
Summary of Cyclic Pressure Testing: Prototype 
Cuffs 
Evaluation of RGH Sphincter Cuff Animal Studies -
In Vivo 
Bench Pressure Test Urinary-Colostomy Sphincter 
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23. APPENDICES 
A. Animal Trials Protocol 
B. Produot Development Protoool (PDP) 
C. Case Histories - Animal Trials 
D. Histology Reports - Phases 2A and 2B 
E. Explant Analysis: Urinary Sphinoter System 
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APPENDIX A 
~~ Rocli8ster' 
~General 
~Hospital 
.". ,;.1\ .,.J', ':'"'{' •. , / •.•• ! .'t y' -. , ., .... 
OlmGii\!l\l :?:':\e~ U~ 
Ol? flOOR QUf.\UTV 
9/15/82 
ANIMAL TRIllLS PROTOCOL: URINllRY SPHINCTER SYSTEM 
Number of trial = 2nd 
Number of animals = 10 
Septum Systems ~ 
Begin June 1982, complete January 1983 
December 1982, first buman implant 
Tbird generation, produced by Medical Engineering Corporation, using plastic valve from Parker Hannifin, double-pillow cuff and attacbed latcbing system. 
Continence Status of ~Animals: 
Continent animals will be "controlled" by the valve-cuff system. Studies in two dogs designed to evaluate continence revealed tbat 
relative continence returned after extensive uretbral slitting. Also the scarring and bealing after surgical incontinent procedures creates a test animal tbat is not typical of most anticipated buman applications. 
Criteria of Evaluation and Frequency ££ Making Observations: 
1) The ability of 
the test dogs. 
2:00 PM. 
tbe device to set a daily urinary schedule for The open periods each day will be 8:00 AM and 
2) The absence of urine on clean test sheets placed in each cage 
or clean cage after system closure. (If animals are controlled, the test sheets should stay dry during closed periods of tbe 
valve (3 times daily).) 
3) Animal cooperation with the closed system (straining, dribbling, 
etc.). (Two times daily immediately prior to opening valve.) 
4) Urine normality - absence of bacteria, white blood cells, red blood cells, protein (weekly or PRY). 
5) Absence of clinical infection - increased temperature, increased white count, loss of appetite, vigor (daily first three weeks for temperature, vigor; weekly for white count). 
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Animal Trials Protocol - USD 
OFlIGli'!J.\Tl. IPF\~~ [~ 
OF. POOR QUA!.nY 
6) 
7) 
Absence of strong inflammatory lesion in tissue around device 
(once, after tissue analyzed). 
Absence of gross infection in tissue around the device - pus 
accumulation, necrotic tissue, abscess formation (once, at 
time of removal). 
8) Functional ease of use - emphasis on pressure r~lief button, 
easy use of bulb for pressurizing (daily). 
9) Ease of placement at operative table (once). 
10) Size - accommodation to animal urethra (one" ,i 
II) Freedom from mechanical failure - connector!., :ubing kinks, 
valve failure to control hydraulic fluid (do,.::ly, unless it 
fails). Periodic x-ray. 
12) Pressure profile of the urethra with cuff closed and open 
(done once at three weeks post-op and every eight weeks). 
2 
Final Analysis: Criteria 1 through 12 will be given a 0 to 4+ possible 
score each day measured. 4+ will signify correspondence 
with ideal sought after result. 0 = no sought after 
element present. Each animal with a device will receive a 
final score and a graphic profile. 
4 
3 
Score 2 
1 
o 
X""X/-X -x~ \ / 
1 
x,--x 
2 3 4 5 6 7 
Criterion 
The whole group will receive a 
with deviations from the mean. 
can thus be identified. 
8 9 etc. 
composite profile 
Trouble spots 
Duration of Study: 
4 animals 
2 animals 
2 animals 
64 days (double-septum) 
96 days 
66 days 
The healing period will be three weeks prior to device activation. 
Detailed procedures are appended (surgical, post-op nursing, etc.) 
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Animal Trials Protocol - USD 
OiRIG~i'!P.L r:iX~~: ~~~ 
OF POOR QUALITV 
~ Fluid Analysis: 
For biological ions, protein enzymes - done once at time of removal. Device will be returned to Medical Engineering Corporation. Send teardown protocol - remove fluid by clamping off. 
1.0 Purpose 
The purpose of these animal trials is to evaluate the prosthetic sphincter system. This evaluation consists of functional device testing and biological evaluation for pathological changes caused by the device. 
2.0 Scope 
The experiment is intended to implant, assess, test the sphincter in 10 animals for periods of 4 to 43 days, 3 to 75 days, 3 to 45 days, following a 30-day conditioning and 21-day healing period. 
Funding is for 6 animals. RGH funding for first 4 animals. 
3.0 Experimental Design 
-- Interval to Sacrifice --
43 days ~ days 75 days Number of test animals 433 
4.0 System Description 
3 
The urinary sphincter system is an hydraulic system that consists of a two balloon cuff which encircles the urethra and is used to occlude; a bulb-valve which acts as a fluid reservoir and way to inflate one balloon of the cuff; and the valve which maintains fluid in the cuff a~d can self-adjust to relieve increases in pressure. The final com-ponent consists of a self-sealing septum that is attached to the second balloon in the cuff to pressure/size fit the cuff of the sphincter system. 
System materials are as follows: (or as specified by manufacturers) 
Cuff, septum body, bulb, valve parts - silicone elastomer 
septum needle stop - polysulfone 
Connectors - titanium 
Valve - polysulfone 
Valve springs - MP35 
5.0 Selection 9!. ~ Animals 
5.1 Obtain from Dog Dealer, multi-parous female 
5.2 Weight, 15 to 25 kg. 
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Animal Trials Protocol - USD 
5.3 
5.4 
5.5 
Short hair 
a bservation period of 10 days 
5.4.1 
5.4.2 
If healthy, place in conditioning cycle for an 
additional 20 days 
If sick, terminate 
Behavior - happy, tough, aggressive, playful 
6.0 Preconditioning 
6.1 Hold for 30 days observation (includes 10-14 days initial 
observation) 
6.2 Assign dogs names, numbers and start documentation 
6.2.1 
6.2.2 
Number system should consi~t of a 6-digit code similar 
to example given below: 
Project Device ~ 
US 01 02 
Voiding habits observed and recorded. 
6.3 Vaccinated with canine distemper - hepatitis, leptospira 
canicola - licterahaemorrhatiae bacteria vaccine (Fort Dodge). 
Given day 14. Worm medication given days 1 and 14, and as 
necessary. 
6.4 Behavior assessed 
6.5 Start handling dogs daily around area of bulb-valve placement 
so dog is comfortable with technician. 
6.6 Normal pressure profile 
6.7 Clinical assessment 
6.7.1 Overall 
6.7.2 Laboratory tests (day 15 conditioning period) 
6.7.2.1 
6.7.2.2 
6.7.2.3 
Chemistry - SNAC, lipid profile, protein 
electrophoresis 
Hematology - CBC, differential, RBC 
morphology, ESR 
Urinalysis - routine 
23A-4 
4 
I 
I 
"1 
i! ,. 
~ 1 
: ~ 
I 
" 1 
~ ~ •.. -
r: I 
'I 
I 
I 
I 
I 
I 
I 
I 
I 
J' 
I 
J 
I 
J 
I 
I 
Animal Trials Protocol - USD 
7.0 Pre-operative 
7.1 Select preconditioned subject randomly (random # list) 
7.2 No food 36 hours before surgery 
7.3 Laboratory tests (same day as surgery) 
7.3.1 
7.3.2 
SMAC, lipid profile, protein electrophoresis 
(every 3 weeks) 
CBC, differential, RBC morphology, ESR 
7.4 Antibiotics 
Keflin or Ancef 
7.4.2 500 mg I.M. 12 hours pre-op 
7.4.3 1 gm I.M. immediately pre-op 
7.4.4 1-2 gm I.V. push 15-20 min. before surgery 
7.5 Anesthesia 
7.5.1 60 mg Pentobarbital/SIbs. body weight, I.P. 
7.5.2 Maintain I.V. as necessary 
7.6 Prep 
7.6.1 Shave back for electrocautery ground 
7.6.2 Shave abdomen for implant, wash with Isopropyl alcohol 
7.6.3 Prep with Betadine. ;"et dry 10 to 15 minutes 
7.6.4 In sterile fashion, ,ilpply Steridrape 
7.6.5 Place drape sheet 
7.7 Endotracheal intubation 
7.8 I.V. as necessary 
7.9 Rinse powder from gloves with sclline 
8.0 Preparation and placement of Sphincter 
8.1 Obtain sphincter system from storage 
8.2 Documentation on device and animal records. Both device and 
animal numbers, date of fill, sterilization and implantation. 
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Animal Trials Protocol - USD 
9.0 
8.3 Sterilize device (empty), 30 min., 15 PSI, liquid oyole. 
8.4 Autoolave and allow to 0001. 
8.5 In sterile, partiole-free area, open and fill the sphinoter 
system (0.9% NaCl, filtered 0.22 mioron). Make the necessary 
conneotions. 
8.6 Test the system manually to Verify function. 
8.7 Important to make sure surgeon's gloves are rinsed free of powder. 
8.8 Surgeon places sphinoter cuff around urethra, septum sub-
outaneously in abdominal area, and the valve-bulb in the 
abdominal area near fold of hind leg. 
8.9 Bulb-valve mld septum placed suboutaneously by tunneling through fasoia and ~ using midline. 
8.10 Once in place sphincter system is examined for leaks and funotionally tested, left in open position. 
8.11 Pressure profile and intradevice pressure. 
Operative Protocol 
9.1 Dog anesthetized - sodium pentobarbital (1 ml for SIbs. body 
weight) 
9.2 Area of inoision shaved to remove hair 
9.3 Operative systemio antibiotic given I.V. or I.M. 
9.4 Sterile procedure (gown, gloves, mask) with care in rinsing powder from gloves with sterile saline (0.9%). 
9.5 Dog restrained on operating room table. 
9.6 Endotracheal tube inserted. 
9.7 Shaved area of incision sorubbed with Betadine 15 min. time given for aotion before surgery. 
applied. 
for 3 min. and 
Steridrape 
9.8 Urethra inspected witn cystoscope for any abnormalities (i.e., stricture, cysts). 
9.9 Pressure profilimetry performed. 
9.10 Bladder filled to help in identification. Start to monitor O.R. time. 
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Animal Trials Protocol - USD 
9.11 In female, a lower midline incision is made just anterior to the pubis using Surgistat Electrocautery to cut tissue and 
coagulate bleeders. 
9.12 The bladder is located and the urethra identified. 
9.13 Proceed with careful dissection of tissue around the urethra 
and isolation of a 2-3 am segment with surrounding tissue and coagulate bleeders. 
9.14 The cuff is then placed around the urethral segment wj.th the tubing exiting the cuff towards the anterior (head) of the dog. 
7 
9.15 The septum is then placed subcutaneously with minimum dissection to the right of the incision (left side of the dog) and secured in place with one, 3-0 absorbable suture. (Type, size, material 
of suture to be determined by surgeon at the time of operation, but will be the same throughout trials once decided upon.) 
9.16 Midline incision closed (indicate time wound alosed). The incision is then rinsed with Betadine which is allowed to dry. Then the ,incision is rinsed with Betadine post-op to prevent infection and animal intervention at suture line. 
9.17 Urethral pressure profile is performed once midline incision is closed. 
9.18 Animal is removed from O.R. table, endotracheal tube is re-
moved, and animal is placed in observation room until shivering is observed. The animal is kept warm using blankets. 
9.19 The animal is then placed into its cage with water only. 
10.0 Post-operative 
10.1 Antibiotics: Ancef, 1 gm, 7 days post-op 
10.2 Betadine wash of wounds for 3-4 days 
10.3 Normal diet two days after surgery 
10.3.1 Diet of water and Similac for 2 days immediately post-op 
10.4 Activity - ad lib 
10.5 Weight at weekly intervals 
10.6 Lab tests: bimonthly blood - SMAC, CBC, urinalysis 
10.7 Observations - daily 
10.7.1 Activity - lethargy, etc. 
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Animal Trials Protocol - USD 8 
10.7.2 Wound - condition (i.e., swollen, inflamed, healing, etc.) 
10. 7.3. Feedings - amount, etc. - quantitate 
10.7.4 Urine - color, volume, smell 
10.8 Urethral pressure profile to be determined using CO2 and membrane 
catheter after 3 weeks at start of operating sphincter, at which 
time cuff will be pressure fit by filling septum side balloon of 
cuff to 75 cm of water. 
10.9 Start post-operative testing when wound is healing well and 
micturition function has stabilized (3 weeks). 
10.10 Functional testing to consist of actuation of the occlusive cuff 
to obtain continence during 23 hours daily. 
10.11 Cuff to be opened at 8:00 AM and 2:00 PM to permit voicUng 
(animal must void when open cuff at some time). 
10.12 Following daily voiding periods, cuff to remain closed at night. 
10.13 Successful functioning of occlusive sphincter to be determined 
by continence during the normal observation period during which 
the cuff is closed. 
10.14 Cuff to remain closed overnight. Verify bulb is empty in A.M. 
(subjective). 
10.15 Follow and record work, results on checklist. ., 
11.0 Sacrifice = Necropsy 
11.1 If sphincter system fails to operate OR continence occurs after 
both pressure-fit and 10 fun~tional trials OR end of experi-
mental period, the sphincter will be removed from the animal. 
11.2 System testing, teardown and analysis: Each system will be 
functionally tested upon removal from animal in the fill fluid 
that was in the system. Teardown to be performed to identify 
material anaracteristic changes. Functional testing and tear-
down according to mutually developed explant protocol. 
11.3 Biological analysis 
11.3.1 
11.3.2 
Histology to be performed on tissue around bulb-valve, 
cuff, and ,septum (kidneys, bladder, urethra). Other 
tissues not to be analyzed unless clinical indication. 
Bacteriological cultures to be taken of each component 
area of implant/tissue interface. Cultures taken at 
wounds as indicated. Urine cultures 1 day post any UPP. 
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Animal Trials Protocol - USD 9 
11.3.3 Fluid analysis: Intradevice fluid will be obtained and 
analyzed for SMAC, macro. Details appear in RGH 80-1. 
11.3.4 
11.3.5 
12.0 Results 
BLood: Serum will be analyzed on SMAC, CBC, lipid 
profile. 
Urinalysis: Routine urinalysis will be performed. 
Clinical, functional and laboratory results will be assessed for 
evidence of pathology. 
Results will be summarized on each dog at the end of each 
experimental period, as outlined previously. 
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APPENDIX B O~i'i?..a~JA1L f.Ji~~~ U3 
OF POO~ QUAlrr; 
PRODUCT DEVELOPMENT PROTOCOL 
FOR THE EVALUATION OF A 
URINARY SPHINCTER PROSTHESIS 
For submission to: 
Dennis J. Cotter, Executive Secretary 
Gastroenterology and Urology Section of the 
General Medical Devices Panel 
Bureau of Medical Devices (HFK-420) 
8757 Georgia Avenue 
Silver Springs, Maryland 20910 
By: 
Rochester General Hospital 
Rochester, New York 14621 
Dow Corning Corporation 
Midland, Michigan 48640 
Parker-Hanni fin Corporation 
Irvine, California 92715 
June 27, 1979 
Revised August 27, 1979 
Revised November 13, 1979 
NOTE: This document is intended as a discussion draft for all parties 
participating in the development of elements for the urinary sphincter 
prosthesis being developed under NASA Contract 8-32815. 
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Statement of Purpose: 
The purpose of this dooument is to desoribe planned aotivities for the development of a urinary sphinoter prosthesis intended for use in male and female patients for the oontrol of urinary inoontinenoe. The pro-posed prosthesis would be a Class III devioe under MEDICAL DEVICE A}lEND-MENTS of 1976, and would require pre-market approval. This protoool is submitted under the provisions of Seotion 515 (f), whioh provide that 
"the development of a devioe and the oolleotion of information neoessary to demonstrate safety and effeotiveness evolve simultaneously." 
The proposed devioe does not represent a new applioation for an im-plant, but rather attempts to advanoe the state of the art in existing implant design through the use of advanoed teohnology. Implantable urinary sphinoters ourrently exist in the marketplaoe (referenoes are oontained in Appendix GG), and the literature desoribing these devioes is extensive. While these devices have been aooepted by patients and surgeons, many of them oontinue to be subjeot to meohanioal failures, partioularly in the area of meohanioal valve design. The proposed pros-thesis would offer a signifioant advanoe in the performanoe and reliabi-lity of the pressure relief valve used to olose the devioe. The devioe is being developed oonourrently by a team oomposed of Roohester General Hospital, Roohester, New York (total system oontraotor), Parker Hannifin Corporation, Irvine, California (valve manufaoturer), and the Dow Corning Corporation, Midland, Miohigan (proposed manufaoturer for the ultimate assembled system). 
This protoool desoribes planned aotivities through the olinioal trials phase, whioh would be performed by this team prior to applioation for market approval. 
Seotion 1 - Desoription of Device: 
1.1 General 
The prosthesis oonsists of a fluid-filled ooclusive ouff whioh is used to surround the urethra of male and female patients. This f1uid-filled ouff is attaohed to a pump-bulb whioh is looated where it oan be manipulated suboutaneously to drive fluid to the ooolusive ouff. A oheok valve in the system prevents the fluid from returning to the bulb, thus insuring that pressure is applied to the urethra to insure oontinenoe. Pressure applied to the urethra is oarefully oontro11ed within presoribed design limits through the use of a preoision valve whioh ora oks automati-oal1y and returns fluid to the pump-bulb (or fluid reservoir), if pressure develops above pre-set physio1ogioa11y aooeptable levels. 
In order to simplify the fit-up of an ooolusive ouff to a wide range of sizes and anatomies enoountered in a large patient population, the ouff is fabrioated with two ohambers. One ohamber is attaohed to a self-sealing 
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septum which permits fluid to be added to or removed from the occlusive 
cuff at the time of implantation. This technique, combined with the use 
of intra-operative, intra-urethral pressure profiling, insures a form-fit 
of the occlusive cuLf. The use of a close fitting cuff which circles the 
urethra snugly permits occlusion of the urethral passage to occur by the 
introduction of a small fluid volume. This in turn minimizes the fluid 
volume that must be transmitted from the pump-bulb to the cuff. This 
design approach I~ill permit pre-operative filling of the pump-bulb while 
eliminating or minimizing opportunities for particulate contamination. 
By fabricating the cuff with two isolated chambers, the smaller chamber 
attached by tubing to the pump-bulb can be filled under carefully con-
trolled conditions while the larger chamber used to insure the snug fit 
of the cuff can be filled intra-operatively and is less vulnerable to 
damage by particulate contamination. The fully assembled system is shown 
schematically in Figure 1. When implanted in a male patient, the system 
would have the general configuration shown in Figure 2. When the system 
is implanted in female patients, the configuration would be as sholm in 
Figure 3. The system is fabricated from proven and accepted biocompatible 
materials, primarily from medical grade silicone rubber (silastic). Metal 
elements of the valve are fabricated from biologically acceptable metal 
alloys as described subsequently, but these materials will not come in con-
tact with tissue because they I~ill be encapsulated in silicone rubber. 
Ingrowth material (dacron velour) is used at selected locations to stabi-
lize the system within the patient as described subsequently. All selected 
ingrowth materials have an extensive documented history of successful use 
(dacron velour, medical grade silicone rubber). 
1.2 Occlusive Cuff 
Key elements of the urethral occlusive cuff are shown in Figure 4. 
The cuff will initially be made in four sizes to fit the expected patient 
popUlation. The cuff is fabricated from thin wall, formed silicone rubber 
to insure uniform pressure transmission to periurethral tissue. The out-
side wall of the urethral cuff is thickened and reinforced to resist ten-
sile forces in the cuff and to direct the inflation pressure of the cuff 
inward to constrict the urethra. A simple latch system is provided for 
reliability and ease of implantation. As previously mentioned, the cuff 
has two independent chambers. The smaller chamber is attached by tubing 
which leads to a valve/pump-bulb and a larger chamber is connected to a 
self-sealing septum. 
1.3 Valve/Pump-Bulb 
Key elements of the valve/pump-bulb are shown in Figure 5. This 
component is placed in the scrotum of the male o~ in the labia of the 
female, subcutaneously where it can be easily palpated by the patient. 
Pressure on the pump-bulb drives fluid through the valve into the oc-
clusive cuff providing continence. To empty the bladder, the patient 
simply touches the pressure relief valve, permitting fluid to return 
to the bulb. This sequence of events is shown in Figure 6. Pressure 
on the occlusive cuff is prevented from exceeding predetermined values 
by the design of the valve, which cracks automatically when pre-set 
physiologically determined pressures are exceeded. 
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1.4 Self-Sealing Septum 
Key elements of the self-sealing septum are shown in Figure 7. This 
septum is connected by tubing to the large chamber of the occlusive cuff. 
The purpose of the septum is to permit fluid to be added to or removed 
from the cuff at the time of operation to insure a snug fit. This feature 
reduces the number of cuff sizes required to fit a varied patient popula-
tion, and it facilitates the careful fit-up of the cuff to individual pa-
tients. 
A careful review of the literature of current urinary incontinence 
prostheses indicates that active devices do not permit pressure adjust-
ment without re-operation. The self-sealing septum in our proposed de-
vice is provided to permit changes in fluid volume post-operatively with-
out re-operation. This technique has been used successfully in adjusting 
the volume of passive devices [5, 6}, and has been used previously in at 
least one active system [21} • 
The septum will be placed subcutaneously at the time the device is 
placed in the patient. It will be accessible by percutaneous needle 
puncture using local anesthesia. 
1.5 Assembled System 
Key elements of the fully assembled system are shown in Figure 8. 
The implanted system will be radiopaque, either through the use of 
contrast media such as Hypaque in the fluid fill media, or through the 
preferred technique of barium-impregnated silicone rubber. The pre-
ferred techniqu" hds the advantage of eliminating the need for radio-
contrast media in the fill fluid, however the use of opaque tubing can 
complicate pre-operative and intra-operative filling since air bubbles 
in the fluid are not visible. 
Section 2 - Description of Pre-clinical Trials: 
2.1 Purpose of Trials 
This section of the report describes two categories of proposed pre-
clinical trials on all elements and components of the device. These 
categories are (1) bench tests, and (2) animal trials. Each category 
will be described separately. 
2.2 Bench Tests 
2.2.1 Valve/Pump-Bulb (Parker-Hannifin) 
The valve/pump-bulb system has been developed by the Parker-Hannifin 
Corporation to specifications developed jointly by Parker-Hannifin, 
N.A.S.A., and Rochester General Hospital. The specification for this 
system is attached as Appendix A. The valve is fabricated from ap-
proved biocompatible materials as tabulated in Figure 8. None of these 
materials will be in contact with tissue, but they will be in contact 
with the fluid media for the occlusive cuff, physiological saline. 
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2.2.1.1 Qualification Tests 
In order to qualify the Parker-Hannifin valve/pump-bulb, a 
series of qualification tests were performed, including tests for more than 50,000 operational cycles. This cyclic testing 
was performed after the device had been subjected to tr~o steri-lization cycles and was followed by the application of high pressures (burst testing) to verify the integrity of the device. These tests are described in the System Performance Specification (Appendix F). 
2.2.1.2 Acceptance Tests 
Every bench test unit fabricated by Parker-Hanni fin for trans-
mission to Rochester General Hospital will be subjected to ac-
ceptance testing both by the manufacturer and by Rochester General Hospital. These test procedures are described in Appendix B. These tests include a verification of function through 100 cycles of operation, followed by checks for internal 
and external leakage, cleanliness verification, and an overall 
examination for product workmanship. Each device is also sub-jected to proof pressure testing. The acceptance test procedure for the ultimate manufactured device will differ and will be described separately. 
2.2.2 Occlusive Cuff (Dow Corning Corporation) 
The occlusive cuff is fabricated by the Do" Corning Corporation to 
specifications developed jointly by DoW Corning and Rochester General Hospital. The cuff specification is attached as Appendix C. The 
cuff is fabricated exclusively from silicone rubber materials with a proven history of biocompatibi1ity in similar applications. 
2.2.2.1 Qualification Tests 
The design of the occlusive cuff has been verified by qualifica-tion testing as described in the specification. This testing includes operational performance for more than 100,000 cycles, following two sterilization cycles and followed by exposure to proof pressure levels. 
2.2.2.2 Acceptance Testing 
Every occlusive cuff fabricated by Dow Corning will be subjected to acceptance testing by Rochester General Hospital which includes 100 cycles of operation, following two sterilization cycles. Subsequent to operational verification, each device is examined 
carefully for internal and external leakage and is proof pressure 
che':ked. Each device is also given a cleanliness verification. Th~ acceptance test procedure for the occlusive cuff is described in detail in Appendix D. 
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2.2.3 Self-Sealing Septum (Rochester General Hospital) 
The self-sealing septum is fabricated by Rochester General Hospital in accordance with the specification contained in Appendix E. 
2.2.3.1 Qualification Testing 
The design of the self-sealing septum shall be verified by qualification testing as described in the specification. Quali-fication testing shall include statistical testing as required to verify that the septum can withstand at least 20 penetrations by 25 gauge (or smaller),non-coring needle. The septum shall also be cycle-tested through 100,000 operational cycles in parallel with the occlusive cuff. The qualification test se-quence for the self-sealing septuJR is contained in the specifi-cation. 
2.2.3.2 Acceptance Testing 
Each septum fabrica~ed for use in animal trials shall be sub-jected to the acceptance sequence described in the septum specification. This testing shall include penetration tests (20 penetrations), sterilization cycling, 50,000 operational cycles, internal and external leakage checks, visual examina-tion for defects in workmanship, exposure to proof pressure, and cleanliness verification testing. 
2.2.4 Assembled System 
Requirements for the fully assembled system are described in Appendix p, Sustems Specifiqation, developed by Rochester General Hospital. The assembled system will be subjected to qualification testing to verify the design. Each individual system will be acceptance tested subsequent to assembly. 
2.2.4.1 Qualification Test 
Performance of the fully assembled system will be verified by qualification testing to levels defined in the systems speci-fication. This testing includes 100 operational cycles, sub-sequevt to two cycles of sterilization, and followed by in-terna~ and external leakage checks, proof pressure testing, visual inspection for workmanship and cleanliness verification, See Appendix F, Systems Specification, for details of qualifi-cation testing on the assembled system. 
2.2.4.2 Acceptance Test 
Each fully assembled system will be acceptance tested as des-cribed in the system performance specification. See APpendix F, Systems Specification, for details of qualification testing on the assembled system. 
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2.2.5 Expected Test Results - Bench Testing 
The expected results of bench tests on system components and on the 
assembled system are directed toward verifying repeatable and reli-
able functional performance, with emphasis on cyclic operation of 
components and devices without malfunction. Successful testing is 
predicated on the control of particulate contamination in the fill 
fluid within specified levels. All elements of the system should 
be capable of withstanding at least 50,000 operational cycles and 
testing should be continued to 100,000 cycles on the assembled sys-
tem. Test results should verify that the self-sealing septum can 
survive 20 penetrations in service without leaking; This figure 
is four times greater than the maximum number of re-operations en-
countered in the literature and will be verified to 95 per cent 
competence levels by appropriately designed statistical testing. 
Testing will be conducted to gain confidence that metallic com-
ponents of the system can operate in a saline environment without 
degradation which will impair or limit the usefulness of the de-
vice. Examination of the filling fluid subsequent to testing may 
show traces of metallic contamination, but the device should func-
tion within specified tolerances for 50,000 operational cycles. 
Estimates will be made of the rates at which filling fluids might 
be lost from the system through diffusion. The migration of fluid 
across the silicone barrier by diffusion will be examined carefully 
during animal trials. Fluid loss from devices used during clinical 
trials will be minimized by careful control of the assembly process 
and the pre-operative filling technique as discussed subsequently. 
2.3 Pre-Clinical Animal Studies (Rochester General Hospital) 
2.3.1 Purpose of Trials 
The purpose of proposed animal trials is to verify the efficacy and 
safety of the device in a biological setting similar to its use in 
man, and to evaluate the ability of the device to function success-
fully in occluding the urethra through an experimental model. These 
trials sre oriented toward verifying the ability of the device as 
implanted to maintain pressure on the urethra for a prescribed inter-
val during normal increases in bladder pressure until the valve is 
intentionally activated to deflate the occluding cuff. These studies 
are required to supplement and extend work which has been previously 
demonstrated by the Rosen prosthesis (Heyer-Schulte Corporation) and 
by the Scott prosthesis (American Medical Systems), currently in the 
market. Our proposed device focuses primarily on the increased reli-
ability of valve hardware and on design changes which simplify the 
fit-up of the occlusive cuff and which improve the mechanical reliabi-
lity of the system as a whole. For this reason the proposed experi-
mental protocol is not as extensive as might be required for a device 
for which there is no precedent. 
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2.3.2 Experimental Protocol 
The proposed experiment is summarized in Appendix II. The experi-
mental design consists of two replications of l2 trials, one of 
which would receive a functional device and one of which would re-
ceive a passive dummy implant. We propose to implant the functional 
device in animals which have not been rendered incontinent by sur-
gical procedures due to technical difficulties in the reliable sur-
gical creation of an incontinent animal. We believe that proper 
functioning of the device can be observed in the animal subject by 
demonstrating that voiding can be restricted to selected periods 
through the use of the valve on the implanted cuff. This approach 
is consistent with information indicating that previous investigators 
have not always relied on the creation of an incontinent animal for 
their animal studies [7]. 
For this experiment we have proposed the use of mongrel dogs, how-
ever the possibility exists that new legislation may make the use 
of pound animals difficult or illegal, in which case, we propose 
the use of either beagles or foxhounds. In any event, all trials 
will be fully compatible with local, state and federal regulations. 
All animal test facilities at Rochester General Hospital are fully 
accredited for research of this type and careful attention will be 
paid to record keeping, as described subsequently. 
2.3.3 Animal Selection 
The criteria for animal selection for the proposed experiment is 
shown in Appendix G. Once animals are selected, they will be pre-
conditioned in accordance with the protocol shown in Appendix H. 
All animal studies will be conducted in the research facilities at 
Rochester General Hospital. These facilities satisfy all federal, 
state, and local requirements, and are operated by a permanent staff 
of trained technicians. 
2.3.4 Pre-operative Protocol 
Prior to implanting the device in a subject animal, the pre-operative 
protocol shown in Appendix I will be employed. 
2.3.5 Operative Protocol - Device Implantation (Animal Studies) 
The proposed protocol for implanting the device in test subjects is 
shown in Appendix J. Animal surgery will be performed by or under 
the direction of the project surge.:>n, Ronald Rabinowitz," M.D. in the 
animal' laboratories of Rochester General Hospital. 
2.3.6 Post-operative Protocol (Animal Studies) 
Following implantation of the devices in test animals, post-operative 
protocols shown in Appendix K will be used to evaluate the tissue 
reaction and efficacy of the device over selected observation periods. 
Follow-up activities will be performed by animal technicians and labo-
ratory technicians at Rochester General Hospital. 
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2 • .3.7 Laboratory studies (Animal Studies) 
Laboratory studies in support of animal tests will be performed in the 
facilities of Rochester General Hospital. Rochester General Hospital 
is a fully accredited teaching hospital with equipped animal research 
facilities directed by experienced biomedical researchers who are 
faculty members at the University of Rochester School of Medicine. 
2.3.8 Expected Test Results (Animal Studies) 
Proposed animal trials are expected to demonstrate the following 
results: (1) That the device can be successfully implanted into a 
test animal and will function, upon operation, to occlude the urethra 
at the volition of the operator. In other words, the occlusive cuff 
can successfully occlude the urethra of a healthy animal, preventing 
the bladder from being emptied until pressure has been released. 
(2) That the materials used in fabricating the device have an accept-
able level of biocompatibility at the proposed implantation sites. 
(3) That there are no significant differences in the ability of the 
test subjects to accept either an active or passive device. In other 
words, the dimensional changes associated with an active cuff do not 
produce any unacceptably abnormal tissue changes. (4) That the de-
vice will operate successfully in test animals for the proposed dura-
tion of the trials (6 to 12 months, as described in the protocol). 
Animal trials are intended to permit extrapolations which will pro-
vide confidence of successful operation for the intended life cycle 
of the device (approximately 30 years) after implantation in man. 
(5) That the device remain implanted securely with migration or re-
orientation ~ 
2.3.9 Permissible Variation in Results 
Some variability in test results between animals may be anticipated. 
These variations may be due in part to the fact that the geometry of 
the device is based on considerations of human anatomy and the con-
figuration of certain system components (for example, the pump-bulb) 
have not been optimized for animal use. In general, the cuff sizes 
selected for use in animal trials will be the smallest size cuff 
available for human use. 
Current success ratios for similar devices are about 2 in 3, including 
failures of all types. Of the failures, approximately one-half or a-
bout one-sixth of total cases are due to mechanical causes. For this 
reason, we will look for a high degree of ,-'echanical, structural and 
technical performance. Correctable mechanical failures from all causes 
should not exceed one in ten during these trials and will only be 
tolerated if clearly defined solutions with high probabilities of suc-
cess can be identified. In addition, performance from a physiological 
and biological point of view should not exceed I failure in 10 due to 
all causes and will be tolerated only when causes and corrective ac-
tions are clearly understood. Failures, malfunctions or rejections in 
excess of these values shall result in changes to the experimental pro-
tocol or in the design of the device. All experimental results shall 
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be reviewed carefully by suitable team composed of representatives 
from Rochester General Hospital, Dow Corning, N.A.S.A. and F.D.A. 
prior to a formal decision to initiate the clinical trial phase of 
the program. 
Section 3 - Clinical Trials (Rochester General Hospital): 
3.1 Purpose of Trials 
Clinical trials will be conducted to test the efficacy, safety and 
biocompatibility of the proposed prosthesis in man after animal trials 
have demonstrated acceptable levels of performance. The purpose of the 
proposed clinical trials would be to introduce on a carefully controlled 
basis an improved urinary sphincter prosthesis for implantation in se-
lected patients as a preliminary step to the introduction of an improved 
product into the market. The proposed clinical trials l?ould be initiated 
at Rochester General Hospital under the general direction of a multi-
functional program team composed of Rochester General Hospital, the Parker 
Hannifin Corporation, the Dow corning Corporation, and N.A.S.A. Specific 
surgical direction would be provided by the program surgeon, Ronald 
Rabinowitz, M.D., supported by others as designated by the multi-functional 
program team. After the initiation of clinical trials, work will be ex-
panded to include selected investigators at other sites as described in th
e 
experimental protocol. 
Upon the completion of clinical trials, we propose the introduction of 
the product into the market under the manufacturing responsibility of the 
Dow Corning Corporation, Midland, Michigan. Following a successful clini-
cal trial phase, responsibility for manufacturing and distribution l~otlld 
rest with Dow Corning. 
3.2 Experimental Protocol 
The proposed experimental protocol for the clinical trial phase is 
described in Appendix L, Protocol for Clinical Trials. This protocol 
identifies (I) number of investigators, (2) number of subjects per in-
vestigator, (3) qualifications for investigators - scientific training 
and experience, (4) data to be collected in the evaluation of the effi-
cacy and safety of the device . 
3.3 Patient Selection Criteria 
The selection of patients for this proposed experiment is an essen-
tial element in defining the future scope of applications for this product. 
The patient population should be sufficiently varied to insure that the 
device can be used in both male and female patients over a range of ages. 
Initially the patient population should not be biased toward conditions 
which could prevent the device from obtaining a balanced assessment, i.e. 
cases should not be restricted to those for which all other possible sur-
gical solutions have previously been attempted. 
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Not all patients with urinary incontinence are candidates for this 
device. Screening criteria are shown in Appendix M. 
All patients who become candidates for the evaluation of this device 
will be thoroughly oriented to the characteristics of the device and its 
relationship to non-mechanical options or to other devices currently in 
the market. The contents of this briefing are summarized in Appendix N. 
Formal criteria for patient selection as described in Appendix M will 
be evaluated by the surgical staff at Rochester General Hospital and se-
lected participating surgical investigators and the organizations which 
they represent. In addition, concurrence on patient selection by the Dow 
Corning Corporation will be required to provide additional information on 
market size and composition. 
All patients who agree to participate in the proposed study and (~ho 
meet selectio~, criteria established by the program team and evaluated by 
participating surgeons and Dow corning will be requested to execute a 
consent form. This consent form has been drafted after careful considera-
tion of similar instruments for research purposes and with particular at-
tention to recent trends in informed consent practices [8,9,10,11]. The 
consent form has also been reviewed by the Human Experimentation Committee 
at Rochester General Hospital, a standing committee which satisfies DHEW, 
state, and local requirements for committees of this type. The consent 
form has also been reviewed by the legal staff of Dow Corning, a firm 
which currently manufactures a broad line of approved medical implants. 
Surgeons will be responsible to communicate information to patients 
as appropriate concerning possible complications and side effects of the 
proposed device. In this regard, all participating surgeons wil be re-
quested to execute a Clinical Investigation Agreement as shown in Appendix 
Q. This requires each investigator to submit information for evaluation 
by an evaluation team composed of the program surgeon, and composed 
of at least one physiologist, engineer, statistician, and a business !'SP-
resentative of Dow Corning Corporation. Each surgeon participating in the 
clinical investigation phase of the urinary sphincter prosthesis must sign 
a clinical investigation agreement stating his or her commitment to the 
terms of the agreement and must also submit a curriculum vitae for review 
by the evaluating team. Contents of the curriculum vitae are shown in 
Appendix R. In addition to representatives from Rochester General Hospital 
and Dow Corning, the evaluating team may also have members from the Parker 
Hannifin corporation and from the National Aeronautics and Space Adminis-
tration, Marshall Space Flight Center, Alabama. 
Typical etiologies for which the device may be appropriate are sum-
marized in Appendix O. 
3.4 Pre-operative Protocol 
The pre-operative protocol for patients in the clinical trials phase 
is shown in Appendix T. This protocol recognizes that variations or devia-
tions may be dictated by individual patient conditions and will guide the 
specific decisions taken by the responsible surgeon. Specific details of a 
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pre-operative protocol for each patient will be determined on a case-by-case basis by the attending surgeon. 
During the pre-operative phase, funding details for the device will be worked out between the patient, the surgeon and participating institu-tions. In general, the proposed approach for this protocol assumes that the cost of the device provided for clinical trials and the cost (nominal) for administrative program support will be borne by the government funds augmented by corresponding funds from the potential device manufacturer. The cost of operations and direct patient care will be borne by the pa-tient or by appropriate "3rd parties" (i.e. Blue Cross, etc.). 
3.5 Operative Protocol/Procedure 
The operative protocol for emplacing the proposed device in the male is shown in Appendix U. The procedure for implanting the device in the female is shown in Appendix V. Again, these techniques are intended to illustrate the basic technique only. Differences in etiology and in ana-tomy will require surgeons to make changes and adaptations in operative procedures as required by circumstances. Participating surgeons are ex-pected to describe (record and document variations) these deviations to the extent that they provide insight into the successful functioning of the device. 
3.6 Post-operative Protocol 
The protocol for post-operative care and follow-up for each patient is shown in Appendix W. Prior to introduction of the device into the mar-ketplace, it is proposed that at least 25 per cent of the patient popula-tion has been followed post-operatively for a period of two years. In addition to standard information maintained on the patient, a chronological performance history of the device including assessments of the patient's subjective response to its use will be developed by the participating sur-geon. 
3.7 Laboratory / Clinical Tests 
The laboratory and clinical tests required to support the clinical trials phase of the program will be carried out at Rochester General Hos-pital or by selected participating institutions meeting the requirements of the evaluating team. These laboratory tests include the commonly used tests for post-operative evaluation and general medical tests, as well as specific urological and urodynamic tests. Details of required tests are included in the pre-operative (Appendix T) and post-operative (Appendix W) protocols. In all situations in which the participating surgeon is affil-iated with an approved institution, all laboratory tests to support the clinical trials phase will be provided by the institution and will be funded by sources to be determined. 
Financial support for laboratory and clinical tests will require pre-negotiation between the device manufacturer (sponsor), participating hos-pitals (Rochester General Hospital, etc.), and appropriate third parties (Blue Cross, etc.). 
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3.8 Functional/Operational Tests 
The functional and operational data on sphincter system performance will be provided by all surgeons participating in the program. The format for operational data sheets is shown in Appendix X. Surgeons will be re-quested to provide copies of roentgenographic plates, developed to verify the position or orientation of the implanted device, particularly in cases where problems arise in connection with orientation or placement. 
3.9 Test Reports (Clinical Trials) 
Test reports summarizing the result of clinical trials will be pre-pared by Rochester General Hospital at intervals during the first year following the .initiation of clinical trials and by sponsoring manufacturer (Dow Corning) or their designates during the 2nd and 3rd years of observa-tion. Patients will be observed and reported for at least three years post-operatively. These reports will be developed for the use of partici-pating investigators or participating agencies with specific emphasis on Dow Corning and by the F.D.A. 
3.10 Expected Results 
Clinical trials are expected to demonstrate the safety and effective-
ness of the device for the purposes indicated by the device manufacturer. The key criteria for evaluating the device include: (1) ability to provide continence, (2) biocompatibility as demonstrated by long-term tolerance in absence of infection, (3) long-term functionality within prescribed perfor-mance limits, (4) absence of complications introduced by configurational aspects, for example urethral or scrotal erosion or formation of excessive scar tissue, (5) successful mechanical performance of all silicoT!e .r:ubber components including seams, joints and bond lines, (6) flexibility in use including compatibility with post-operative adjustment using the septum. Claims made for the device should be supported by scientific evidence and by data obtained from studies on human subjects. One of the key elements of these claims is that the mechanical valve will function effectively and reliably to apply, maintain and release when activated, pressure on the urethra within prescribed limits to create continence. 
Experience with comparable devices indicates that some devices have been rejected by patients for reasons which are largely unexplained while other devices fail to provide continence even though they function mechani-cally within acceptable limits. We believe it is essential fo~ the as-sembled system to function correctly within specified limits when posi-tioned in the recommended manner and when undamaged by the operative pro-cedure to provide a measure of reliable and volitional urinary control to a cooperating patient. 
3.11 Permissible Variations in Results 
Some variation in results between patients can be anticipated. As described in the literature on urinary incontinence, there are many vari-ations in the degree to which incontinence is experienced, and a precise 
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vocabulary is required. We will adopt the definitions proposed by the 
cognizant international authorities as defined in references 12,13, and 
14. We recognize that in active patients intra-abdominal pressures may 
be raised periodically to levels which may cause the valve to crack and 
permit fluid to bleed back from the cuff to the pump-bulb. Under these 
conditions, cuff pressures may lower in time and may require periodic 
repressurization (up to several times daily in some cases) by manipulat-
ing the pump-bulb. Since the volume of fluid to be transferred is quite 
small and since pressure need only be applied for a very small interval, 
the requirement for a periodic re-inflation for either males or females 
should not present an undue restriction on this device. Nevertheless, a 
full understanding of the capabilities and limitations of the prosthesis 
may require some learning on the part of the patient, even in the most 
successful circumstances, and consequently some variation in use can be 
expected. 
section 4 - Methods, Facilities and Controls for Manufacture, Processing, 
Packing, and Installing: 
4.1 Summary of Methods, Facilities and Controls 
The manufacturer for the assembled device will be tbe Dow Corning 
Corporation, Midland, Michigan. Dow Corning currently manufactures a 
wide line of implants which completely satisfy all F,D.A. requirements. 
For this reason, the methods, facilities, and controls necessary to 
satisfy pertinent federal, state, and local requirements for the manu-
facture of medical and surgical implants from silicone rubber are under-
stood by, and routinely practiced by Dow Corning. 
For this device, the valve would be designed and manufactured by the 
Parker Hannifin Corporation, Irvine, California. Parker Hannifin is an 
experienced manufacturer of high precision valves for the aerospace in-
dustry, and their organization for quality control, materials testing, and 
materials documentation are among the best in the industry. As a matter 
of routine, each valve produced for this application would be serialized 
and all materials would be traceable to their source. Parker Hannifin will 
manufacture and supply valves to Dow Corning under contract and these con-
tractual agreements will include appropriate quality assurance support and 
materials traceability support. 
4.2 Dow Corning 
4.2.1 Manufacture / Processing / Quality Assurance 
4.2.1.1 Methods 
The completed device would be fabricated under carefully con-
trolled conditions using detailed process sheets describing 
each step in the assembly procedure. These process sheets are 
routinely used for fabricating similar devices, including mam-
mary prostheses, testicular prostheses, penile implants, and 
a wide range of orthopaedic implants from medical grade sili-
cone rubber. 
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All assembly steps would take place in the controlled facili-
ties of Dow Corning in Midland, Michigan, which includes clean 
room facilities, satisfying all applicable federal, state and 
local regulations. 
Each assembled unit would be serialized to facilitate subse-
quent traceability. 
Sterilization at the time of manufacture may be performed by 
gamma irradiation (cobalt source) of the prepackaged system 
following assembly to pre-specified levels. 
The device will be subjected to appropriate cleaning procedures 
at each step in the assembly process. The filling procedure 
will be selected based on careful consideration of all factors 
relating to subsequent control of particulate contamination in 
the seal system and to ease of implantation by the using surgeon. 
Detailed quality assurance procedures will be developed for each 
element of the system and for the system assembly. 
Detailed sterilization procedures will be verified by approp-
riate tests and will be transmitted in each packaged device. 
Recommended sterilization procedures are shown in Appendix Y. 
4.2.1.2 Facilities 
Manufacture and assembly fer all elements of the system, with 
the exception of the valve, will be provided by Dow Corning at 
Midland, Michig~n. The characteristics of these facilities 
have been approved by the F.D.A. for the manufacture of similar 
devices and are routinely inspected to insure continued compli-
ance with F.D.A. regulations. 
4.2.1.3 Controls 
Manufacture of this device would be subjected to the full spec-
trum of quality assurance in manufacturing process controls rou-
tinely employed by Dow Corning to meet applicable F.D.A. regUla-
tions. In particular, "good manufacturing practices" as speci-
fied in appropriate DHEW regulations shall be followed. 
4.2.2 Packaging / Shipping (DOW Corning) 
Specific requirements for packaging and shipping the device will be 
carefully controlled by the manufacturer. Requirements are summarized 
in Appendix AA. 
4.2.3 Returned / Damaged Goods 
The manufacturer will specify a policy for return of damaged goods. 
Suggested details are shown in Appendix BB, but may require modifi-
cation as experience is gained in the clinical trials phase of the 
program. 
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4.2.4 Principal Subcontractor 
The prinuipal subcontractor for this prosthesis is the Parker Hannifin 
corporatior., who will manufacture tIle valve. During the animal trial 
phase of the program, Parker Hannifin will provide not only the valve 
but the pump-bulb, together with the tubing connecting the bulb to 
the cuff. This arrangement results from the fact that the initial 
program was funded by N.A.S.A. under contractual agreements which made 
the interface between the valve and the bulb difficult to integrate 
between two manufacturers. For devices which are fabricated in produc-
tion quantities, all silastic components of the system, with the pos-
sible exception of components internal to the metallic valve, will be 
fabricated by Dow Corning. 
Parker Hannifin will employ detailed process sheets for the assembly 
of the valve. 
All drawings and specifications will be available for F.D.A. inspec-
tion upon request. 
All materials employed in the manufacture of the valve will be ap-
proved for biocompatibility in spite of the fact that they will re-
main isolated from tissue under normal operating conditions. 
Each valve will be serialized for traceability. 
All raw materials used in the manufacturing process will be traceable 
to the source. These records will be retained for subsequent inspec-
tion by Dow Corning or by the F.D.A. 
Final assembly will occur in a controlled facility (Class 1000 clean 
room or better). 
The valve will be capable of functioning within specified limits after 
withstanding specified sterilization cycles. 
Techniques for packaging, shipping and storing will be reviewed and 
approved for production devices by Dow Corning to insure that valves 
are not damaged in shipment. 
4.3 Material Traceability 
The device manufacturer, Dow Corning, will be responsible to assure 
that records are retained as required to provide material traceability for 
all elements of the assembled system. 
4.4 Documentation I Records 
The manufacturer, Dow Corning, will be responsible to assure that suit-
able documentation and records in the form of drawings, specifications, 
process sheets, material traceability records, quality assurance inspection 
reports, and similar documentation, as required by federal, state and local 
regulations or by good manufacturing practices, are maintained throughout 
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the product development cycle and while products remain in use in a pa-tient population. In general, the methods and techniques for maintaining suitable records will be comparable to similar documentation maintained for the current product line. 
4.5 Permissible Variations in Uethods and Controls 
Variations or deviations in methods, processes and controls as speci-fied in this PDP will be submitted to the F.D.A. for review and comment as appropriate. 
section 5 - Performance Standards Under Section 514, 
Not applicable to this device. 
Section 6 - Samples of Proposed Labelling: 
A description of the labelling proposed for this device is included in Appendix CC. This description is provided for general information only and may require revision subsequent to the clinical trials phase. 
section 7 - Other Relevant Information: 
7.1 Organizational Relationships 
The development of the urinary sphincter is a joint project with par-ticipation by --- Rochester General Hospital, the Dow Corning Corporation, Parker Hannifin Corporation, N.A.S.A.-Marshall Space Flight Center. This project was initiated by N.A.S.A.-M.S.F.C. based upon their recognition that aerospace technology might permit significant improvement in the mech-anical reliability of valves based upon reports of valve failures in the medical literature [15,16,17]. N.A.S.A. initiated two simultaneous con-tracts. The first contract to Parker Hannifin was for the development of a high reliability valve which would satisfy the requirements of the sphincter prosthesis. The second contract to Rochester General Hospital was for the development of the remaining elements of the system and for the execution of bench tests, animal trials, and a limited number (20) of clinical trials to determine the potential marketability of the device. Rochester General recognized that the ultimate marketability of the device is dependent upon a number of factors unrelated to simply improving valve reliability. Mar-ket.,bility depends UpOll (1) the willingness of a qualified manufacturer to undertake the product development activities necessary to manufacture a precision implant of this type, and (2) completion of a test program suit-able to satisfy F.D.A. requirements. Dow Corning was requested to join this program team as a participant, and their participation has led to the develop-ment of this PDP. Rochester General Hospital will act as the system manager for the program through the initial phases of clinical trials. It is clearly recognized that the ultimate responsibility for managing th~ total program will rest with the Dow Corning Corporation. Organizational relationships are further clarified in Appendix DD. 
23B-17 
, 
,. 
., 
, 
'. ,
" rf' 
r'(' 
'" 
~ ~ 
, I L 
I 
c 
J 
1 
J 
~-
i 
f 
u 
, 
d 
, 
,I 
J 
"" :.1 
,1 
u, 
I 
U 
n_ 
, 
I 
u 
, 
U" 
0_ 
i 
, 
J 
" 
.,. ... 
f 
~ i , 
,[ 
,~. I 
r 1 
~- . 
I 
t 
17 
7.2 Roles and Responsibilities 
Key program personnel and their roles are briefly described in 
Appendix EE. The curriculum vitae for medical and technical personnel 
at Rochester General Hospital are attached as Appendix FF. 
7.3 References 
During the execution of this program, an extensive bibliography on 
the management of urinary incontinence by means of active prosthetic de-
vices has been assembled. Because of the relevance of this bibliography 
to this project, it is attached as Appendix GG. 
section 8 - Progress Reports: 
Rochester General Hospital is responsible to collect, maintain and 
distribute suitable records to describe progress through the early clini-
cal trials phase of this program. In order to demonstrate compliance with 
this PDP, a series of special reports are proposed. These reports would be 
issued to the recipients of the PDP at the following three points: (1) 
completion of all animal trials, (2) completion of the first year of clini-
cal trials, (3) the third report would be submitted at completion of the 
second year of clinical trials. These reports would be developed jointly 
by the program team and would be coordinated by Rochester General Hospital. 
A fourth and final report would be submitted to the F.D.A., requesting mar-
ket approval at ~ suitable interval following the second year of clinical 
trials. This report would originate from Dow Corning. All progress reports 
would contain detailed records of the trials conducted under this protocol, 
together with a careful report of any deviations from the protocol. Reports 
would be submitted in quantities and formats reoommended through disoussions 
with the PDP approval oommittee. 
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APPENDIX C 
CASE HISTORIES - ANIMAL TRIilLS 
C-l through C-6, Phase 2A (6 subjects) 
C-7 through C-16, Phase 2B (10 subjects) 
This appendix contains summary case histories for each test subject 
for this experiment. 
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APPENDIX C-l: CLINICAL OBSERVATIONS AND DATA - USD - PHASE 2A 
DOG: #1 NAME: Tara 
DEVICE: PH SS prototype 2 / DC cuff prototype 3 / RGH septum 1 
SURGERY: Prior to surgery and in response to the anesthetic, the dog ex-
perienced convulsions, tachycardia and apnea. Surgery was uneventful. 
POST-oP: Uneventful. 
EXPERIMENTAL PERIOD: 
CLINICAL OBSERVATIONS - At day 21 it was noted that the dog had difficulty 
in voiding completely, associated with the increased pressure from the 
device and the inflammation of the lower urinary tract from infection. 
Urine culture was taken. On day 49 a urine culture identified E. coli 
as the responsible organism. Throughout the remainder of the experi-
mental period, functional test and UPP continued. The behavior I~as 
excellent. Near the end of the eXperimental period, the dog became 
more submi~sive due to the increase in popUlation of test subjects. 
LABORATORY TESTS AND CORRELATIONS - Initially, in response to the convul-
sions and probable damage during the excited anesthesia, the SGOT was 
elevated to 217. As evidenced by the increase in difficulty in voiding 
there was an increase of the BUN from 14 to 20 and remained elevated 
and increased to 33 before the urinary tract infection was successfully 
treated. Thereafter, the BUN dropped to normal values. 
CONCLUSIONS: Behavior is excellent. The weight was stable throughout 
the experimental period. Moderate to good success in functional testing 
with learned behavior which promoted successful observations. There were 
no problems experienced with the device pressure or function, although 
cage sores developed near the end of the 246-day experimental period. 
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APPENDIX C-2: CLINICAL OBSERVATIONS AND DATA - USD - PHASE 2A 
DOG: /12 NAME: ~!arni 
DEVICE: PH titaniWII spring 10 / DC cuff prototype 4 / RGH septWII lot 1 
SURGERY: Uneventful. 
POST-OP: Normal. 
EXPERIMENTAL PERl'OD: 
CLINICAL OBSERVATIONS - Throughout the experimental period, this dog exper-
ienced retention of urine in the bladder which was probably due to the 
chronic infection of the urinary tract. The dog's overall behavior 
and condition is excellent. There l~ere 2 or 3 periods when the dog 
seemed to be a little less active due to the inflamed urethra imme-
diately or one day following urethral pressure profiling. Vitamin C 
was given throughout the experimental period in order to try to mini-
mize urinary tract infection. 
LABORATORY T.&STS AND CORRELATIONS - Chemistry values appeared normal except 
for tl~O instances at days 44 and 71 post-op of a high CPK. BUN ranged 
from 17 to 22 and was 27 at a point when the dog was unable to void 
for 3 days, but afterwards when normal urine flow returned the BUN 
dropped to 12. Day 22 to day 56 the A/G ratio decreased from 1.1 to 
0.97. The hematology white cell count determination showed a constant 
decrease throughout the experimental period. The eosinophil count was 
initially 43% and dropped to 18%. It is not understood why this oc-
curred. Urinalysis showed trace non-hemolyzed blood prot,ein and an 
alkaline pH through most of the experimental period. Once vitamin C 
treatment was started, pH returned to a value of 7. At sacrifice, 
crystals were present in the bladder. Overall, these values are 
typical of a post-operative healing period with an artificial 
sphincter. 
CONCLUSIONS: Successful testing of prosthetic sphincter. 
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APPENDIX C-3: CLINICAL OBSERVATIONS AND DATA - USD - PHASE 2A 
DOG: #3 NAME: Vera 
DEVICE: PH valve 9 / DC cuff prototype 5 / RGH septum lot I 
SURGERY: Uneventful. 
POST-OP: Up to one week showed ~_, edematous midline. Thereafter, the condition was resolved. 
EXPERIMENTAL PERIOD: 
CLINICAL OBSERVATIONS - The dog's behavior was v~ry good, except when the post-uPP anesthesia and infections caused a slower activity. Tolerated the test of the sphincter very well. LABORATORY TESTS AND CORRELATIONS - Chemistry: all values were normal ex-cept the BUN ranged from 9 to 23 throughout the experimental period. The value increased to the maximum when there was evidence of de-creased voiding and infection. All other values are normal. The phosphorous was 4.5 most of the time. Hematology: all parameters were normal. Urinalysis: the dog showed evidence of a urinary tract infec-tion at times throughout the experimental period, indicated by a 4+ protein. 
CONCLUSIONS: Positive continence tests and successful evaluation of prosthesis. 
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APPENDIX C-4: CLINICAL OBSERVATIONS AND DATA - USD - PHASE 2A 
DOG: #4 NAME!: Diane 
DEVICE: PH valve 5 IDe animal trial cuff (ATC) 1 I RGH septum lot 1 
SURGERY: Uneventful. 
POST-OP: Uneventful. 
EXPERIMENTAL PERIOD: 
CLINICAL OBSERVATIONS - The dog's behavior was excellent and the dog was 
playful at all times, even when urodynamic measurements and edema was 
present. 
LABORATORY TESTS AND CORRELATIONS - Chemistry: Values showed a BUN of 21-
22 that decreased during the healing period and increase~ up to 26 
when a high pressure area was noted on the urethral pressure profile. 
The BUN decreased with decreased pressure, indicating that retention 
was resolved. All other parameters are normal. Hematology: hematocrit 
dropped by 5% 28 days post-op from 50 - 45. Evidence of crenated red 
cells and increased microcytes during the experimental period and 
there was avidence of an increased platelet count during the experi-
mental p,eriod which returned to normal. Urinalysis: normal. 
CO~CLUSION~' Successful ev~luation of the prosthesis. 
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APPENDIX C-5: CLINICAL OBSERVATIONS AND DATA - USD - PHASE 2A 
DOG: #5 NAME: Sue 
DEVICE: PH valve 4 I DC ATC 2 I RGH septum lot 1 
SURGERY: Uneventful. 
POST-OP: Uneventful. 
EXPERIMENTAL PERIOD: 
CLINICAL OBSERVATIONS - Behavior, very good. All aotivity normal. LABO~TORY TESTS AND CORRELATIONS - Chemistry: the BUN inoreased to 21 and then deoreased to 11, oorresponding to elevated intraouff pres-sures found on the urethral pressure profile. Protein, albuminl globulin ratio were abnormal, with protein of generally greater than 17.8 to 8.1 gldl. The AIG ratio value was 0.5 due to the high globulin value of 5. All other ohemistry parameters were normal and stable. Hematology: normal. Urinalysis results were within normal 
range. 
CONCLUSIONS: Exoellent te.;;f: subjeot demonstrated prosthetio funotion. 
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APPENDIX C-6: CLINICAL OBSERVAT.rONS AND DATA - USD - PHASE 2A 
DOG: 06 NAME: Pat 
DEVICE: PH valve <5 ; DC ATC 4 I RGH septum lot 1 
SURGERY: Uneventful. 
POST-OP: At 8 days post-op, the midline opened, was closed and rinsed 
with Betadine with subsequent normal healing. 
EXPERIMENTAL PERIOD: 
CLINICAL OBSERVATIONS - The dog had excellent health throughout the exper-
imental period, except for soreness around the vagina and infection of the 
urinary tract from the repeated urethral pressure profilimetry. 
LABORATORY TESTS AND CORRELATIONS - Chemistry: the BUN, creatinine and 
uric acid were normal throughout the experimental period. Hematology 
values were normal and shor~ed the appropriate shift to the left whioh 
was oorrelated with the urinary tract infeotions. The urinalysis from 
oatheter specimens showed for the first 21 days a normal urinalysis, 
exoept for a few REC's and wac's and epithelial cells. The remainder 
of the experimental period baoteria was identified in the urine from 
few to many and, at saorifice, there was 3+ protein with large amounts 
of blood and wac's with many bacteria [,resent in the urine, indicating 
gross infection. 
CONCLUSIONS: Sucoessful evaluation of prosthetio sphincter function • 
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APPENDIX C-7: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG /I: 1 NAME: Savik DEVICE /I: MEC 1 
PLANNED TIME IMPLANTED: 64 days 
43 days 
ACTUAL: 64 days 
ACTUAL: 43 days PLANNED FUNCTIONAL TEST PERIOD: 
SURGERY: Uneventful. 
POST-OP: There was normal recovery during the 21-day healing period. 
CLINICAL OBSERVATIONS: The dog's activity was normal throughout the 
experimental period. The body weight loss was 9.7%. 
CHEMISTRY - All values were within normal limits, except for 7/15 when the 
HEMATOLOGY 
URINALYSIS 
creatinine kinase level was 395. 
- All parameters normal. 
- Pre-op urine samples showed a dark yellow color that was 
cloudy, pH of 8, with moderate blood, a RBC count of 5-10, a 
w.eC count of 0-2. The urinalysis results improved throughout 
the experimental period. The pH was always 8, with trace of 
protein and there was always evidence of 2-10 RBC's and 0-2 
w.eC's with few epithelial cells. 
CORRELATIONS - The dog's laboratory tests and clinical conditions indicate 
that the dog was in normal health, but had a urinary tract 
infection which is common in dogs. The urinalysis which 
showed RBC's and epithelial cells correlates well with the 
increased difficulty of inserting the urethral pressure 
profile catheter. This mag also explain the elevated 
creatinine kinase level seen near the mid-portion of the 
experimental period. 
PRESSURE STUDIES: (amH 20 ) 
ACTIVE, DEVICE CLOSED: 73-93 (85) /PASSIVE: 4i'-70 /INTRALUMINAL: 119-251 
CUFF UCP: 90-183 
ACTIVE, DEVICE OPEN: 0-30 (0) /PASSIVE:(-)3.4-3/INTRALUMINAL: 107-150 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 2% of time, 
partial continence 0%, incontinence 7%, no flow 91%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 27%, partial 
continence 25%, incontinence 0%, no flow 48%. 
INTERPRETATION: This dog was a verg good test subject who voided routinelg 
in the pit. There were verg definitive continence test observations. 
Post-operative pressure was reduced to less than 100 cmH20 immediatelg following implant, but profile pressures (intraluminal) alwags were greater 
than 100 amH~ and usually greater than 150 amH20 throughout the experi-
mental pariod indicating that either fibrosis due to the sharp cuff edge or 
repeated lirofiling caused stricture. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc. The valve 
button was face down and one of the septa was flipped. There WaS a 1/4 
fold in the reservoir as it lay in its capsule. The tubing length was too 
long and allowed the tubing to curl around one of the self-sealing septa. 
Cultures were negative at the device-capsule interface. 
MACROSCOPIC TISSUE EXAM: The kidneys appeared normal. The bladder was 
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extremely thickened and contained a yellow, proteinaceous material. There 
was evidence of hematoma and erosion at tr.e distal cuff edge and capsule. 
MICROSCOPIC TISSUE BXAM: All capsules are made up of fairly dense, yet 
moderately cellular fibrous connective tissue with no foreign body 
reaction. From the ureter to the distal urethra, there appears to be edema, 
inflammation and inflammatory infiltrates including neutrophils, lympho-
cytes, histiocytes and plasma cells in the mucosa. In the bladder, the 
infiltrates exist in the deeper portions of the submucosa touching the 
muscularis propria. In the area under the cuff, there is a full t],ickness 
of mucosa with fairly prominent inflammation. Submucosa is made up pre-
dominantly of plasma cells, lymphocy/:.,>s illld moderate component of granulo-
cytes. Submucosa similarly is somewhat fibrous and appears rather vas-
cular. The bladder neck shows prominently dilated blood vessels. 
CONCLUSION AND RBCOMMBNDATIONS: It should be noted that natural external 
sphincter pressure for this animal was approximately 80 cmH 0 when 
measured under anesthesia. The urethral closure pressure o~ the external 
sphincter is approximately 60 cmHfJ. This animal was an excellent test 
subject who displayed evidence of artificial sphincter device function. 
Repetitive profiling to determine sphincter function led to urethral 
erasion. It was noted throughout the period that when the dog voided blood 
appeared in the urine after straining to void. Following this animal trial, 
it was decided to decrease the passive pressure to less than 0 in the next 
paired test subjects. 
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APPENDIX C-8: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 2 NAME: Renata DEVICE #: MEC 2 
PLANNED TIME IMPLANTED: 64 days 
43 days 
ACTUAL: 64 days 
43 days PLANNED FUNCTIONlJL TEST PERIOD: ACTUAL: 
SURGERY: Uneventful. 
POST-OP: Normal post-operative healing, except that there was a drainage 
or 50cc of fluid from the midline, and on the 7th post-op day there was a 
moderate amount of edema noted around one of the septa. 
CLINICAL OBSERVATIONS: The dog's weight was stable throughout the experi-
mental period and remained at pre-operative values. 
CHl!1MISTRY - All values were normal, except for BUN which was high normal 
at two intervals, one during the middle and one at the end 
of the experimental period. Creatinine was normal. 
Creatinine kinase levels were elevated throughout the 
experimental period. 
Hl!1MATOLOGY - The white count was normal with a slight shift to the left 
over the experimental period. All other values were normal. 
It should be noted that the dog was in heat during the 
experimental period. 
URINlJLYSIS - The urinalysis was normal at time of implant and throughout 
the experimental period there were large amounts of blood and 
protein eXhibited, with a pH of 7. At sacri.fi.ce, the WEC 
count was greater than 40, the RBC count was greater than 40. 
CORRELATIONS - The chemistry, hematology and urinalysis values correlate 
with the visual observation of gross blood in the urine 
during most of the dog's voiding periods and relate well to 
the high intraluminal pressures noted, although the dog's 
activity and clinical behavior were excellent. 
(amH20) CLC]SE.O: 58-92 (80) /PASSIVE: 37-92 /INTRALUMINAL: 150-197 
CUFF UCP: 140-146 
ACTIVE, DEVICE OPEN: 0-7 (0) /PASSIVE: 32-42 /INTRALUMINAL: 50-183 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 0% of time, 
partial continence 0%, incontinence 3%, no flow 97%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 20%, partial 
continence 0%, incontinence 0%, no flow 80%. 
INTERPRETATION: This dog was a very good test subject, but there was 
evidence of blood in the urine throughout the experimental period indicat-
ing urethral erosion above and beyond the damage caused due to profiling. 
Pressures in the device were normal. The passive side pressure measured 
32 QfflHzO. Intraluminal pressure was always greater than 140 amH20 when 
closed and was approximately 100 cmHzO when open. This dog was in heat 
during the experi.mental period and results show that the dog voided at 
times that were unobservable to the technician. 
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NECROPSY: IMPLANT RETRIEV!lL: The device was removed en bloc. The 
reservoir was slightly folded and the capsule was thick. One of the septa 
was flipped. The tubing was twisted at the capacitor, indicating an im-
proper connect, and the tubing was too long between the components and the 
sphincter cuff. There was also fluid in the bottom of the self-sealing 
septum under the needle stop which was introduced during a pressure measure-
ment and occurred since the septa was flipped. 
MACROSCOPIC TISSUE EXAM: All capsules appeared normal. The bladder was 
thickened with engorged vessels on the surface. There was a fibrin plug in 
the bladder. The kidneys appeared normal. There was a hematoma on the 
left lateral side of the urethra under the sphincter cuff. 
MICROSCOPIC TISSUE EXAM: All capsules are thin to thick, non-reactive 
fibrous capsules. Ureters are normal. Bladder shows submucosal edema and 
very prominent inflammation with fairly extensive neutrophilic infiltration 
of the lining of the urothelium, with some shallow ulceration. The sub-
mucosa is very edematous with prominent dilated vessels. The surface sub-
jacent to the mucosa shows a band of fairly intense inflammation made up 
of plasma cells, neutrophils and some lymphocytes. Deeper in the submucosa 
t.1Jere are lymphoid aggregates with germinal centers. Another section of 
the bladder shows fairly extensive denudation of the lining of the mucosa 
with its replacement by regenerating urothelium and some granUlation tissue. 
The bladder neck shows fairly normal architecture with slight submucosal 
inflammation. The area under the cuff shows an intact epithelium with sub-
jacent edematous submucosa diffusely infiltrated with lymphocytes, plasma 
cells, histiocytes and occasional neutrophils. There is intense neutro-
philic invasion of the epithelium itself. Deeper portions of the submucosa 
show no significant fibrosis. Findings indicate that there is strong 
evidence of straining and probable infection. Kidneys appear normal. 
CONCLUSION AND RECOMMENDATIONS: This animal's overall activity was ex-
cellent, although showing retention of urine due to the pressure caused by 
the occlusive cuff of the urinary sphincter device. Tubing length should 
be shortened, fixation material should be applied to self-sealing septum to 
prevent Slipping and migration. Reservoir should be stiffened to prevent 
folding and lines should be placed on tubing to allow surgeons to prevent 
twists when connecting tubing ends. This dog provided evidence that the 
sphincter functioned, but that the healing period pressures in the passive 
side of the system were too high. 
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APPENDIX C-9: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 3 NAME: Harriet DEVICE #: MEC 3 
PLANNED TIME IMPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
SURGERY: Uneventful. 
64 days 
43 days 
ACTUAL: 
ACTUAL: 
POST-OP: This dog experienced a normal recovery period. 
75 days 
54 days 
CLINI~ OBSER~TIONS: This dog was a hyperactive dog whose behavior was 
excellent throughout the experimental period. The dog maintained its pre-
operative weight throughout the experimental period. 
CEIB~IISTRY Normal, except for BUN which was slightly elevated near the 
beginning or pressure fit time of the experimental period 
and returned to high normal values near the end of the 
experimental period. Creatinine was normal, creatinine 
kinase was elevated at the time of operation and at the time 
of sacrifice. 
HEMATOLOGY - Elevated at the time of operation and decreased to normal at 
sacrifice. All other hematologic values were normal. 
URINALYSIS - Calcium oxylate crystals were identified at pre-op urine 
examination. All other urinalysis was normal, except for 
evidence of 0-2 WBC's throughout the experimental period and 
0-2 REC's at the time of sacrifice only. 
CORRELATIONS - Parameters suggest that there was a slight retention of 
urine, but all other values correlate well with the 
excellent clinical condition of this test subject. 
PRESSURE STUDIES: ( cmH 20 ) 
ACTIVE, DEVICE CLOSED: 76-93 (81) /PASSIVE: 27-49 /INTRALUMINAL: 145-152 
CUFF UCP: 115-132 
ACTIVE, DEVICE OPEN: 3-17 (0) /PASSIVE:(-)12-34/INTRALUMINAL: 93-152 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 0% of time, 
partial continence 0%, incontinence 100%, no flow 0%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 0%, partial 
continence 7%, incontinence 4%, no flow 89%. 
INTERPRETATION: Even though open and closed intraluminal pressures ex-
ceeded 90 amHP, this dog voided most of the time in its cage. This dog 
was extremely hyperactive, with virtually no positive continence test re-
sults observed or verification through functional test observations that 
the device functioned. Pressure tests showed that the device functioned as 
designed. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc and appeared 
as it did before implantation. 
MACROSCOPIC TISSUE EXAM: The bladder showed only minor thickening. There 
appeared to be a hematoma on the urethra underneath the cuff which appears 
on the mucosa. The bulb capsule was quite thick which tended to restrict 
flowback of the bulb reservoir. The kidneys appeared normal. 
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MICROSCOPIC TISSUE EXAM: Mucosa from the ureters and bladder through the 
sphincter cuff to the distal urethra is intact and appears normal. In the 
ureter, the submucosa appears somewhat more cellular in terms of fibrous 
tissue. In the area under the cuff, the mid-cuff shows a fairly attenuated 
mucosa and a somewhat edematous and prominent submucosa. No significant 
inflammation or fibrosis or hemosiderin. The distal cuff has an intact 
mucosa with a moderate degree of fibrosis in the submucosa with an oc-
casional lymphocyte. No significant inflammation. The distal urethra 
shows a slight mixed infiltrate in the submucosa. All capsules are bland, 
fibrous and non-reactive, except for the reservoir which shows evidence of 
recent interstitial hemorrhage, but has no significant inflammation. 
Bladder is normal. Pathology shows that this subject has no pathology. 
CONCLUSION AND RECOMMENDATIONS: This animal was a poor test subject for 
functional test observations due to hyperactivity, but was a successful 
model for device placement and function. Implanting the sphincter system 
in this dog caused no pathophysiology. Damage which was seen previously to 
the urethra due to the high pressures was not experienced in this dog and 
may be due to lower passive pressures during the healing period and 
throughout the experiment. 
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APPENDIX C-IO, CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 4 NAME: Weenie 
PLANNED TIME IMPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
64 days 
43 days 
SURGERY: Uneventful. 
DEVICE #: MEC 4 
ACTUAL: 
ACTUAL: 
39 days 
14 days 
POST-OP: This dog experienced normal healing, but had abnormal behavior 
exhibited by failure to thrive and lack of straining to void. 
CLINICAL OBSERVATIONS: The dog experienced a rapid 32% decrease in body 
weight, had evidence of urinary retention and kidney damage which lead to 
death. 
CHEMISTRY 
HEMATOLOGY 
URINALYSIS 
- Normal to abnormal, with a BUN which started out at 8 and 
ended up at 183. Alkaline phosphatase was elevated through-
out the experimental period. 
Normal to elevated. 
Pre-op values were normal. Values at 6 days and all subse-
quent values indicated large amounts of blood, WBC's and 
casts in the urine. 
CORRELATIONS - The clinical behavior and laboratory results show that this 
dog died due to obstruction caused by an overpressurized 
urinary sphincter cuff, failure to thrive and lack of desire 
to void. 
PRESSURE STUDIES: (cmB2O) ACTIVE, DEVICE CLOSED: 76-80 (85) /PASSIVE: 40-73 /INTRALUMINAL: 
CUFF UCP: > 150 
ACTIVE, DEVICE OPEN: 0-20 (0) /PASSIVE: 8-25 /INTRALUMINAL: 
These pressures indicate that the active side was overfilled. 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 0% of time, 
partial continence 0%, incontinence 0%, no flow 100%. 
> 150 
> 150 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 100%, partial 
continence 0%, incontinence 0%, no flow 0%. 
INTERPRETATION: This dog was a purebred subject who could not overcome the 
pressure of the implanted device. Even with adjustments the active side 
appeared to be overfilled and intraluminal pressures were always greater 
than 150 cmB20. The presence of the sphincter cuff led to obstruction 
and subsequent kiduey failure and death. Error on the part of the tech-
nician to decrease passive side pressure so that resulting intraluminal 
pressure was less than 100 led to the blockage. Even with subsequent 
decompression and removal of fluid from the passive side of the system, the 
dog could not overcame the sphincter cuff pressure. This dog had failure 
to thrive. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc. The device 
appeared normal. No cultures were taken of the device-capsule interface, 
but the tissue over the septum appeared yellowish and discolored, 
indicating possible infection. 
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MACROSCOPIC TISSUE EXAM: The kidneys, especially the right kidney, showed 
gross hemorrhagic areas. The bladder was thin and flaccid. There was a 
hematoma on the urethra at the area of the cuff. 
MICROSCOPIC TISSUE EXAM: The bladder's epithelium is intact. The 
submucosa shows fairly prominent dilated venules. Stroma contains 
hemosiderin-laden histiocytes, suggesting previous submucosal hemorrhage. 
There is some inconspicuous inflammation and some interstitial fibrosis. 
The area under the proximal cuff has an intact mucosa. The submucosa 
exhibits recent interstitial hemorrhage, fairly prominent submucosal 
fibrosis, and fairly inconspicuous inflammation. The cuff capsule is usual 
compressed, parallel arranged, fibrous connective tissue. At one focal area 
there is an aggregate of mixed inflammation including some neutrophils and 
histiocytes which contain hclmosiderin suggestive of an inflammatory 
response to a moderately recent hemorrhage. The dog shows mostly 
hemorrhagic diathesis rather than inflammatory. These findings are 
consistent with disease caused by obstruction. 
CONCLUSION AND RECOMMENDATIONS: This animal was a poor test subject due to 
its failure to thrive and small body weight. Error in decreasing passive 
side pressure immediately post-operati~ely and overfilling caused high 
pressures Which resulted in obstruction and death. Recommendations include 
picking a more vigorous and healthy specimen and following prescribed post-
operative pressure measurements and deactivation philosophy. 
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APPENDIX C-ll: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 5 NAME: Elaine 
PLANNED TIME IMPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
SURGERY: Uneventful. 
96 days 
75 days 
POST-OP: This dog had a normal healing period. 
DEVICE #: MEC 5 
ACTUAL: 
ACTUAL: 
89 days 
65 days 
CLINICAL OBSERVATIONS: The dog waS an excellent test subject who l~as healthy. The dog gained 11 lbs by the end of the experimental period and was found to be pregnant at necropsy. 
CHEMISTRY - The BUN was normal, became slightly elevated at the middle 
of the experimental period, and then returned to normal throughout the majority of the remaining experimental period. HEMATOLOGY - Normal throughout, except for a high white count which 
correlated with the high BUN. URINALYSIS - The dog experienced 0-2 RBC's throughout the experimental period and at sacrifice had large amount of blood, greater than 40. WEC's throughout the experimental period of 0-2, 
except near the end when had 10-20, up to 2000. CORRELATIONS - The chemistry and hematology are normal. The high BUN and 
white count and positive staph culture of the urine indicate that retention and inflammation are due to an infection. 
PRESSURE STUDIES: (cmS ~ ) 
ACTIVE, DEVICE CLOSED: (86) 
CUFF UCP: 120 
ACTIVE, DEVICE OPEN: (0) 
/PASSIVE: 0-27 /INTRALUMINAL: 135- >150 
/PASSIVE:(-)17-17/INTRALUMINAL: 68-150 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 7% of time, partial continence 0%, incontinence 17%, no flow 76%. SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 9%, partial continence 17%, incontinence 19%, no flow 54%. INTERPRETATION: This test subject always overcame the system during voiding, although there was some evidence that the closed device did influence the urine stream (pulsating). Pressure studies, which were elevated, may be due to the inflamed tissue caused by the urinary tract infection. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc and appeared normal. 
MACROSCOPIC TISSUE EXAM: The bladder internal mucosa showed evidenqe of gross cystitis. The dog was gravid approximately 6 weeks, with all other tissue appearing normal. 
MICROSCOPIC TISSUE EXAM: This dog had acute and marked chronic cystitis and chronic urethritis. There is evidence of some chronic pyelitis. All other organs are normal and there is the expected bland, non-reactive capsule around all device portions. 
CONCLUSION AND RECOMMENDATIONS: This animal was an excellent test subject in which device placement and function was satisfactory. 
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APPENDIX C-12: CASE STUDIES - URINlfRY SPHINCTER DEVICE - RGH 
DOG 1/: 6 NAME: Lynette DEVICE II: MEC 6 
PLANNED TIME IMPLANTED: 96 days 
75 days 
ACTUAL: 89 days 
65 days PLANNED FUNCTIONAL TEST PERIOD: ACTUAL: 
SURGERY: Uneventful. 
POST-OP: This subject exhibited a normal healing period. 
CLINICAL OBSERVATIONS: This dog's activity and behavior were excellent 
throughout the experiment. The device was left completely open during the 
healing period with no signs of straining except immediately before the 
pressure fit. 
CHEMISTRY - BUN started out slightly elevated at the time of the 
HEMATOLOGY 
URINALYSIS 
operation and decreased to normal and remained normal 
throughout the experimental period. All other values were 
normal. 
- Normal. 
Initially, this dog exhibited signs of a urinary tract 
infection at the time of the operation. The urinalysis 
determinations returned to normal for the first part of the 
experimental period and for the last third of the experi-
mental period was slightly abnormal with a pH varying 8.5 to 
6.5. Evidence of slight 1+ protein, and 2-40 RBC's. The 
sacrifice urinalysis showed evidence of 0-2 wec's. 
CORRELATIONS - Values shown indicate a normal subject and correlate very 
well with the exceptional clinical behavior. Blood in the 
urine is evidenced following insertion of the urethral 
pressure profile catheter which irritates and causes erosion 
to the mucosa of the urethra. 
PRESSURE STUDIES: (cmH 20 ) 
ACTIVE, DEVICE CLOSED: (79) /PASSIVE: (- )8.S-26/INTRALUMINAL: 148- >150 
CUFF UCP: 120->130 
ACTIVE, DEVICE OPEN: (0) /PASSIVE: (-)34-5.1/INTRALUMINAL: 86-117 
With the system in the open configuration, the tracing from the urethral 
pressure profile showed a sharp peak at the distal cuff edge that measured 
150 cmH20. 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 2% of time, 
partial continence 1%, incontinence 13%, no flow 84%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 30%, partial 
continence 24%, incontinence 3%, no flow 43%. 
INTERPRETATION: This subject is one of our best animal models providing 
numerous continence observations. Immediately before the pressure profile 
for the pressure fit, straining to void was observed with the device in the 
open configuration so that O.Scc were removed from the passive side which 
eliminated the dog from straining. Closed, the device caused changes in 
the urine stream and sometimes continence. Open, the stream was low volume 
and flowed normally. At the pre-sacrifice profile, the technician was 
unable to insert the profile catheter due to stricture or fibrosis caused 
by erosion from the catheter during subsequent successive profiles. 
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NECROPSY: l'M,.'LANT RETRIEVAL: The device was removed en bloc from the dog. 
The septum was flipped. Cultures of the capsule-device interface were 
negative. 
MACROSCOPIC TISSUE EXAM: The urethral mucosa under the proximal cuff edge 
was rugose and hemorrhagic. 
MICROSCOPIC TISSUE EXAM: There appears to be some denudation of the urethra 
with subacute and some acute inflammation. This appears to be verg recent 
and mag have been agonal or close to it. No significant inflammation in 
the urinarg bladder. No significant changes in the organs. 
CONCLUSION AND RECOMMENDATIONS: This animal was an excellent model to 
displag the function of the urinarg sphincter device as indicated bg the 
operating pressures and the functional test observations. Recommendations 
are to place ingrowth material on the septum, and to place the valve-bulb 
in subcutaneous pockets that are closed to prevent migration of the com-
ponents towards the midline. 
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APPENDIX C-13: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 7 NAME: Vi vi an 
PLANNED TIME IMPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
96 days 
75 days 
SURGERY: Uneventful. 
DEVICE #: MEC 7 
ACTUAL: 
ACTUAL: 
91 days 
70 days 
POST-OP: Midline healing was normal, although this dog experienced large 
amounts of edema over the reservoir and capacitor. On the 20th post-op day. 
immediately before the pressure profile, the device lias noted to be non-
functioning and the capacitor and valve-reservoir components were tangled on 
top of one another. At this time, an incision was made and the capacitor 
valve-bulb isolated. A break in the bond line of the tubing and capacitor 
on the cuff side was found subsequent to manipulation to activate the 
device. The system tubing was trimmed and reconnected and placed on the 
ribcage of this test subject, at which time the device functioned normally. 
CLINICAL OBSERVATIONS: This dog's behavior was excellent. Dog's weight 
was stable throughout the experimental period. 
CHE~JISTRY - All values were normal. 
HEMATOLOGY - White count was normal. There was always evidence of a 
shift to the left in the differential. All other values 
were normal. 
URINALYSIS - Mostly normal with slight 0-2 RBC's, 0-2 WBC's, few 
epithelials recorded throughout the experimental period. 
CORRELATIONS - This dog showed a normal healing period and was normal with 
no pathophysiology throughout the experimental period. 
PRESSURE STUDIES: ( amB 20 ) 
ACTIVE, DEVICE CLOSED: (76) /PASSIVE: 29-59 /INTRALUMINAL: 120->150 
CUFF UCP: 100->140 
ACTIVE, DEVICE OPEN: (0) /PASSIVE:(-)22-25/INTRALUMINAL: 83-135 
Please note that there was a spike of 148 amBO at the distal edge of the 
cuff. 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 0% of time, 
partial continence 0%, incontinence 33%, no flow 67%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 17%, partial 
continence 7%, incontinence 10%, no flow 66%. 
INTERPRETATION: This dog was a good test subject. Urethral pressures were 
slightly elevated in this dog even in the open configuration. This subject 
displayed no positive cage continence tests, but showed a relatively good 
positive continence and partial continence test on spontaneous evaluation. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc and appeared 
normal. Cultures were negative. 
MACROSCOPIC TISSUE EXAM: Tissue appeared normal. 
MICROSCOPIC TISSUE EXAM: There is some attenuation of mucosa in the urethra 
without significant inflammation. Presence of some slight lymphocytic 
infiltration in the submucosa of the ureter and pelvis of both kidneys. 
The absence of plasma cells suggests that the inflammation is not due to 
bacterial antigens. 
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CONCLUSION AND RECOMMENDATIONS: This animal showed a functional sphincter 
device with positive subjective continence observations and pressures in 
acceptable operating ranges. Recommendations include placing sphincter 
components on the ribcage and isolating them in a pocket which has been 
closed with absorbable suture. 
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APPENDIX C-14: c..r,sE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 8 NAME: Gueni vere 
PLANNED TIMB IMPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
66 days 
45 days 
SURGBRY: Uneventful. 
DEVICE #: MBC 8 
ACTUAL: 
ACTUAL: 
64 days 
43 days 
POST-OP: Post-operative healing period was normal. 
CLINICAL OBSERVATIONS: The dog's behavior and activity were normal, 
although the dog exhibited fear and this affected continence observations. 
CHEMISTRY - Normal. 
HEMATOLOGY - wac was slightly elevated during the healing period, but 
returned to normal during the experimental period. All 
other values were normal. 
URINALYSIS - The dog showed a normal urinalysis for dogs, which showed 
0-5 RBC's, 0-2 wac's, with a few epithelial cells present 
after inserting the catheter. 
CORRELATIONS - This dog's laboratory values correlate well with a normal 
test subject. 
PRESSURE STUDIES: ( cmH 20 ) 
ACTIVE, DEVICE CLOSED: (77) /PASSIVE: 6-43 /INTRALUMINAL: 148->150 
CUFF UCP: 118- >150 
ACTIVE, DEVICE OPEN: (0) /PASSIVE: (- )13-25/INTRALUMINAL: 70-110 
It should be noted that this dog's external sphincter pressure under 
anesthesia was 132 cmH20. 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 0% of time, 
partial continence 0%, incontinence 34%, no flow 66%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 6%, partial 
continence 18%, incontinence 0%, no flow 76%. 
INTERPRETATION: Pressures and functional tests indicate that the device 
is functioning as designed. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc. 
MACROSCOPIC TISSUE EXAM: All organs appear normal. The bladder appeared 
very slightly thickened. When the urethra was dissected, there appeared to 
be some submucosal hemorrhage present. 
MICROSCOPIC TISSUE EXAM: All device capsules are thin and non-reactive. 
Kidneys are normal. Bladder is normal. The urethra underneath the cuff 
shows an intact to attenuated mucosa with some fibrosis. The attenuated 
mucosa appears at the distal edge. There is no inflammation and the tissue 
appears normal. 
CONCLUSION AND RECOMMENDATIONS: This animal was a good test subject who 
demonstrated the proper functioning of the urinary sphincter device and 
showed no pathophysiology. 
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APPENDIX C-15: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG #: 10 NAME: Momma DEVICE #: MEC 10 
PLANNED TIME IMPLANTED: ACTUAL: 
PLANNED FUNCTIONAL TEST PERIOD: ACTUAL: 
SURGERY: Uneventful. 
POST-oP: Post-operative healing period was normal. 
CLINICAL OBSERVATIONS: Dog's behavior and activity were excellent. Dog's 
weight was stable throughout the experimental period and remained at pre-
operative levels. 
CHEMISTRY - All values normal. The BUN was a high normal at the second 
HElg,TOLOGY 
URINALYSIS 
post-op week, but returned to normal throughout the 
remainder of the experimental period. 
- Normal. 
- The initial operative sample was normal and remained normal 
considering the profiling which caused 5-10 RBC's or 0-2 
wac's and a few ,epithelial cells. There was some evidence 
of protein in the sacrifice sample. 
CORRELATIONS - This dog showed normal health. 
PRESSURE STUDIES: (c:mH 20 ) 
ACTIVE, DEVICE CLOSED: (74) /PASSIVE: (-)34-25/INTRALUMINAL: 126->150 
CUFF UCP: 100- >150 
ACTIVE, DEVICE OPEN: (0) /PASSIVE:(-)49-9/INTRALUMINAL: 60-129 
Please note that there was evidence of a distal peak with the device in the 
open configuration that measured 148 cmSt'. 
FUNCTIONAL TEST OBSERVATIONS: CAGE: Total continence 30% of time, 
partial continence 4%, incontinence 20%, no flow 46%. 
SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continence 28%, partial 
continence 36%, incontinence 0%, no flow 36%. 
INTERPRETATION: This animal was an excellent test subject which experienced 
closed pressures greater than 150. Stricture occurred at the distal edge 
of the sphincter cuff as with the other dogs and caused difficulty when in-
serting the profiling catheter. Probable damage to the mucosa occurred 
from passing the catheter at this point. 
NECROPSY: IMPLANT RETRIEVAL: The device was removed en bloc from the dog. 
There was a tubing curl near the capacitor and the septum. 
MACROSCOPIC TISSUB EXAM: The cuff capsule was thick, but non-reactive. 
There appeared to be a slight visible stricture at the distal cuff edge. 
Kidneys appeared normal. Bladder appeared normal. There appeared to be 
some hemorrhage in the submucosa. 
MICROSCOPIC TISSUB EXAM: No significant inflammatory or anatomical changes 
in the urinary tract. We have an incidental small renal granuloma. There 
is hyperemia of the spleen and liver. All capsules are bland, thin, with 
no inflammation, although there is some prominent hyperemia of submucosal 
vessels underneath the sphincter at the mid-cuff section. 
23C-22 
, 
I 
I 
I (j, 
, 
• I 
/,1 
11 
" 
" I' j 
, 
" II I 
I 
I, 
l 
! j:, 
I 
I' 
" I: 
.Ii 
11 
" :-i' 
'I: 
II , 
,I 
11 
'I 
" 
:1 il 
1.1 
\1 
II II 
II 
Ii 
II 
1,,'1 I 
,I 
'I 
,I 
I 
" 
" 
ri 
, , 
:": 
CONCLUSION AND RECOMMENDATIONS: This animal was an excellent test subject 
who demonstrated device function and was apparently healthy with no detri-
mental effects from the device. 
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APPENDIX C-16: CASE STUDIES - URINARY SPHINCTER DEVICE - RGH 
DOG U: 11 NAME: Ohura 
PLANNBD TIUE nIPLANTED: 
PLANNED FUNCTIONAL TEST PERIOD: 
66 days 
45 days 
SURGJilRY: Uneventful. 
DEVICE #: MEC 11 
ACTUAL: 
ACTUAL: 
62 days 
41 days 
POST-OP: At day 2 post-implant, the midline skin incision started to open and was repaired. The remainder of the healing period was uneventful. 
CLINICAL OBSERVATIONS: This dog's activity and behavior were excellent. The dog showed a weight gain throughout the experimental period. CHEMISTRY - All normal. 
HEMllTOLOGY - All hematologio values ,~ere normal. URINALYSIS - Urinalysis throughout the experimental period, exoept for 
one oooasion, was normal. The one urinalysis sample showed 
rare RBC's and oocasional epithelial oells. CORRELATIONS - Clinical behavior and laboratory values show that this dog 
was healthy. 
PRESSURE STUDIES: (omS P ) 
ACTIVE, DEVICE CLOSED: (77) 
CUFF UCP: 38-108 
ACTIVE, DEVICE OPEN: (0) 
Please note that this test subjeot 
omS~ at the distal ouff edge. 
/PASSIVE: (-)43-17/IN'l'RALUMINAL: 88-150 
/PASSIVE:(-)66-(-)8/IN'l'RALUMINAL: 40-82 
also showed a pressure spike of 150 
FUNCTIONAL TEST OBSERVATIONS: CAGJil: Total oontinenoe 1% of time, partial continenoe 1%, inoontinenoe 44%, no flow 54%. SPONTANEOUS FUNCTION TEST OBSERVATIONS: Total continenoe 37%, partial oontinenoe 26%, inoontinenoe 5%, no flow 32%. INTERPRETATION: This test subjeot was an exoellent animal model whioh provided positive oontinenoe demonstrations and towards the end of the experimental period was oonditioned to void only when the observer was not watohing. Even though this oocurred, this dog demonstrated the greatest number of positive oontinenoe demonstrations and also demonstrated the best pressures intraluminally, whioh was due to the faot that the passive pressures were set so low and caused the ouff to be conoave. 
NECROPSY: IMPLANT RETRIEVAL: The devioe was removed en bloo from this test subjeot at whioh time the active ouff was damaged, causing a leak in the system. There was a tubing curl and knot around the self-sealing septum. MACROSCOPIC TISSUE EXAM: Showed some visible blood on the urethral muoosa and some muoosal blood visible but minimal. The bladder, kidneys and all other tissue appeared normal. 
MICROSCOPIC TISSUE EXAM: The usual bland oapsule with a few foci of histiooytio aggregates towards the surfaoe of the oapsule facing the 
applianoe is seen. All other tissue is normal. 
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CONCLUSION AND RECOMMENDATIONS: This animal was our best test subject: and 
through experience we have learned to pressure fit the cuff at a very low 
passive pressure. The operating pressure of this system was good. The dog 
exhibited no pathophysiology. The cuff has been redesigned so that the 
faying edges at the proximal and distal edges are not as sharp, whiCh 
caused pressure peaks at those areas. 
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APPENDIX D 
HISTOLOGY REPORTS - P~JSE 2A AND 2B 
Tables 13A and 13B 
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FIGURE 13-1: KEY TO HISTOLOGICAL SAMPLES 
DIAGRA~l: 
"'.;fl't:, "I,',f t Lc,UJe'i<. Uf\\NAt"j 'i(lJ\C~' F'fMl\lE. 
\. ' /''\1"'. . ~ • ~,(' ,", '. t ~ 
, -- ~ . 
, 
, , 
g; (13) I' 
'(I1.) 
- ' 
, ' 
\ ' 
, , 
, I 
I I 
I 
(10) ___ C' ) 
\I'~ '----
NoT TO SCME. 
(1) Ureters - one section from each 
(2) Bladder - proximal 
(3) Bladder - distal 
(4) Bladder neck 
(5) Urethra - proximal cuff edge 
(6) Urethra - mid-cuff 
(7) Urethra - distal cuff 
(8) Capsular tissue - cuff 
(9) Urethra - distal near meatus 
(10) Capsule - sUbcutaneous septum or "drum" 
(11) Capsule - attenuator 
(12) Capsule - bulb or reservoir 
(13) Capsule - valve 
(Organs) Heart, lung, liver, spleen, small bowel, kidney 
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TABLE 13A-l: HISTOLOGY REPORT - USD 
DOG: #1 NAME: Tara TI~fE IMPLANTED: 246 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: Dog experienced a urinary tract infection of E. coli 
during the experimental period which was treated and cured. During dissec-
tion of the bladder, stones were found. 
SECTIONS OF TISSUE: 
(1) Missing 
(2)(3)(4) There is evidence of subacute and chronic submucosal inflammatory 
reaction. ~!ostly focal areas three to four times as thick as mucosa. 
(5)(6)(7) The urethra shows focal chronic urethritis with slight chronic 
inflammation. 
(10) The septum capsule is inert • 
(12) The bulb capsule is inert, showing few histiocytes. 
(Organs) All organs are OK. The kidneys show slight pyelitis with no 
nephritis. 
SUMMARY: This dog shows histology compatible with infection during the 
experimental period. No other pathology. Calculous fragments are composed 
of compact, intimately mixed masses of cryptocrystalline to well developed 
orthorhombic crystals of magnesium, ammonium phosphate, hexahydrate, 
microcrystalline carbon apetite, dried blood and protein. 
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TABLE 13A-2: HISTOLOGY REPORT - USD 
DOG: #2 NAME: Marni TIME IMPLANTED: 85 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: There was evidence of infection and urinary retention 
due to the high pressure zone of the cuff throughout the experimental 
period. 
SECTIONS OF TISSUE: 
(1) Ureters are normal. 
(2)(3)(4) Bladder is normal. 
(5) There is evidence of an attenuated epithelial layer, 3 compared to 5 
cells. Otherwise no significant reaction. 
(6) Portions of the slide are normal, others show congested area with 
superficial abrasions and surface alterations. All other tissue 
normal. 
(7) Normal. 
(8) The cuff capsule shows a small foreign body response with some lympho-
cytes present, although it is fairly inert. 
(9) The distal urethra is normal. 
(10) The septum capsule is normal. 
(12) The bulb capsule is normal. 
(Organs) Kidneys are normal, as are all other samples of majo~ organs, 
except an area of the small intestine where there was a reactive 
vascular fibrotic area. This area was not located near the device. 
SUMMARY: Unsure of significance of reactive tissue in the small intestine. 
The abrasion evidenced on the mucosa of the urethra is due to the u~etllral 
pressure profiles performed on this dog even when a significant high pres-
sure area was indicated. 
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TABLE 13A-3: HISTOLOGY REPORT - USD 
DOG: #3 NAME: Vera TIME IMPLANTED: 103 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: None. 
SECTIONS OF TISSUE: 
(1) Chronic ureteritis was present. 
(2)(3)(4) These sections show normal histology. 
(5)(6)(7) The urethra shows chronic urethritis with chronic epithelial 
cell layer involvement only. 
(8) The cuff capsule shows normal reactive tissue with a relative degree 
of inertness. 
(9) Distal urethra shows same as areas (5) through (7). 
(10) The septum shows normal reactive tissue. 
(12) The bulb capsule shows normal reactive tissue. 
(Organs) Kidneys are normal, except for chronic pyelitis, with retrograde 
inflammation of epithelial cells. Some lymphoid reaction, no involve-
ment of the cortex or medulla. All other organs sampled are normal. 
SUMMARY: Chronic inflammatory reaction of all urinary tract specimens 
corresponds with evidence throughout the experimental period of infection. 
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TABLE 13A-4: HISTOLOGY REPORT - USD 
DOG: #4 NAME: Diane TIME IMPLANTED: 59 days 
REASON FOR SACRIFICE: 
GROSS OBSERVATIONS: Tissue of urethra appears to be fibrotic. There 
appears to be two areas of infarct 1800 to each other perpendioular to the 
longitudinal line of the urethra. 
SECTIONS OF TISSUE: 
(1) Hissing 
(2)( 3) (4) Normal. 
(5)(6)(7) There is evidence of venous dilatation of submucosal veins (not 
uniform, correlates with macro infarct observation) and some fibrosis. 
(8) Missing 
(9) Normal. 
(10) Septum capsule is non-reactive. 
(12) Bulb capsule is non-reactive. 
(Organs) Kidneys and all organs sampled are normal. 
SUMMARY: This dog showed no significant pathology. 
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TABLB 13A-5: HISTOLOGY REPORT - USD 
DOG: #5 NAME: Sue TIME IMPL1lNTED: 63 days 
REASON FOR SACRIFICE: Bnd of the experimental period. 
GROSS OBSERVATIONS: None. An tissue appears to be normal. 
SBCTIONS OF TISSUE: 
( 1) ~!issing 
(2)(3)(4) The b1aeder appears to be hypertrophied with evidence of mild, chronic cystitis in the submucosa and slight submucosa fibrosis (bacterial culture is positive). 
(5)(6)(7) The urethra shows subacute and chronic urethritis with subacute chronic inflammation and dilatation of the submucosal veins, more than for inflammation which indicates increase due to presence of cuff pressure. 
(8) Compact pseudocapsu1e around cuff. 
(9) This section again shows dilatation of submucosal veins. 
(10) The septum capsule shows subacute inflammation. 
(12)(13) The external capsule is inert with a focal area of slight inflam-matory reaction with histiocytes. 
(Organs) Kidneys are normal. The lung shows chronic pneumonia with patchy areas of mononuclear bronchi. The liver has two or three reactive areas. All other organs are normal. 
SUMMARY: No significant pathology. 
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TABLE 13A-6: HISTOLOGY REPORT - USD 
DOG: #6 NAME: Pat TIME IMPLANTED: 56 days 
~SON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: Prior to sacrifice, the bladder was filled with 
approximately 300 cc of saline in an effort to override the cuff mechanism 
(!"hich could not be done). The abdomen was distended. Upon examination of 
the bladder, hemorrhagic cystitis was present, assumed to be due to abnormal 
distention of bladder. 
SECTIONS OF TISSUE: 
(1) None 
(2)(3)(4) Acute hemorrhagic cystitis (please see gross observations). 
(5)(6)(7) In reviewing these slides proximal to distal, there is 
to moderate increase in focal areas of chronic inflammation. 
distal slide shows slight edema only. 
(8) The cuff capsule is inert. The distal urethra is normal. 
a slight 
The 
(10) The septum capsule shows some chronic inflammation and foreign body 
reaction. 
(12) The bulb capsule is normal. 
(Organs) Kidneys - the pelvis shows chronic pyelitis which is marked, but 
no pyelonephritis. The lung shows a focal area of lumbar pneumonia 
and one ballooned alveoli. All other organ samples are normal. 
SUmIARY: This dog shows no significant pathology except for ch,.'onic 
pyelitis. 
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TABLE 13B-l: HISTOLOGY REPORT - USD 
DOG: #1 NAl1E: Savik TIfl!E IMPLANTED: 64 days 
REASON FOR SACRIFICE: End of the experiment. 
GROSS OBSERVATIONS: Bladder was extremely thickened and contained a 
yellow, proteinaceous material. There was evidence of hematoma and erosion 
at the distal cuff edge and capsule. 
SECTIONS OF TISSUE: 
(1) Ureter shows some edema in the submucosa and has slight degree of 
inflammation and is predominantly of mature cell plasma cells and 
some lymphocytes. The muscle walls are OK. 
(2) Section of the urinary bladder which shows a very conspicuous, 
probably real thickening in the submucosa which shows fairly dense 
inflammatory infiltrate and edema in the superficial portions. In-
flammatory infiltrate includes neutrophils, which involve the 
epithelium, urethelium itself and the submucosa. In addition to this 
there is generous component of lymphoid aggregates, histiocytes and 
plasma cells. The deeper portions of the submucosa are touching the 
muscularis propria; may show some increase of loose areolar fibrous 
tissue. 
(3) This is also bladder showing identical changes. Another thing that is 
fairly conspicuous, which may need confirmation or titration relation-
ship to some normals, is that the individual fascicles of muscle seem 
very well defined and distinct. Possible suggestion of hypertrophy. 
(4) 
(5) 
(6) 
Bladder neck shows similar and identical surface inflammation of the 
mucosa and immediate submucosa. Deeper portion of the submucosa sho<~s 
much denser and more cellular fibrous connective tissue and prominently 
dilated almost to blood vessels. 
Unfortunately a portion of the mucosa is missing, but shows some 
chronic inflammation in the submucosa. Muscle layers seem intact. 
The outside of the muscle layers appears to have a fairly thick, 
moderately cellular, dense collagenase, fibrous connective tissue 
capsule with somewhat compressed surface fibroblasts defining the 
interface between the cuff and the bladder neck. There is no foreign 
body reaction or any other inflammation at that surface. 
Mid-cuff which shows a full thickness of mucosa with fairly p.rominent 
inflammation. The submucosa made up predominantly of plasma cells, 
lymphocytes and moderate component of granulocytes. Submucosa 
similarly is somewhat fibrous and appears rather vascular. The cuff 
changes are identical to that previously described. 
(7) Changes identical to that described in mid-portion. 
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Table 138-1 Dog: #1 
(8) Cuff capsule is made up of fairly dense, yet moderately cellular, 
fibrous connective tissue. There is some recent hemorrhage within 
the stroma as well as presence of fairly abundant hemosiderin-laden 
histiocytes diffusely interspersed within the fibrous capsule, sug-
gesting previous bleeding and/or organizing hematoma 
(9) Mucosa appears fairly intact. There is again similar chronio in-
flammation and prominent vasoularity in submuoosa. There is obviously 
no cuff oapsule. 
(10) Dense cellular, somewhat organized appearing, 
tissue. No significant hemosiderin on H + E. 
reaotion. 
(11) Thiok fibrous oapsule, no inflammation. 
fibrous oonneotive 
No foreign body 
(12) Another capsule-like struoture, fairly thin, similar parallel-arranged 
fibroblasts with oollagen and no inflammation. No foreign body 
reaction. 
(13) Another oapsule with similar configuration. 
(Organs) Spleen - no signifioant changes. Kidneys - renal cortioal tissue 
is oompletely normal. There's no evidenoe of dilatation or inflamma-
tion. There appears to be a very well defined and delineated wedge-
shaped lesion within the kidney. Fairly sharp transition from 
relatively normal cortex to abnormal cortex. It shows very extensive 
interstitial inflammation made up of plasma cells and lymphooytes, 
with triplase atrophy tubules. Many tubules are dilated and contain 
some casts, some of whioh appear to be brown stained, presumably 
blood. The lobular artery is full of blood and may represent 
thrombus. It certainly has some superficial resemblance of a pyelo-
r.ephritis and/or inflammation following an isohemio episode. Lungs-
no significant pathologio changes. Heart - similarly histologically 
normal. Small intestine - shows no significant changes. Liver-
normal. 
SUMMARY: All capsules are made up of fairly dense, yet moderately cellular 
fibrous oonnective tissue with no foreign body reaotion. From the ureter 
to the distal urethra, there appears to be edema, inflammation and inflam-
matory infiltrates inoluding neutrophils, lymphocytes, histiooytes and 
plasma oells in the mucosa. In the bladder, the infiltrates exist in the 
deeper portions of the submucosa touohing the muscularis propria. In the 
area under the cuff, there is full thiokness submucosa tdth fairly 
prominent inflammation. The submucosa is made up predominantly of plasma 
cells, lymphocytes and moderate component of granulooytes. Submuoosa 
similarly is somewhat fibrous and appears rather vascular. The bladder 
neck shows prominently dilated blood vessels. The tissue appears to be 
non-pathologic under the given conditions, with the presence of the urinary 
sphincter system and straining. 
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TABLE 13B-2: HISTOLOGY REPORT - USD 
DOG: 1/2 NA~1E: Renata TIME IMPLANTED: 64 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: All capsules appeared normal. The bladder was 
thickened r~ith engorged vessels on the surface. There was a fibrin plug in 
the bladder. The kidneys appeared normal. There was a hematoma on the 
left lateral side of the urethra under the sphincter cuff. 
SECTIONS OF TISSUE: 
(1) Fairly normal submucosa, occasional lymphocytes and rare plasma cells. 
No significant edema. 
(2) There is submucosal edema and very prominent inflammation. There is 
fairly extensive neutrophilic infiltration of the lining urethelium 
with some shallow ulceration. Submucosa is very edematous with 
prominent dilated vessels. The surface subjacent to mucosa shows a 
(3) 
band of fairly intense inflammation made up of plasma cells, neutro-
phils and some lymphocytes. Deeper in the submucosa there are 
lymphoid aggregates without germil.'al centers. 
The surface shows fairly extensive denudation of the lining mucosa 
with its replacement by regenerating urethelium and some granulation 
tissue. Submucosal changes are same as previously described. 
(4) Bladder neck shows a fairly normal-appearing architecture with slight 
submucosal inflammation made up of fairly irregularly arranged and 
moderately rare plasma cells and lymphocytes. 
(6) An intact epithelium with subjacent edematous submucosa, diffusely 
infiltrated with lymphocytes, plasma cells, histiocytes and occasional 
neutrophils. There is more intense neutrophilic invasion within the 
epithelium itself. Deeper portion of submucosa shows no significant 
fibrosis. The fibrous capsule is made up of parallel-arranged 
cellular fibrous connective tissue. Surface shows no reaction. 
(7) No good evidence of the capsule. The mucosa and submucosa show 
similar inflammations as previously. 
(8) Cuff capsule showing a fairly thin, non-reactive fibrous capsule. 
(9) Distal urethra shows again inflammatory infiltrate similar to those 
seen elsewhere. The mucosa seems somewhat thinner and more 
attenuated. The mucosa contains fairly numerous neutrophils. Sub-
jacent submucosa is edematous and contains some neutrophils super-
ficially but more prominently has numerous plasma cells and lympho-
cytes and occasional lymphoid aggregates. 
(10) A fairly thick, probably tangentially cut, fibrous capsule. No 
reaction, no inflammation, no foreign body response, no old hemorrhage. 
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Table 138-2 Dog: 112 
(11) Thin capsule, irregular degree of cellularity, some areas of fairly 
acellular fibrous tissue, although it is moderately sO. NO foreign 
body reaction. No inflammation. 
(12) Fairly thin, moderately cellular, no reaction. 
(13) Not very reactive, no changes. 
(Organs) Small intestine - normal. Lung - normal. Kidney - normal. 
Heart - normal. Liver - somewhat normal. It has an appearance of 
pseudonodularity with areas around terminal hepatic veins showing 
greater degree of glycogen content. 
SU~1~1ARY: The bladder shof~s very prominent inflammation f~ith fairly 
extensive neutrophilic infiltration of the lining of the urothelium, with 
some shallow ulceration. Another section of the bladder shows fairly ex-
tensive denudation of the lining of the mucosa with replacement by regeller-
ating urothelium and some granulation tissue. The area under the cuff 
shows an intact epithelium with subadjacent edematous submucosa diffusely 
infiltrated with lymphocytes, plasma cells, histiocytes and occasional 
neutrophils. Findings indicate that there is a strong evidence of 
straining and probable infection. Kidneys appear normal. All capsules are 
thin to thick, non-reactive. Findings correlate with high cuff pressure. 
The only clinical indication of problems was constant fresh blood at 
voiding. 
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TABL7JJ 13B-3: HISTOLOGY REPORT - USD 
DOG: 113 NAl'IE: Harriet TIUE IUPLANTED: 75 days 
REASON FOR SACRIFICE: End of e;rperimental period. 
GROSS OBSERVATIONS: The bladder shol1ed only minor thickening. There 
appeared to be a hematoma on the urethra underneath the cuff on the mucosa. 
The bulb capsule is quite thick, ",hich tended to restrict flowback into the 
bulb reservoir. The kidneys appeared to be normal. 
SECTIONS OF TISSUE: 
(1) Epithelium intact, submucosa moderately prominent. No significant 
inflammation. The submucosa appears to be somewhat more cellular in 
terms of fibrous tissue. 
(2)(3)(4) No inflammation, intact mucosa, normal submucosa, fairly 
prominent, more pink fibrous tissue than submucosa. 
(5) One surface, fibrous cuff with no reaction. The opposite side, fairly 
attenuated mucosa, a somel1hat edematous and prominent submucosa. No 
significant inflammation or fibrosis or hemosiderin. 
(6) Intact mucosa. Moderate degree of fibrosis in the submucosa. 
Occasional lymphocytes, but no significant inflammation. 
(8) Cut tangentially thick. No problem. 
(9) ~!ucosa intact, submucosa shows slight mixed infiltrate including some 
neutrophils, plasma cells, lymphocytes not very prominent in the 
aggregate. 
(10) Bland, moderately thick capsule. Focal areas of fairly cellular-
appearing connective tissue and perhaps more capillary network than 
the usual. 
(12) Showing a fibrous capsule with recent interstitial hemorrhage and what 
looks like possible response to this hemorrhage. No significant in-
flammation. 
(13) F~irlybland, thin fibrous capsule. 
(Organs) Small intestine - normal. Lung - normal. Liver - normal. 
Heart - normal. 
SU~MnlRY: Histology shows that this subject had no pathology. 
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TABLE 13B·-4: HISTOLOGY REPORT - USD 
DOG: #4 NAME: Weenie TIME IMPLANTED: 39 days 
REASON FOR SACRIFICE: Failure to thrive and death due to urinary tract 
obstruction and subsequent kidney damage • 
GROSS OBSERVATIONS: The kidneys, especially the right, showed gross 
hemorrhagic areas. The bladder was thin and flaccid. There was a hematoma 
on the urethra at the area of the cuff. 
SECTIONS OF TISSUE: 
(1) Moderate degree of edema, prominent vascularity in submucosa. Fairly 
inconspicuous inflammation except for a rare lymphocyte. 
(2) Epithelium is intact, the submucosa shows fairly prominently dilated 
venules. The stroma contains hemosiderin-laden histiocytes suggesting 
previous submucosal hemorrhage. There is a recent intramuscular 
hemorrhage of unknown reason. 
(3) Fairly intact mucosa without significant intra-epithelial inflamma-
tion. The submucosa .is more fibrous and less edematous than those 
previously described. As in the top of the bladder, there are fairly 
prominent hemosiderin-laden histiocytes within the stroma and prom-
inently dilated small venules. There appears to be some interstitial 
fibrosis surrounding individual muscle fascicles and veins that seems 
to accentuate and separate individual fascicles. 
(4) Similar changes to that described above. Inconspicuous inflammation, 
some interstitial fibrosis and some submucosal fibrosis and hemosiderin. 
(5) Intact mucosa, submucosa which exhibits recent interstitial 
hemorrhage. Fairly prominent submucosal fibrosis. Fairly incon-
spicuous inflammation. The cuff is made up of the usual compressed 
parallel-arranged fibrous connective tissue fibers with moderately 
irregular patterns of cellularity. At one stretch there is an ag-
gregate of mixed inflammation including some neutrophils in association 
with hemosiderin-laden histiocytes, suggestive of an inflammatory 
response to moderately recent hemorrhage. 
(6) No significant changes. Submucosa prominently fibrous. Again, 
showing recent hemorrhage and organizing interstitial hemorrhage 
making up tiny submucosal hematomas. No significant inflammation. 
(7) Distal cuff edge is OK, but the submucosa is extremely bloody. It 
has some interstitial hemorrhage and small hematomas which are 
organizing which suggested they are real. In one area there is a 
hematoma producing a pseudopolyp which may partly occlude the urethra 
with a portion of the mucosa herniating into the lumen of the urethra. 
(8) The usual fibrous cuff with prominent superficial layer of 
hemosiderin-laden histiocytes, again suggesting invasion. 
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Table 13B-4 Dog: #4 
(9) Very thin attenuated mucosa, somewhat fibrous submucosa. Again, 
conspicuously absent inflammation. 
(10) Located in subcutaneous area. Fibrous capsule. One stretch shows 
fairly recent hemorrhage interstitially. 
(11) Lined capsule, no problems. 
(12) Same as (11). 
(13) Capsule showing no Significant changes. 
(Organs) Kidney - one section reveals ureter and pelvis with no signifi-
cant changes. The architecture of one biopsy appears fairly intact. 
The Bowman's capsules appear somewhat prominent in terms of the space 
between the glomerular tuft and the Bowman space itself. There is no 
significant dilatation of tubules. Another section shows a portion of 
a renal pyramid showing fairly extensive recent interstitial hemorrhage 
between tubules including some cellular neutrophilic casts within some 
of the tubules. There appears to be an area of old infarction with 
complete necrosis in an area. This may contain microorganisms. 
Spleen - OK. Lungs - OK. Heart - OK. Liver - very prominent con-
gestion of terminal hepatic veins and marked congestion of the hepatic 
sinusoids. 
SUMMARY: The above histologic findings are consistent with disease caused 
by obstruction. 
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TABLB 13B-5: HISTOLOGY REPORT - USD 
DOG: #5 NA~1E: Elaine TIME IMPLANTED: 89 days 
RBASON FOR SACRIFICB: End of the experimental period • 
GROSS OBSERVATIONS: The bladder internal mucosa showed evidence of gross cystitis. The dog was gravid approximately six weeks, with all other tissue appearing normal. 
SECTIONS OF TISSUE: 
(1) Missing 
(2) Bladder - Mucosa is almost polypoid. There is extensive inflammatory infiltrate beginning within the urothelium itself in which there are small intra-epithelial absoesses containing neutrophils. The sub-
mucosa is very heavily infiltrated with mature plasma cells, edema and occasional neutrophils, Russell bodies are readily identifiable. 
(3) Bladder shows similar changes to the previous bladder. 
(4) Bladder neck. Here, two kinds of findings are present. One consists of nodular and diffuse lymphoid infiltrates including plasma cells in the submucosa, as well as presence of fairly numerous hemosiderin-laden histiocytes suggestive of old bleeding in the submucosa. 
(5) Proximal cuff. The cuff surface contains a thin capsule without 
evidence of any reaction whatever. The lining mucosa is partly 
mechanically denuded but present and somewhat attenuated down to 3-4 cell thickness in few areas. There is moderate degree of plasmacytic and occasional neutrophilic infiltration in the submucosa. 
(6) Similar changes are identified consisting of nodular and diffuse sub-mucosal inflammatory infiltrates, intact yet attenuated mucosa. 
(7) Partial section. No mucosa identifiable. 
(8) Cuff capsule. Thin capsule, no reaction. 
(9) Distal urethra. No mucosa. 
(10) Drum. Thin capsule, no reaction. 
(11) Capacitor capsule somewhat thicker than the rest, yet no reaction, bland. 
(12) Reservoir capsule. Same changes. 
(13) Valve capsule. No change. 
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Table 13B-5 Dog: #5 
(Organs) Heart - no significant pathologic changes. Kidney - architecture intact. Glomeruli tubules, interstitium and intrarenal vessels show no significant alterations. Bowman's capsule does not appear unusual. There is clear separation between the glomerular tuft and the Bowman's capsule. Slight mixed infiltrate in the calyces made up of plasma cells and occasional neutrophils. Liver - no significant change, some congestion of terminal hepatic veins. Spleen - no significant change. Lungs - no significant change. Small intestine - normal • 
SUMMARY, Basically in this dog we have acute and marked chronic cystitis and chronic urethritis. There is evidence of some chronic pyelitis. Normal organs, normal kidney, as expected bland, non-reactive capsule around appliance portions. 
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TABLE 13B-6: HISTOLOGY REPORT - USD 
DOG: #6 NAME: Lynette TIME IMPLANTED: 89 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: The urethral mucosa under the proximal cuff edge was 
rugose and hemorrhagic. 
SECTIONS OF TISSUE: 
(1) The ureter is normal. 
(2) Bladder shows no significant changes. Mucosa intact. No significant 
inflammation. 
(3) Another bladder section. Does not contain mucosa, but no changes. 
(4) Bladder neck. Mucosa present. Submucosa perhaps has more dense, 
fibrous tissue than expected. 
(5) Proximal cuff. Good section showing a bland capsule. There are few 
areas of greater degree of cellularity within the capsule, but no 
hematopoietic inflammatory elements. The submucosa is normal. The 
mucosa is only focally attenuated. In many other areas it has about 
7-8 cell layer thick. Otherwise appears totally unremarkable. 
(6) Mid-cuff showing pretty much the same alterations, perhaps somewhat 
prominent vascularity in the submucosa. Again, focal areas of in-
creased cellularity compared to the usual acellular capsule. 
(7) Distal cuff. Most of the mucosa is absent, but otherwise no inflam-
mation or other changes. 
(8) Cuff capsule. No significant changes. 
(9) Distal urethra. There is some denudation of the mucosa. It is not 
clear whether this is mechanical or ante-mortem. There appears to be 
some acute inflammation focally lining the lumen suggesting possibility 
that that is an acute reaction. The mucosa was present, appears 
to be in crevices. There is submucosal inflammation in those areas 
made up of lymphocytes, some neutrophils and some histiocytes. 
(10) Drum. Bland capsule, somewhat cellular. 
(13) Valve capsule. No problem. 
(Organs) Spleen - histologically normal. Liver - shows no significant 
changes. Small intestine - normal. Lung - normal. Kidneys-
architecture intact. A few calcifications in the medulla. Normal 
distribution of glomeruli tubules, interstitium and vessels. No 
inflammation. Opposite kidney - histologically normal. Heart-
normal. 
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Table 138-6 Dog: #6 
SU~~Y: Some denudation of the urethra with subacute and some acute in-
flammation. This appears to be very recent and may have been agonal or 
close to it. No significant inflammation in the urinary bladder. No 
significant changes in the organs. 
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TABLE 13B-7: HISTOLOGY REPORT - USD 
DOG: #7 NAME: Vivian TIME IMPLANTED: 91 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: Normal. 
SECTIONS OF TISSUE: 
(1) Ureter is intact and shows some lymphocytic infiltration within the 
epithelium and the submucosa and occasional plasma cells. 
(2) Bladder. Muscle intact. Urothelium intact. Submucosa intact. No 
significant inflammation. 
(3) Bladder. Shows no mucosa. Otherwise normal. 
(4) Bladder. No urothelial lining. 
(5) Proximal cuff edge. Has some attenuation of epithelium 3-4 layers 
thick. The submucosa is somewhat more prominent than expected, fairly 
vascular, but no significant inflammation. 
(6) Mid-cuff. Identical changes with those described in (5). Capsule is 
bland, fibrous, fairly standard. 
(8) Capsule showing bland changes. No significant reaction. 
(9) Distal urethra. Attenuated mucosa, spongy-appearing hyperemic 
vascular submucosa. No significant inflammation. 
(11) Capacitor capsule. Very unusually thin, moderately cellular capsule. 
No inflammation. 
(13) Portion of a capsule. Bland, no reaction. 
(Organs) Small intestine - normal. Kidney - histologically normal. 
Glomeruli tubules, interstitium and vessels are normal. There is some 
chronic inflammation around the pelvis and made up of mature-appearing 
small lymphocytes, no plasma cells. Spleen - somewhat hyperemic but 
otherwise normal. Heart - normal. Kidney - histologically norma.!, 
except again for some chronic inflammation around the pelvis with an 
intact mucosa. Lung - normal. 
SU~UMRY: There is some attenuation of mucosa in the urethra without signi-
ficant inflammation. Presence of some slight lymphocytic infiltration in 
the submucosa of the ureter and in the pelvis of both kidneys. The absence 
of plasma cells suggests that the inflammation is not due to bacterial 
antigens. 
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TABLE 13B-8: HISTOLOGY REPORT - USD 
DOG: #8 NAME: Guenivere TIME IMPLANTED: 64 days 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: The bladder appeared very slightly thickened. There 
was submucosal hemorrhage in the urethra. 
SECTIONS OF TISSUE: 
(1) Fairly normal. No significant change. 
(2)(3)(4) Intact mucosa, intact submucosa. No significant inflammation. 
(5) Fairly attenuated mucosa. Some edema in the submucosa. Slight mixed 
infiltrate including some neutrophils. 
(6) No cuff. Fairly intact mucosa, some fibrosis, no inconspicuous 
inflammation. 
(7) No cuff. Tissue very thin, attenuated-appearing mucosa. No signifi-
cant inflammation" 
(8) Fibrous capsule without reaction. 
(9) Appears to be a portion of a conduit, possibly urethra. Attenuated 
mucosa. Slight submucosal inflammation including some neutrophils, 
lymphocytes. No muscle walls. 
(10) Fairly vascularized-appearing capsule. One stretch has a thin fibrin 
layer at the surface of the fibrous tissue. Otherwise, negative. 
( 11) Unreadable. 
(12) Portion of a thin capsule. No problems. 
(Organs) Spleen - normal. Intestine - normal. Lung - normal. Liver-
essentially normal. Heart - normal. Kidney - normal. 
SUMMARY: Histology is normal. 
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TABLE 13B-9: HISTOLOGY REPORT - USD 
DOG: #9 NM!E: TIME IMPLANTED: 4 days 
REASON FOR SACRIFICE: Dog died due to midline evisceration. (The subject 
was dropped from the experiment, with replacement.) 
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TABLg 13B-IO: HISTOLOGY REPORT - USD 
DOG: #10 NAME: Momma TIME I~lPLANTED: 69 dags 
REASON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: The cuff capsule was thick, but non-reactive. 
appeared to be a slight visible stricture at the distal cuff edge. 
are normal, bladder is normal. There appeared to be hemorrhage in 
mucosa of the urethra • 
SECTIONS OF TISSUE: 
(2) Bladder. Intact. No problem. 
(3) Bladder. No problem. Normal. 
There 
Kidnegs 
the sub-
(4) Bladder. Somewhat flattened mucosa. Submucosal hgperemia. No 
inflammation. 
(5) A capsule which is fairlg bland, somewhat contracted. Intact. 
Prominent hgperemia submucosal vessels. No inflammation. 
(6) Capsule. No mucosa. Capsule unremarkable. 
(7) Capsule. Intact. Some focal cellularitg. Recent interstitial 
hemorrhage, probablg traumatic. Mucosa fairlg intact. Submucosa 
somewhat hyperemic. Rare lymphocytes and occasional plasma cells 
in the submucosa. 
(8) Capsule. Bland, no reaction. 
(9) Urethra with normal submucosa and magbe minimally attenuated mucosa, 
but fairlg good. 
(10) Thicker capsule, no reaction. 
(11) Capsule. Normal. 
(12) Capsule. Normal. 
(13) Capsule. Normal. 
(Organs) Kidneg - no pyelitis. Has some sort of old granulomatous lesion, 
probably fungal because it contains yeast-like forms on H+E unless 
they're calcospherials at the cortex. Otherwise, not remarkable. 
Opposite kidney - no significant changes. Heart - normal. Small 
intestine - normal. Lung - normal. Liver - marked hyperemia of 
sinusoids and terminal hepatic veins. Spleen - markedly hyperemic. 
SUMMARY: No significant inflammatory or anatomical changes in the urinary 
tract. We have an incidental small renal granuloma. We also have 
hyperemia of spleen and liver. 
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TABLE l3B-ll: HISTOLOGY REPORT - USD 
DOG: #11 NAME: Ohura TIME IMPLANTED: 62 days 
~SON FOR SACRIFICE: End of the experimental period. 
GROSS OBSERVATIONS: 7'here was presence of visible blood on the urethra 
mucosa and all other tissue appeared normal. 
SECTIONS OF TISSUE: 
(1) Segment of ureter which is histologically normal. 
(2) Segment of urinary bladder. Mucosa is normal. Submucosa slightly 
fibrotic, no inflammation. Muscularis normal. 
(3) Urinary bladder. No difference from (2). 
(4) Bladder neck. Identically same changes. Prominent submucosa, no 
inflammation. 
(5) Urethra, area under the cuff. Portion of a capsule here. In one 
area the surface shows some aggregates of histiocytes and fibroblasts, 
although no granuloma or inflammation. The epithelial surface of the 
urethra is entirely intact. There is no inflammation. Basically 
normal. 
(6) Mid-cuff. The cuff is bland, non-remarkable. Mucosa is intact. It's 
partly mechanically separated but where it is intact shows no signifi-
cant attenuation. Submucosa moderately vascular, no inflammation. 
(7) Portion of cuff still in evidence on the outside. Submucosa not re-
markable. Recent probably agonal hemorrhage without reaction. No 
significant fibrosis or inflammation. Mucosa intact. 
(8) Cuff capsule. Portion of some mucosa, thin, but no cuff as such on 
this section. 
(9) Distal urethra. Large portion of cuff which presents the usual 
laminated, somewhat acellular, cuff. 
(10) Another portion of cuff showing no significant changes. There is no 
inflammation, evidence of old hemorrhage, granulomas or other reac-
tion. 
(11) Small segment of cuff showing identical bland appearance. 
(12) Valve area. No significant change. Occasional single lymphocytes 
close to surface. 
(13) Cuff around the reservoir. Here we have some larger epithelioid, 
probably histiocytic, cells close to the surface along portion of 
the cuff. No inflammatory infiltrate. 
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Table 138-11 Dog: #11 
Organs: Spleen - normal. Heart - normal. Lung - normal. Liver - normal. Small intestine - normal. Kidney - a pyramid sho,dng no significant 
alterations, no glomeruli seen in one block. In another block, the kidney is entirely histologically normal. The opposite kidney is simi1~rly totally normal. 
SUNMANY: No significant pathologic alterations in the entire material. The usual bland capsule, few bland foci of histiocytic aggregates toward the surface at the capsule, that is surface facing the appliance. 
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APPENDIX E 
EXPLANT ANALYSIS: URINARY SPHINCTER SYSTEMS 
Purpose: 
The purpose of the explant analysis is to determine chemical and 
physical changes of the device after implant in biological tissue. 
Specifically: To perform functional and material tests on components; 
to identify cellular and particulate contamination of the fluid, thus 
components; to determine device and tissue sterility; to analyze for 
physio/chemical species (ions, water) which can be used indirectly to 
understand processes of molecular movement through silicone elastomer, 
degradation of polymers (enzymes), corrosion of metal components, and 
.ion concentration leading to microaggregation and tears in elastomer. 
Procedure: 
l. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Photograph dog's abdominal area -- reservoir 
for orientation relative to midline incision. 
included in all slides. 
and septa through skin 
Dog # and device # card 
Cuff is to be isolated intra-abdominally and system is to be func-
tionally tested in place and UPP performed. 
Device will be explanted by surgeon or expe.rienced surgical research 
technician (as a block), device intact with surrounding tissue. 
Pressure tests are performed using needles to penetrate septa or a 
T-connector. Device pressures are then characterized (set point, 
decay 5 min., cuff-septum side). 
Photographs are taken of each component of sphincter system as 
removed from surrounding tissue. 
Saline moistened swabs are rubbed on device and surrounding tissue, 
then p1at"d onto blood culture plates . 
Tissue from each component is placed into formalin and each jar 
labeled. 
The sphincter system is then removed to bench area where the whole 
device is weighed (g). Macroscopic and microscopic observations of 
material. 
Each component is packaged in 
and dog # labels, placed into 
along with data sheets. 
heat-sealed freezer bags with device # 
foam containers and sent to M.E.C., 
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10. 
11. 
12. 
13. 
All test results obtained at RGEI will be forwarded to NEC and PH. 
MEC is to perform explant functional and material reliability tests 
and compare to pre-implant data for changes. The valve is removed 
from the sphincter system and sent to PH for teardown. Data will be 
sent to RGH and PH. 
PH will perform valve performanC'e and teardown procedures according 
to established protocols. Data I.'ill be sent to RGH and MEC. 
Integration of test results will be done by three person team: 
MEC (Chairman), PH representative, RGEI representative. Clinical 
data for this will be provided by RGH, where needed. 
Reference documents include: 
1. RGH 80-1, Post-Implant Analysis 
2. Correspondence 12/21/81 to Dr. H. Harrison from Vaughan Weeks 
3. Correspondence 2/25/82 to Vaughan Weeks from Russ Reinsch 
236-2 
I 
, c' 
\: 
I 
(,I 
'i 
I 
" 
-, 
'i 
" 
.' !: 
I 
.. 
I 
,. 
I. 
.. 
r 
f 
.-
~ 
" 
c 
l 
~ 
, 
I 
l. 
f 
l 
~-
j,. 
" , 
! 
SUGGESTED REMOVAL PROTOCOL - SPHINCTER PROJECT 
Subject name or number: Cuff assembly number: 
Valve assembly number: % Conray: 
2. 
3. 
4. 
Functional analysis - external - for pressure set point and decay, after removal. 
Macroscopic analysis - device external - for protruding edges, kinks, disconnects, 
discoloration elastomer 
Bacterial culture: 
Fluid -
Blood -
Capsule surrounding implant -
Summary: 
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